Programme Book

25–28 May 2016

Athens · Greece
Megaron International Conference Centre

www.espghancongress.org
I swear by Apollo the physician, and Aesculapius the surgeon, likewise Hygeia and Panacea, and call all the gods and goddesses to witness, that I will observe and keep this underwritten oath, to the utmost of my power and judgment.

I will reverence my master who taught me the art. Equally with my parents, will I allow him things necessary for his support, and will consider his sons as brothers. I will teach them my art without reward or agreement; and I will impart all my acquirement, instructions, and whatever I know, to my master’s children, as to my own; and likewise to all my pupils, who shall bind and tie themselves by a professional oath, but to none else.

With regard to healing the sick, I will devise and order for them the best diet, according to my judgment and means; and I will take care that they suffer no hurt or damage.

Nor shall any man’s entreaty prevail upon me to administer poison to anyone; neither will I counsel any man to do so. Moreover, I will give no sort of medicine to any pregnant woman, with a view to destroy the child.

Further, I will comport myself and use my knowledge in a godly manner.

I will not cut for the stone, but will commit that affair entirely to the surgeons.

Whatsoever house I may enter, my visit shall be for the convenience and advantage of the patient; and I will willingly refrain from doing any injury or wrong from falsehood, and (in an especial manner) from acts of an amorous nature, whatever may be the rank of those who it may be my duty to cure, whether mistress or servant, bond or free.

Whatever, in the course of my practice, I may see or hear (even when not invited), whatever I may happen to obtain knowledge of, if it be not proper to repeat it, I will keep sacred and secret within my own breast.

If I faithfully observe this oath, may I thrive and prosper in my fortune and profession, and live in the estimation of posterity; or on breach thereof, may the reverse be my fate!
# Table of Contents

## ESPGHAN Annual Meeting
- Venue Map Megaron Athens 4
- Venue Map Hilton Athens 7
- Congress Sponsors 8
- Welcome Messages 10
- ESPGHAN Council & Committees 12
- New/Advanced Technologies 13
- ESPGHAN Society & Membership 14
- Young ESPGHAN 16
- Awards & Grants 18
- Education Partner Programme (EPP) 20

## Scientific Sessions & Meetings
- Society Meetings 22
- For Members Only 23
- ESPGHAN Annual General Meeting 24

## Wednesday, 25 May 2016
- Programme Overview 26
- Chronological Programme 28

## Thursday, 26 May 2016
- Programme Overview 40
- Chronological Programme 42

## Friday, 27 May 2016
- Programme Overview 50
- Chronological Programme 52

## Saturday, 28 May 2016
- Programme Overview 64
- Chronological Programme 66

## Poster Exhibition
- ePoster Presentations 78
- Poster Exhibition 86

## Industry & General Information
- Endoscopy and Motility Learning Zones 121
- Satellite Symposia 129
- Exhibitors List (Overview) 136
- Exhibition Plan 137
- Exhibitors & Sponsors List (short profiles) 138
- Disclosure of Sponsorships 160
- General Information 161
- Metro Athens 166
- Athens Map 167
Venue Map Megaron Athens

Level -1

Room 3
MC 3.4
MC 3.5
MC 3.3
MC 3.2
Speakers Ready Room
ELZ
MLZ
Room 4
Room 2
Level -2
The organiser would like to thank the following companies for their generous support of the ESPGHAN 49th Annual Meeting.

**Congress Sponsors**

**Diamond**
- Mead Johnson Nutrition

**Platinum**
- Alexion

**Gold**
- Nestlé
  - For the most valuable in life.

**Silver**
- Nutricia
  - Early Life Nutrition
- Abbvie
Bronze

Aurora
Arla
Baxter

Fasska
Freeland Companies

HALYARD

Lactalis
Novalac

Chrome

Abbott
AMT

Bedfont

Bühlmann
DSM

Eurospital
Mendes S.A.

Shire
Welcome Letter

On behalf of the ESPGHAN and HELSPGHAN we are delighted to welcome you to the 49th Annual Meeting of ESPGHAN held from Wednesday 25 to Saturday 28 May 2016, in Athens, Greece.

Greece provided a significant part of the foundations of modern democracy, science and medicine, and it is a land of outstanding hospitality and friendliness. The charming and attractive city of Athens offers a fascinating combination of both ancient mystery and modern life and provides an excellent location for our meeting with countless attractions.

The Congress will present a very attractive Scientific Programme of high quality, preceded by comprehensive Postgraduate Courses for Physicians and for Allied Health Care Professionals as well as an additional Postgraduate Course focussing on Paediatric Inflammatory Bowel Diseases. Once again we plan to offer a hands-on Learning Zone on endoscopic and this year also on motility techniques. Last but not least, the congress offers a great platform to meet colleagues in your field from around the world.

We welcome you in Athens and trust you will find your participation in the 49th ESPGHAN Meeting fruitful and enjoyable.

Professor Berthold Koletzko
ESPGHAN President

Honorary Professor Alexandra Papadopoulou
Chair of the Local Organising Committee
Dear Distinguished Delegates,

On behalf of the Hellenic Ministry of Health and the Greek Government I would like to warmly welcome you all to Athens for the 49th ESPGHAN Annual Meeting that will be held in our city for the first time!

Bringing together the international leaders in the field of Paediatric Gastroenterology, Hepatology and Nutrition provides a unique opportunity to distribute knowledge on the advances in the field and create networks for collaboration across different countries of Europe and beyond.

I am aware of the challenges in the field and the efforts of the ESPGHAN leadership towards harmonising training and standardising clinical care throughout Europe.

The Ministry of Health is aware also, of the problems that adolescents with chronic, severe gastrointestinal diseases face in the access to appropriate for their age clinical services and is determined to work together with the Parents and Patients Associations to find solutions that will enable a better quality of life for the patients and their families.

We scientists and politicians, have to put efforts to find ways to build on progress, by pushing boundaries away and working together to be able to meet the real challenges we face at these difficult times and co-create the best solutions for the benefit of our children.

This meeting will make a valuable contribution to that and I look forward on its outcomes!

I wish you all to have a successful meeting with lively discussions throughout the sessions and a safe, enjoyable and most memorable stay in Athens to our distinguished guests!

Andreas Xanthos
Minister of Health of the Hellenic Republic
### ESPGHAN Council & Committees

<table>
<thead>
<tr>
<th><strong>ESPGHAN Council</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>President</td>
<td>Berthold Koletzko, Germany</td>
</tr>
<tr>
<td>President Elect</td>
<td>Raanan Shamir, Israel</td>
</tr>
<tr>
<td>General Secretary</td>
<td>Genevieve Veereman, Belgium</td>
</tr>
<tr>
<td>Treasurer</td>
<td>Alan Phillips, United Kingdom</td>
</tr>
<tr>
<td>Education Secretary</td>
<td>Gábor Veres, Hungary</td>
</tr>
<tr>
<td>International Affairs Representative</td>
<td>Jernej Dolinšek, Slovenia</td>
</tr>
<tr>
<td>Scientific Secretary</td>
<td>Piotr Socha, Poland</td>
</tr>
<tr>
<td>Gastroenterology Committee</td>
<td>Nikhil Thapar, United Kingdom</td>
</tr>
<tr>
<td>Hepatology Committee</td>
<td>Ulrich Baumann, Germany</td>
</tr>
<tr>
<td>Nutrition Committee</td>
<td>Mary Fewtrell, United Kingdom</td>
</tr>
<tr>
<td>Allied Health Professionals Committee</td>
<td>Tena Niseteo, Croatia</td>
</tr>
<tr>
<td>Young ESPGHAN Committee</td>
<td>Nicolette Moes, The Netherlands</td>
</tr>
<tr>
<td>Chair of LOC</td>
<td>Alexandra Papadopoulou, Greece</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Scientific Programme Committee</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>President</td>
<td>Berthold Koletzko, Germany</td>
</tr>
<tr>
<td>Scientific Secretary</td>
<td>Piotr Socha, Poland</td>
</tr>
<tr>
<td>Chair of LOC</td>
<td>Alexandra Papadopoulou, Greece</td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Nikhil Thapar, United Kingdom</td>
</tr>
<tr>
<td>Hepatology</td>
<td>Ulrich Baumann, Germany</td>
</tr>
<tr>
<td>Nutrition</td>
<td>Mary Fewtrell, United Kingdom</td>
</tr>
<tr>
<td>Allied Health Professionals</td>
<td>Tena Niseteo, Croatia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Local Organising Committee Greece</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Alexandra Papadopoulou</td>
</tr>
<tr>
<td>Deputy Chair</td>
<td>Eleftheria Roma</td>
</tr>
<tr>
<td>Chair PG Course</td>
<td>Ioanna Panayotou</td>
</tr>
<tr>
<td>Endoscopy Learning Zone</td>
<td>George Chouliaras</td>
</tr>
<tr>
<td>Motility Learning Zone</td>
<td>Panayota Kafritsa</td>
</tr>
<tr>
<td>Further Members</td>
<td>Konstantina Dimakou</td>
</tr>
<tr>
<td></td>
<td>Smaragdi Fessatou</td>
</tr>
<tr>
<td></td>
<td>Maria Fotoulaki</td>
</tr>
<tr>
<td></td>
<td>Thomai Karagiozoglou</td>
</tr>
<tr>
<td></td>
<td>Stravroula Karyda</td>
</tr>
<tr>
<td></td>
<td>Maria Maragkoudaki</td>
</tr>
<tr>
<td></td>
<td>Maria Rogalidou</td>
</tr>
<tr>
<td></td>
<td>Konstantinos Siafakas</td>
</tr>
<tr>
<td></td>
<td>Aglaia Zellos</td>
</tr>
</tbody>
</table>
New/Advanced Technologies

Get the best out of the Annual Meeting 2016!

We are happy to introduce the following technical features to you to make sure that you get the best out of your conference days.

Congress App
Do you always want to be up-to-date? – The ESPGHAN Congress App will guide you through the conference venue, the industry exhibition, the scientific programme and the social events. Use the interactive modules like the commenting or your personal programme to be an active part of the ESPGHAN congress society.

ePoster
For the first time, the 120 best scored posters will be presented as ePosters at ten ePoster stations (Foyer of Room 1, 1st floor). A full-text search by keywords, title or presenter ensures an easy access to all scientific content. Use the zoom-in, zoom-out function to focus on specific parts of the ePosters.

Kindly note that the classic posters are presented in the Poster Exhibition (Foyer Room 5 ground floor and 1st floor).

Commenting
Do you have a specific question on the running presentation? – Submit your questions via the ESPGHAN Congress App anytime. The chairs will choose the most interesting questions and forward them to the respective speaker during the discussion time.

Kindly note that this feature is only available in Rooms 1, 2, 4, 5, 6. Questions are certainly also possible by using the discussion microphones in the session halls.

Webcast on demand
Are two interesting sessions running in parallel? – Follow one of them live. The other session will be available as webcast (slides & audio) on the Virtual Meeting Site approximately 2 hours after the end of the session.

Kindly note that the publication is based on agreement of the speakers and only the following sessions will be recorded: State of the Art Lecture, Keynote Lectures, Parallel Symposia, Clinical Practice Track.

Virtual Meeting Site
The scientific content of the Annual Meeting is available for all participants on the Virtual Meeting Site:
Oral presentations, ePosters, webcasted sessions as well as speaker CVs are provided under www.espghancongress.org. Please create your personal login by using the same e-mail account as in the registration process.

Overflow
The session halls 1-6 are equipped with screens at the entrance to give you the possibility to follow a presentation even if the session hall is crowded. In case of very high demand, the presentation will be transmitted to the ‘Overflow Room’.

Kindly note that only the slides and the audio signal will be transmitted.
Become a Member

By becoming a member of ESPGHAN, you will experience and gain access to a range of benefits including an international network of specialists who promote and encourage collaboration and exchange of information within GI, Hepatology, Nutrition Committees, working groups and their outcomes.

Subscription to JPGN, the Journal of Pediatric Gastroenterology and Nutrition, receipt of ESPGHAN newsletters, accesses to the member’s area of the ESPGHAN website and discounted registration fees for the ESPGHAN Annual Meeting are among the benefits of ESPGHAN members.

According to your professional status you can choose between full, corresponding, trainee, allied-health professional and emeritus membership.

Members must have an active interest in pediatric gastroenterology and/or hepatology or nutrition (PGHN).
Key Activities

ESPGHAN has three standing committees focusing on gastro-enterology, hepatology and nutrition. All aim to promote child health and increase understanding and treatment of disease states, ESPGHAN members are also involved in various working groups that concentrate on particular aspects of child care and / or disease states. The Allied Health Professional Committee aims to enhance the multidisciplinary approach in G, H & N in Europe, and the Trainee Committee promotes and supports specialist training and guides trainees towards full membership of ESPGHAN.

ESPGHAN also promotes scientific exchange amongst research groups in Europe and amongst trainees, young doctors and scientists through G, H & N Schools, Young Investigator Forums, Monothematic Meetings, International Schools and Eastern European Schools.

ESPGHAN Association Management Office

The ESPGHAN Association Management Office Team will be onsite at the Annual Meeting at the ESPGHAN booth in the exhibition.

For general enquiries about ESPGHAN please contact a member of the team.

ESPGHAN Office

European Society for Paediatric Gastroenterology, Hepatology and Nutrition
office@espghan.org
www.espghan.org

To promote the health of children
The Young ESPGHAN Committee has drafted its mission and rules statement and updated the ESPGHAN training syllabus. Communication between the Young ESPGHAN Committee and the trainees/young investigators is assured by newsletters, social media and via the ESPGHAN website. The Young ESPGHAN Committee has sent around surveys on endoscopy and nutrition training and research opportunities during training.

The Young ESPGHAN Committee has been actively promoting and participating in the organisation of educational activities such as the elearning program. Following the successful model of the well-established ESPGHAN Gastroenterology, Hepatology and Nutrition Summer Schools, a new Endoscopy School has been established with the help of a United European Gastroenterology (UEG) grant.

At the 2015 Annual Meeting in Amsterdam the Young ESPGHAN Committee has liaised with the European Society of Gastrointestinal Endoscopy (ESGE) in setting up an endoscopy learning area and this will be continued at the 2016 Annual Meeting here in Athens. There will be a Young ESPGHAN Lounge where young delegates can get in touch with senior ESPGHAN members. At this year’s Annual Meeting the Young ESPGHAN Committee is organising

Young ESPGHAN, who are we?

Young ESPGHAN – consisting of trainees and young investigators – is the fastest growing members-group within ESPGHAN. The Young ESPGHAN Committee represents their interests, shortlists trainees for scientific committees and encourages them to participate in specific working groups.
the first Young ESPGHAN session with an invited speaker following the Annual Meeting and finishing with an informal get-together. Furthermore, the mentorship programme will be presented at the Young ESPGHAN Lounge.

The Young ESPGHAN Committee is looking for new members!

If you are interested in joining us, please send your motivation letter and CV to: young@espghan.org before 01 September 2016.

Join ESPGHAN, become a Young ESPGHAN Member!

The Young ESPGHAN membership addresses people less than 10 years active in the field of Paediatric Gastroenterology, Hepatology and Nutrition (PGHN).

Being member gives you lots of opportunities like for example:
- Access to the biggest network in PGHN in Europe
- Reduction in congress fees
- Eligibility for grants & research prizes
- Participation in summer schools / masterclasses / young investigator forum

Membership application is now open twice a year!

Please upload your application on the ESPGHAN website before 30 September or 31 March.

For more information on membership application kindly contact us via young@espghan.org or visit our website www.espghan.org/home/join-us.

For detailed information please visit the website: www.espghan.org/about-espghan/committees/young-espghan/
Awards & Grants

ESPGHAN provides a number of awards and grants to members and non-members alike.

These awards are wide ranging and are both project based and travel awards and grants.

★ **Paediatric Nutrition Research Award** (next awarded 2017) ...... 30,000 €
★ **Research and Networking Grants** ............................................... 25,000 €
★ **Charlotte Anderson Travel Award** (next awarded 2017) .......... 3,000 €
★ **ESPGHAN International Exchange Award** .............................. 3,000 €
★ **Young Investigator Awards (YIA)** ........................................ 1,000 €
★ **ESPGHAN Conference Prizes** ................................................... 1,000 €
★ **UEG Week Prizes** ................................................................. 1,000 €
★ **ESPGHAN / NASPghan Travel Award** ................................. 5,000 $/€
★ **UEG Week YIA** ................................................................. 1,000 €
★ **WCPghan YIA** ................................................................. 1,000 €

At the 49th Annual Meeting the ESPGHAN Conference Prizes for the best Gastroenterology, Hepatology, and Nutrition research awards will be presented to the value of 1,000 € respectively. The award ceremony for these prizes will be held during the Closing Session on Saturday 28 May at 13:00. You are cordially invited to come and celebrate with the prize winners.

The Research and Networking Grants are available for ESPGHAN members to apply for funding for research and networking projects that involve cross border partnerships. The deadline for applications is 31 July 2016.

For further information on the Awards and Grants please visit: www.espghan.org
AGM Annual Prizes

The following prizes will be awarded during the Closing Session for the best abstract presentations.

Each winner will be presented with a letter of recognition, certificate and an award of 1,000 €.

★ The Annual John Harries Prize
   For the best presentation on Gastroenterology

★ The Annual Alex Mowat Prize
   For the best presentation on Hepatology

★ The Annual Jean Rey Prize
   For the best presentation on Nutrition

Young Investigator Awards

The purpose of the Young Investigator Awards (now incorporating the AHP Award) is to support expenses of up to 1,000 € for Young Investigators who have had an abstract accepted for presentation at the Annual Meeting.

Please note that the following rules must be met by all candidates:

1. Must be the first author of the work being presented (may be checked against the printed programme)

2. To be working in Paediatric Gastroenterology/Hepatology/Nutrition for less than 10 years

3. For reimbursement, the Treasurer needs to receive the original air or train ticket, and the original hotel bill

4. Candidates may be ESPGHAN members or non-members
Education Partner Programme (EPP)

ESPGHAN provides a variety of educational activities, events and information that are available throughout the year.

The ESPGHAN Education Partner Programme (EPP) was launched in 2015. Based on the 2015 adopted ESPGHAN Code of Conduct, the EPP has been developed to ensure the on-going development and implementation of an up-to-date, independent, high quality educational programme for health care professionals. The dedicated support and financial commitment from our partners helps to enhance and stabilise support for ESPGHAN’s educational activities.

The EPP educational activities for 2016 planned at this time include:

<table>
<thead>
<tr>
<th>Events</th>
<th>Date</th>
<th>Venue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paediatric Hepatology Summer School</td>
<td>27-30 April 2016</td>
<td>Visegrád, Hungary</td>
</tr>
<tr>
<td>ESPGHAN Eastern Europe Summer School</td>
<td>23-25 June 2016</td>
<td>Kazan, Russia</td>
</tr>
<tr>
<td>ESPGHAN Master Class Clinical Trials for Members Involved in Planning and Conducting Clinical Trials in Paediatric Gastroenterology, Hepatology and Nutrition</td>
<td>07-09 July 2016</td>
<td>Budapest, Hungary</td>
</tr>
<tr>
<td>ESPGHAN Baltic Summer School</td>
<td>08-10 September 2016</td>
<td>Vilnius, Lithuania</td>
</tr>
<tr>
<td>Young Investigator Forum</td>
<td>21-24 September 2016</td>
<td>Bergen, The Netherlands</td>
</tr>
<tr>
<td>Paediatric Gastroenterology School</td>
<td>26-29 October 2016</td>
<td>Florence, Italy</td>
</tr>
<tr>
<td>Master Class Evidence Based Medicine Guidelines for ESPGHAN Committee Members and other members actively involved in preparing ESPGHAN guidelines</td>
<td>18-19 November 2016</td>
<td>Budapest, Hungary</td>
</tr>
<tr>
<td>Master Class on Parenteral Nutrition in neonatal and pediatric intensive care units</td>
<td>23-25 November 2016</td>
<td>Paris, France</td>
</tr>
<tr>
<td>2nd Paediatric IBD Master Class</td>
<td>24-26 November 2016</td>
<td>Rotterdam, The Netherlands</td>
</tr>
<tr>
<td>Monothematic Conference: Familial Cholestasis</td>
<td>January 2017</td>
<td>TBA</td>
</tr>
</tbody>
</table>

We sincerely thank the following EPP partners for their generous support and commitment:

Abbott  | Abbvie  | Alexion  | Dicofarm

More details on the ESPGHAN Educational Partner Programme and all ESPGHAN educational events can be found on our website: www.espghan.org
## Society Meetings

### Wednesday, 25 May 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Meeting</th>
<th>Room Access</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 – 12:30</td>
<td>ESPGHAN History Committee Meeting</td>
<td>Terpsichore C, Hilton</td>
</tr>
<tr>
<td>14:00 – 14:45</td>
<td>ESPGHAN Allied Health Professional Annual General Meeting</td>
<td>Terpsichore B, Hilton</td>
</tr>
<tr>
<td>16:15 – 17:45</td>
<td>ESPGHAN Allied Health Professional Committee Meeting</td>
<td>Terpsichore B, Hilton</td>
</tr>
<tr>
<td>16:30 – 18:30</td>
<td>Young ESPGHAN Committee Meeting</td>
<td>Santorini 3, Hilton</td>
</tr>
</tbody>
</table>

### Thursday, 26 May 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Meeting</th>
<th>Room Access</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 – 11:30</td>
<td>ESPGHAN Ethics Committee Meeting</td>
<td>Conference Suite 2, Megaron</td>
</tr>
<tr>
<td>12:30 – 15:30</td>
<td>ESPGHAN Nutrition Committee Meeting</td>
<td>Conference Suite 2, Megaron</td>
</tr>
<tr>
<td>14:15 – 15:15</td>
<td>ESPGHAN Publication Committee Meeting</td>
<td>Conference Suite 1, Megaron</td>
</tr>
<tr>
<td>17:15 – 18:15</td>
<td>ESPGHAN National Societies Meeting</td>
<td>MC 3.2, Megaron</td>
</tr>
<tr>
<td>18:45 – 19:45</td>
<td>ESPGHAN Past Presidents Meeting</td>
<td>Aegli Zappiou Restaurant</td>
</tr>
</tbody>
</table>

### Friday, 27 May 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Meeting</th>
<th>Room Access</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 10:30</td>
<td>ESPGHAN Gastroenterology Committee Meeting</td>
<td>Conference Suite 2, Megaron</td>
</tr>
<tr>
<td>11:00 – 12:45</td>
<td>ESPGHAN Public Affairs Committee Meeting</td>
<td>Conference Suite 2, Megaron</td>
</tr>
<tr>
<td>14:00 – 15:00</td>
<td>ESPGHAN Finance Committee Meeting</td>
<td>Conference Suite 1, Megaron</td>
</tr>
<tr>
<td>17:30 – 19:45</td>
<td>ESPGHAN Annual General Meeting</td>
<td>Room 2, Megaron</td>
</tr>
</tbody>
</table>

### Saturday, 28 May 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Meeting</th>
<th>Room Access</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30 – 12:00</td>
<td>E-Learning Editorial Board Meeting</td>
<td>Conference Suite 2, Megaron</td>
</tr>
</tbody>
</table>
For Members Only

**ESPGHAN Members & Young ESPGHAN Lounges**

**Location**: On the gallery overlooking the exhibition

**Date**: Open all day from Thursday, 26 May through Saturday, 28 May, 14:00

Join our comfortable area for young and senior members on the balcony overlooking the exhibition hall.

**Special activities at the Young ESPGHAN Lounge**

Members of the Young ESPGHAN Committee will be at the lounge to meet you and answer your questions about ongoing activities and voluntary involvement.

During the lunch break on **Thursday, 26 May 2016**, two interesting meetings are scheduled in the lounge, to which all Young and ESPGHAN members are invited:

**12:10 – 12:40**

Presentation of the **ESPGHAN Mentoring Programme**: Prof. Deirdre Kelly & Young ESPGHAN would like to share ideas on mentoring within ESPGHAN and are happy to receive your input!

**12:45 – 13:15**

Meet the President: an informal round table with the ESPGHAN President and the President Elect where subjects of interest to young members and all questions arising can be discussed.

*All ESPGHAN Members have access to the lounges – please present your badge at the entrance.*

**Members’ Evening**

**Location**: Balux Privée

B58, Vasileos Konstantinou, Glifada 166 74

**Date**: Friday, 27 May 2016, 20:30

**Cost**: 50 € per person

**Dress Code**: Casual

**Transfer**: 20:00 from Megaron Conference Centre

Return Transfer to Hilton Hotel from 23.00 onwards

Enjoy a summer night in one of Athens most trendy beach locations.

Cold drinks, delicious food, music and an entertaining surprise will make it an event to remember.

*Don’t forget to bring your ticket!*

*Please note that this event needs to be registered in advance and is for members only.*

**ESPGHAN Annual General Meeting**

**Location**: Room 2

**Date**: Friday, 27 May 2016

17:30 – 19:45

Registration and pre-session drinks from 17:00 onwards

www.espghancongress.org
### ESPGHAN Annual General Meeting  
(*Members Only*)

**Friday, 27 May 2016 · Megaron**  
17:30 – 19:45  
Room 2 (Level –1)

<table>
<thead>
<tr>
<th>Time</th>
<th>No.</th>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:30</td>
<td>1.</td>
<td><strong>President’s Welcome</strong></td>
<td>Berthold Koletzko</td>
</tr>
<tr>
<td></td>
<td>2.</td>
<td>Apologies for absence</td>
<td>Berthold Koletzko</td>
</tr>
<tr>
<td></td>
<td>3.</td>
<td>Notification of other business</td>
<td>Berthold Koletzko</td>
</tr>
<tr>
<td></td>
<td>4.</td>
<td><strong>Approval of AGM Minutes – Amsterdam 2015</strong></td>
<td>Berthold Koletzko</td>
</tr>
<tr>
<td>17:40</td>
<td>5.</td>
<td><strong>President’s Report</strong></td>
<td>Berthold Koletzko</td>
</tr>
<tr>
<td>18:00</td>
<td>6.</td>
<td><strong>Finances</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6.2</td>
<td>Budget Summary 2016</td>
<td>Alan Phillips</td>
</tr>
<tr>
<td></td>
<td>6.3</td>
<td>Membership Fees 2017</td>
<td>Alan Phillips</td>
</tr>
<tr>
<td>18:20</td>
<td>7.</td>
<td><strong>Proposed Changes to Constitution</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>7.1</td>
<td>Legal Status of ESPGHAN</td>
<td>Berthold Koletzko</td>
</tr>
<tr>
<td></td>
<td>7.2</td>
<td>Application for Membership – new dates</td>
<td>Gigi Veereman</td>
</tr>
<tr>
<td>18:45</td>
<td>8.</td>
<td><strong>New Members and Elections</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>8.1</td>
<td>2016_01 - New Members</td>
<td>Gigi Veereman</td>
</tr>
<tr>
<td></td>
<td>8.2</td>
<td>New Council Members</td>
<td>Gigi Veereman</td>
</tr>
<tr>
<td>18:50</td>
<td>9.</td>
<td><strong>Future Meetings</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>9.1</td>
<td>ESPGHAN 2017 – Prague</td>
<td>Jiri Bronsky</td>
</tr>
<tr>
<td></td>
<td>9.2</td>
<td>ESPGHAN 2018 – Geneva celebrating 50 years of ESPGHAN</td>
<td>Berthold Koletzko</td>
</tr>
<tr>
<td></td>
<td>9.3</td>
<td>ESPGHAN 2022 – Bidding</td>
<td>Berthold Koletzko</td>
</tr>
<tr>
<td>Time</td>
<td>No.</td>
<td>Topic</td>
<td>Chairs &amp; Representatives</td>
</tr>
<tr>
<td>-------</td>
<td>-------</td>
<td>--------------------------------------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>19:05</td>
<td>10.</td>
<td>Questions from the Members on Committee and Activity Reports</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10.1</td>
<td>Gastroenterology</td>
<td>Nikhil Thapar</td>
</tr>
<tr>
<td></td>
<td>10.2</td>
<td>Hepatology</td>
<td>Ulli Baumann</td>
</tr>
<tr>
<td></td>
<td>10.3</td>
<td>Nutrition</td>
<td>Mary Fewtrell</td>
</tr>
<tr>
<td></td>
<td>10.4</td>
<td>Young ESPGHAN</td>
<td>Nicolette Moes</td>
</tr>
<tr>
<td></td>
<td>10.5</td>
<td>Allied Health Professionals</td>
<td>Tena Niseteo</td>
</tr>
<tr>
<td></td>
<td>10.6</td>
<td>Public Affairs</td>
<td>Riccardo Troncone</td>
</tr>
<tr>
<td></td>
<td>10.7</td>
<td>Publication</td>
<td>Riccardo Troncone</td>
</tr>
<tr>
<td></td>
<td>10.8</td>
<td>International Affairs</td>
<td>Jernej Dolinsek</td>
</tr>
<tr>
<td></td>
<td>10.9</td>
<td>Ethics</td>
<td>Martin Burdelski</td>
</tr>
<tr>
<td></td>
<td>10.10</td>
<td>History</td>
<td>Lawrence Weaver</td>
</tr>
<tr>
<td></td>
<td>10.11</td>
<td>JPN</td>
<td>Hania Szajewska</td>
</tr>
<tr>
<td></td>
<td>10.12</td>
<td>Education</td>
<td>Gabor Veres</td>
</tr>
<tr>
<td></td>
<td>10.13</td>
<td>E-Learning</td>
<td>Tudor Pop</td>
</tr>
<tr>
<td>19:20</td>
<td>11.</td>
<td>Any other Business</td>
<td>Berthold Koletzko</td>
</tr>
<tr>
<td>19:40</td>
<td>12.</td>
<td>Thanks to Outgoing Council Members</td>
<td>Berthold Koletzko</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Alan Phillips, Treasurer</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ulli Baumann, Chair of Hepatology Committee</td>
<td></td>
</tr>
<tr>
<td>19:45</td>
<td>13.</td>
<td>Close of Meeting</td>
<td></td>
</tr>
</tbody>
</table>
### Venue: Hilton Athens

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 1</th>
<th>Session 2</th>
<th>Session 3</th>
<th>Session 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>In the first year after diagnosis...&lt;br&gt;Nutrition <em>(Combined session PG / AHP)</em>&lt;br&gt;<strong>PEDDCReN (Invite Only)</strong></td>
<td><strong>Coffee Break</strong></td>
<td><strong>Coffee Break</strong>&lt;br&gt;Ongoing <strong>Gastroenterology</strong>&lt;br&gt;<strong>Helicobacter Pylori Infection</strong>&lt;br&gt;<strong>Consensus on GI &amp; Nutritional Problem in Neurodisability (Invite Only)</strong></td>
<td><strong>Coffee Break</strong>&lt;br&gt;<strong>AHP AGM (Members Only)</strong>&lt;br&gt;<strong>Motility</strong>&lt;br&gt;<strong>Early Nutrition Research</strong>&lt;br&gt;<strong>COLORS in IBD</strong>&lt;br&gt;<strong>Coffee Break</strong>&lt;br&gt;Ongoing <strong>Hepatology</strong>&lt;br&gt;<strong>Clinical Cases Quiz</strong>&lt;br&gt;<strong>Multiple choice questions with online-voting</strong>&lt;br&gt;<strong>Coffee Break</strong>&lt;br&gt;<strong>Meet the JPGN Editors</strong>&lt;br&gt;<strong>ERN Rare Hepatic Disease</strong>&lt;br&gt;<strong>Guidelines on CD Diagnosis (Invite Only)</strong></td>
</tr>
</tbody>
</table>
### Programme Overview

**Wednesday, 25 May 2016**

#### Welcome Reception
- **Time:** 18:30
- **Location:** Hilton Athens · Pool Area
- **Details:** Ticket Required

#### Working Groups (Members Only)

<table>
<thead>
<tr>
<th>Santorini 3</th>
<th>Erato A</th>
<th>Erato B</th>
<th>Erato C</th>
<th>Terpsichore C</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>International Registry of Porto Systemic Shunts</strong></td>
<td><strong>Wilson’s Disease</strong></td>
<td><strong>Prevent CD Progress Meeting (Invite Only)</strong></td>
<td><strong>EPaedGHAN</strong></td>
<td><strong>Eosinophilic Esophagitis</strong></td>
</tr>
<tr>
<td><strong>GIGOLO: Graft Injury after LTx (Invite Only)</strong></td>
<td><strong>Paediatric Polyposis</strong></td>
<td><strong>Clinical Malnutrition</strong></td>
<td><strong>History of ESPGHAN</strong></td>
<td><strong>Outcomes in Nutrition Trials (Invite Only)</strong></td>
</tr>
<tr>
<td><strong>Esophageal Atresia</strong></td>
<td><strong>Special Interest Group: Coeliac Disease</strong></td>
<td><strong>Pre and Probiotics I</strong></td>
<td><strong>GENIUS</strong></td>
<td><strong>NAFLD</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Coffee Break</strong></td>
<td><strong>Pre and Probiotics II (Invite Only)</strong></td>
<td><strong>Coffee Break</strong></td>
<td><strong>Cystic Fibrosis and Pancreatic Disease</strong></td>
<td><strong>Coffee Break</strong></td>
</tr>
<tr>
<td><strong>NITE</strong></td>
<td><strong>Special Interest Group: Endoscopy</strong></td>
<td><strong>IBD Interest and Porto Group Annual Meeting</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*see page 35–39*

---

**18:30 Welcome Reception (Ticket Required)** · Hilton Athens · Pool Area
### IBD Course

#### Session 1: In the first year after diagnosis...

**Chairs** Dan Turner, Israel · Christos Tzivinikos, United Kingdom

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>Chair’s introduction</td>
<td>Dan Turner, Israel · Christos Tzivinikos, United Kingdom</td>
</tr>
<tr>
<td>08:05</td>
<td>What should we be doing at diagnosis?</td>
<td>Sibylle Koletzko, Germany</td>
</tr>
<tr>
<td>08:30</td>
<td>To what degree do immunomodulators and biologics actually change the natural history of the disease?</td>
<td>Anne Griffiths, Canada</td>
</tr>
<tr>
<td>09:00</td>
<td>Risk stratification in Crohn’s and UC: how to select children for biologics upon diagnosis</td>
<td>Johanna Escher, The Netherlands</td>
</tr>
</tbody>
</table>

09:30 – 10:00 Coffee Break

#### Session 2: And for the long term...

**Chairs** Alexandra Papadopoulou, Greece · Javier Martin de Carpi, Spain

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>Goals of treatment in Crohn's disease and UC - how far should we go?</td>
<td>Paolo Lionetti, Italy</td>
</tr>
<tr>
<td>10:30</td>
<td>Tandem talk: Know the risks with immunomodulators and anti-TNF: malignancy</td>
<td>Gerassimos Mantzaris, Greece</td>
</tr>
<tr>
<td>10:45</td>
<td>Tandem talk: Know the risks with immunomodulators and anti-TNF: infections</td>
<td>George Chouliaras, Greece</td>
</tr>
</tbody>
</table>
### Session 3: Complicated disease course

**Chairs**  Paolo Lionetti, Italy · Lissy de Ridder, The Netherlands

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>Managing fistulizing and stricturing disease (excluding perianal)</td>
<td>Nicholas Croft, United Kingdom</td>
</tr>
<tr>
<td>11:30</td>
<td>Early onset IBD and &gt;50 genes: What have we learnt from whole exome sequencing?</td>
<td>Frank Ruemmele, France</td>
</tr>
</tbody>
</table>

**Lunch Break**

### Session 4: IBD specialist topics

**Chairs**  Paolo Lionetti, Italy · Lissy de Ridder, The Netherlands

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00</td>
<td>Enteral Nutrition – tricks of trade</td>
<td>Lissy de Ridder, The Netherlands</td>
</tr>
<tr>
<td>13:30</td>
<td>Acute severe UC in children – a case based discussion with online-voting</td>
<td>David Wilson, United Kingdom</td>
</tr>
<tr>
<td>14:00</td>
<td>Methotrexate versus thiopurines: time to choose?</td>
<td>Javier Martin de Carpi, Spain</td>
</tr>
</tbody>
</table>

**Coffee Break**
### Session 5: Difficult cases – session interactive with an expert panel and online-voting

**Chairs**

Anne Griffiths, Canada  
Hania Szajewska, Poland  
Mel Heyman, USA

**Panel Experts**

Athos Bousvaros, USA  
John Papaconstantinou, Greece

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00</td>
<td>How to manage perianal fistulas in Crohn’s disease - A case based discussion</td>
<td>Alexandra Papadopoulou, Greece</td>
</tr>
<tr>
<td>15:30</td>
<td>Fistulizing and strictureing Crohn’s disease (excluding perianal) - A case based discussion</td>
<td>Christos Tzivinikos, United Kingdom</td>
</tr>
<tr>
<td>16:00</td>
<td>Relapsing and refractory UC - A case based discussion</td>
<td>Dan Turner, Israel</td>
</tr>
</tbody>
</table>

### Meet the JPGN Editors

**Chairs**

Hania Szajewska, Poland  
Mel Heyman, USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30</td>
<td>How to get your paper published? Writing a successful manuscript.</td>
<td>Hania Szajewska, Poland</td>
</tr>
<tr>
<td>16:45</td>
<td>What are the editor’s criteria for good manuscript?</td>
<td>Mel Heyman, USA</td>
</tr>
<tr>
<td>17:00</td>
<td>The peer-review publication process. How can you contribute to peer review?</td>
<td>Lorenzo D’Antiga, Italy</td>
</tr>
<tr>
<td>17:15</td>
<td>Presenting data optimally</td>
<td>Hans van Goudoever, The Netherlands</td>
</tr>
<tr>
<td>17:30</td>
<td>Publication ethics</td>
<td>Michael Lentze, Germany</td>
</tr>
<tr>
<td>17:45</td>
<td>FAQ. Informal discussion with the audience</td>
<td>Hania Szajewska, Poland · Mel Heyman, USA</td>
</tr>
</tbody>
</table>
## Session 1: Nutrition *(combined session with AHP)*

**Chairs**  Thomais Karagiozoglou-Lampoudi, Greece · Nataša Fidler Mis, Slovenia

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>Welcome Message</td>
<td>Ioanna Panayotou</td>
<td>Greece</td>
</tr>
<tr>
<td>08:00</td>
<td>Recognizing trace element and vitamin deficiencies</td>
<td>Konstantinos Gerasimidis</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>08:30</td>
<td>Diagnosis and management of infantile feeding disorders and food refusal</td>
<td>Arie Levine</td>
<td>Israel</td>
</tr>
<tr>
<td>09:00</td>
<td>Indications and clinical aspects of tube feeding</td>
<td>Rosan Meyer</td>
<td>United Kingdom</td>
</tr>
</tbody>
</table>

09:30 – 10:00 Coffee Break

## Session 2: Gastroenterology

**Chairs**  Maria Fotoulaki, Greece · Panayota Kafritsa, Greece

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>Cyclic vomiting</td>
<td>Keith Lindley</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>10:30</td>
<td>Acute recurrent pancreatitis - what is new?</td>
<td>Michael Wilschanski</td>
<td>Israel</td>
</tr>
<tr>
<td>11:00</td>
<td>Coeliac disease mimics</td>
<td>Luigi Greco</td>
<td>Italy</td>
</tr>
<tr>
<td>11:30</td>
<td>IBD masquerades</td>
<td>Athos Bousvaros</td>
<td>USA</td>
</tr>
</tbody>
</table>

12:00 – 13:00 Lunch Break
### Session 3: Hepatology

**Chairs** Ioanna Panayotou, Greece · Aglaia Zellos, Greece

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00</td>
<td>Persistently elevated transaminases</td>
<td>Alastair Baker</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>13:30</td>
<td>Sclerosing cholangitis</td>
<td>Florence Lacaille</td>
<td>France</td>
</tr>
<tr>
<td>14:00</td>
<td>Novelties in paediatric liver transplantation</td>
<td>Andreas Tzakis</td>
<td>USA</td>
</tr>
</tbody>
</table>

14:30 – 15:00  Coffee Break

### Session 4: Clinical Cases Quiz

**Chairs** Eleftheria Roma, Greece · Stavroula Karyda, Greece

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00</td>
<td>Gastro case</td>
<td>Panayota Kafritsa</td>
<td>Greece</td>
</tr>
<tr>
<td>15:20</td>
<td>Nutrition case</td>
<td>Konstantina Dimakou</td>
<td>Greece</td>
</tr>
<tr>
<td>15:40</td>
<td>Liver case</td>
<td>Constantinos Siafakas</td>
<td>Greece</td>
</tr>
</tbody>
</table>

### Session 5: Multiple choice questions with online-voting

**Chairs** Constantinos Siafakas, Greece · Theodoros Ziambaras, Greece

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00</td>
<td>Multiple choice questions with online-voting</td>
<td>Ioanna Panayotou</td>
<td>Greece</td>
</tr>
<tr>
<td>16:30</td>
<td>Closing Remarks</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## AHP Course

### 08:00 – 09:30  Terpsichore A (Hilton Athens)

### Session 1: Nutrition *(combined session with PG)*

**Chairs**  Thomais Karagiozoglou-Lampoudi, Greece · Nataša Fidler Mis, Slovenia

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>Welcome Message</td>
<td>Ioanna Panayotou, Greece</td>
</tr>
<tr>
<td>08:00</td>
<td>Recognizing trace element and vitamin deficiencies</td>
<td>Konstantinos Gerasimidis,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>United Kingdom</td>
</tr>
<tr>
<td>08:30</td>
<td>Diagnosis and management of infantile feeding disorders and food refusal</td>
<td>Arie Levine, Israel</td>
</tr>
<tr>
<td>09:00</td>
<td>Indications and clinical aspects of tube feeding</td>
<td>Rosan Meyer, United Kingdom</td>
</tr>
</tbody>
</table>

09:30 – 10:00 Coffee Break

### 10:00 – 12:00  Terpsichore B (Hilton Athens)

### Session 2: Gastroenterology

**Chairs**  Sarah Macdonald, United Kingdom · Tena Niseteo, Croatia

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>Can we prevent coeliac disease?</td>
<td>Katharina Werkstetter,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Germany</td>
</tr>
<tr>
<td>10:30</td>
<td>Improving experience and satisfaction of children and parents undergoing endoscopy procedures</td>
<td>Claire Barnes, United Kingdom</td>
</tr>
<tr>
<td>11:00</td>
<td>Problems and pitfalls with the GF diet - how are we doing?</td>
<td>Elaine Buchanan, United Kingdom</td>
</tr>
<tr>
<td>11:30</td>
<td>Improving dietary compliance</td>
<td>Evangelia Koliass, Greece</td>
</tr>
</tbody>
</table>

12:00 – 13:00 Lunch Break

*All presentations are supposed to include adequate times for discussion*
### Session 3: Selected Oral Abstract Presentations

**Chair:** Janusz Ksiazyk, Poland

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00</td>
<td>Predictors of non-compliance to a gluten free diet in coeliac disease - a tertiary centre experience</td>
<td>Betina Lorentzen, United Kingdom</td>
</tr>
<tr>
<td>13:10</td>
<td>Reducing the maternal dietary intake of indigestible and slowly absorbed short-chain carbohydrates is associated with improved infantile colic: a pilot study</td>
<td>Marina Iacovou, Australia</td>
</tr>
<tr>
<td>13:20</td>
<td>Effects of postnatal overfeeding and ω3PUFAs diet on hepatic ACC in rats</td>
<td>Nan Zhou, China</td>
</tr>
<tr>
<td>13:30</td>
<td>Early induction with Infliximab in Paediatric Crohn’s disease is associated with sustained primary response with less frequent need for dose intensification</td>
<td>Jessica Ling, Australia</td>
</tr>
<tr>
<td>13:40</td>
<td>Mucosa-associated ileal microbiota in new-onset pediatric Crohn’s disease</td>
<td>Amit Assa, Israel</td>
</tr>
<tr>
<td>13:50</td>
<td>Lower the threshold, a study of normal reference values of PH-Impedance in children</td>
<td>Taha Yousif, United Kingdom</td>
</tr>
</tbody>
</table>

### Session 4: Hepatology

**Chairs:** Brigitte Kochavi, Israel · Irena Jankowska, Poland

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:45</td>
<td>Parenteral nutrition and the liver</td>
<td>Jonathan Hind, United Kingdom</td>
</tr>
<tr>
<td>15:15</td>
<td>Prescribing parenteral nutrition – how to prevent liver disease</td>
<td>Maria Skouroliakou, Greece</td>
</tr>
<tr>
<td>15:45</td>
<td>Management of home parenteral nutrition</td>
<td>Gordana Bukovina, Croatia</td>
</tr>
</tbody>
</table>
## Working Groups *(Members Only)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 – 10:30</td>
<td>Santorini 2</td>
<td>PEDDCCReN: Paediatric European Digestive Diseases Clinical Research Network <em>(Invite Only)</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chair Nicholas Croft, United Kingdom</td>
</tr>
<tr>
<td>09:00 – 10:30</td>
<td>Santorini 3</td>
<td>International Registry of Porto Systemic Shunts</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chair Valérie McLin, Switzerland</td>
</tr>
<tr>
<td>09:00 – 10:30</td>
<td>Erato A</td>
<td>Wilson’s Disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chair Piotr Socha, Poland</td>
</tr>
<tr>
<td>09:00 – 12:00</td>
<td>Erato B</td>
<td>Prevent CD Progress Meeting <em>(Invite Only)</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chair Luisa Mearin, The Netherlands</td>
</tr>
<tr>
<td>09:00 – 10:30</td>
<td>Erato C</td>
<td>EPaedGHAN: Epigenetics in Paediatric Gastroenterology, Hepatology and Nutrition</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chair Andreas Jenke, Germany</td>
</tr>
<tr>
<td>09:00 – 11:00</td>
<td>Terpsichore C</td>
<td>Eosinophilic Esophagitis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chair Jorge Amil Dias, Portugal</td>
</tr>
</tbody>
</table>

10:30 – 11:00 Coffee Break
Wednesday, 25 May 2016 · Hilton Athens

11:00 – 12:30  **Santorini 1** (Hilton Athens)

**Helicobacter Pylori Infection**

Chair  Sibylle Koletzko, Germany

11:00 – 13:30  **Santorini 2** (Hilton Athens)

**Consensus on GI & Nutritional Problem in Neurodisability (Invite Only)**

Chair  Frédéric Gottrand, France

11:00 – 13:00  **Santorini 3** (Hilton Athens)

**GIGOLO: Graft Injury after LTx (Invite Only)**

Chair  Deirdre Kelly, United Kingdom

11:00 – 12:30  **Erato A** (Hilton Athens)

**Paediatric Polyposis**

Chair  Warren Hyer, United Kingdom

11:00 – 12:00  **Erato C** (Hilton Athens)

**Clinical Malnutrition**

Chair  Jessie Hulst, The Netherlands

11:00 – 12:30  **Terpsichore C** (Hilton Athens)

**History of ESPGHAN**

Chair  Lawrence Weaver, United Kingdom

12:00 – 13:00  **Erato B** (Hilton Athens)

**Outcomes in Nutrition Trials (Invite Only)**

Chair  Hania Szajewska, Poland
<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Topic</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 – 13:00</td>
<td>Erato C (Hilton</td>
<td>Malnutrition Study (<em>Invite Only</em>)</td>
<td>Jessie Hulst, The Netherlands</td>
</tr>
<tr>
<td></td>
<td>Athens)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30 – 13:30</td>
<td>Santorini 1</td>
<td>COLORS in IBD</td>
<td>Holm Uhlig, United Kingdom</td>
</tr>
<tr>
<td></td>
<td>(Hilton Athens)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00 – 14:00</td>
<td></td>
<td>Lunch Break</td>
<td></td>
</tr>
<tr>
<td>14:00 – 15:30</td>
<td>Santorini 1</td>
<td>Motility</td>
<td>Annamaria Staiano, Italy</td>
</tr>
<tr>
<td></td>
<td>(Hilton Athens)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00 – 16:00</td>
<td>Santorini 2</td>
<td>Early Nutrition Research</td>
<td>Berthold Koletzko, Germany</td>
</tr>
<tr>
<td></td>
<td>(Hilton Athens)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00 – 15:30</td>
<td>Santorini 3</td>
<td>Esophageal Atresia</td>
<td>Frédéric Gottrand, France</td>
</tr>
<tr>
<td></td>
<td>(Hilton Athens)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00 – 16:00</td>
<td>Erato A (Hilton</td>
<td>Special Interest Group: Coeliac Disease</td>
<td>Steffen Husby, Denmark</td>
</tr>
<tr>
<td></td>
<td>Athens)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00 – 15:00</td>
<td>Erato B (Hilton</td>
<td>Pre and Probiotics I</td>
<td>Hania Szajewska, Poland · Zvi Weizman, Israel</td>
</tr>
<tr>
<td></td>
<td>Athens)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Wednesday, 25 May 2016 · Hilton Athens**

<table>
<thead>
<tr>
<th>Time</th>
<th>Venue</th>
<th>Event</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 – 15:30</td>
<td>Erato C (Hilton Athens)</td>
<td>GENIUS: Genetically Determined Immune-Mediated Enteropathies</td>
<td>Frank Ruemmele, France</td>
</tr>
<tr>
<td>14:00 – 15:00</td>
<td>Terpsichore C (Hilton Athens)</td>
<td>NAFLD: Non-alcoholic fatty liver disease</td>
<td>Piotr Socha, Poland</td>
</tr>
<tr>
<td>15:00 – 16:00</td>
<td>Erato B (Hilton Athens)</td>
<td>Pre and Probiotics II (<em>Invite Only</em>)</td>
<td>Hania Szajewska, Poland · Zvi Weizman, Israel</td>
</tr>
<tr>
<td>15:00 – 16:00</td>
<td>Terpsichore C (Hilton Athens)</td>
<td>Transition</td>
<td>Pietro Vajro, Italy</td>
</tr>
<tr>
<td>16:00 – 18:00</td>
<td>Santorini 1 (Hilton Athens)</td>
<td>European Reference Network Rare Hepatic Disease</td>
<td>Ekkehard Sturm, Germany</td>
</tr>
</tbody>
</table>

**ESPGHAN 49th Annual Meeting**
<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>16:30 – 18:00</strong></td>
<td><strong>Santorini 2</strong> (Hilton Athens)</td>
<td>Guidelines on Coeliac Disease Diagnosis <em>(Invite Only)</em></td>
</tr>
<tr>
<td>Chair</td>
<td>Steffen Husby, Denmark</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>16:30 – 17:30</strong></td>
<td><strong>Erato A</strong> (Hilton Athens)</td>
<td>NITE: Nutrition, Intestinal Failure and Small Bowel Transplantation Network Europe</td>
</tr>
<tr>
<td>Chair</td>
<td>Jutta Koeglmeier, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>16:30 – 18:00</strong></td>
<td><strong>Terpsichore C</strong> (Hilton Athens)</td>
<td>IBD Interest and Porto Group Annual Meeting</td>
</tr>
<tr>
<td>Chair</td>
<td>Dan Turner, Israel</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>17:30 – 18:30</strong></td>
<td><strong>Erato B</strong> (Hilton Athens)</td>
<td>Special Interest Group: Endoscopy</td>
</tr>
<tr>
<td>Chair</td>
<td>Mike Thomson, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>07:00 – 08:30</strong></td>
<td><strong>Room 3</strong> (Megaron)</td>
<td>Hepatology Interest Group</td>
</tr>
<tr>
<td>Chair</td>
<td>Ulrich Baumann, Germany</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>14:00 – 17:00</strong></td>
<td><strong>Santorini 2</strong> (Hilton Athens)</td>
<td>Porto Group: A Position Paper on Nutrition in Paediatric IBD <em>(Invite Only)</em></td>
</tr>
<tr>
<td>Chair</td>
<td>Dan Turner, Israel</td>
<td></td>
</tr>
</tbody>
</table>
## Venue **Megaron Athens**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room 1</th>
<th>Room 2</th>
<th>Room 3</th>
<th>Room 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td></td>
<td>Hepatology Interest Group <em>(Members Only)</em></td>
<td>Breakfast Symposium</td>
<td>see page 42</td>
</tr>
<tr>
<td>07:30</td>
<td></td>
<td></td>
<td></td>
<td>see page 129</td>
</tr>
<tr>
<td>08:45</td>
<td>Opening Session</td>
<td>see page 42</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td>State of the Art Lecture</td>
<td>see page 42</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td>Plenary Session - Highest Scoring Abstracts</td>
<td>see page 43</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>Keynote Lecture: Hepatology</td>
<td>see page 44</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td>Lunch Break</td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td>Lunchtime Symposium</td>
<td>see page 129</td>
<td></td>
</tr>
<tr>
<td>14:15</td>
<td>When anti-TNF fails?</td>
<td>see page 45</td>
<td>Liver transplantation</td>
<td>see page 45</td>
</tr>
<tr>
<td>16:15</td>
<td></td>
<td></td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>16:45</td>
<td>Clinical Practice in Hepatology</td>
<td>see page 47</td>
<td>Hepatology Parallel Session 1</td>
<td>see page 47</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Gastroenterology Parallel Session 2</td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Location</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>----------------------------------------------------------------------</td>
<td>----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:00</td>
<td>Hepatology Interest Group (Members Only)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:30</td>
<td>Breakfast Symposium</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clinical Cases: Nutrition 1</td>
<td>Room 5</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clinical Cases: Nutrition 2</td>
<td>Room 6</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 42</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 42</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:45</td>
<td>Opening Session</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 42</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td>State of the Art Lecture</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 42</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 42</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>Plenary Session - Highest Scoring Abstracts</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 43</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>Keynote Lecture: Hepatology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 44</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>Lunch Break</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lunchtime Symposium</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 46</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 130</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Short bowel syndrome</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Controversies in paediatric PN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 46</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 46</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:15</td>
<td>When anti-TNF fails?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Liver transplantation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Short bowel syndrome</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>controversies in paediatric PN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:15</td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 48</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:45</td>
<td>Clinical Practice in Hepatology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Parallel Session 1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gastroenterology</td>
<td>Room 5</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nutrition Parallel Session 1</td>
<td>Room 6</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 48</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 49</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Evening Symposium</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 132</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td>Evening Symposium</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 132</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Room</td>
<td>Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>------------</td>
<td>--------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:00 – 08:30</td>
<td>Room 3</td>
<td>Hepatology Interest Group (<em>Members Only</em>)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chair: Ulrich Baumann, Germany</td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:30 – 08:30</td>
<td>Room 4</td>
<td>Breakfast Symposium</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Industry sponsored &gt; Details on page 129</td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:30 – 08:30</td>
<td>MC 3.2</td>
<td>Clinical Cases: Nutrition 1 (<em>Ticket Required</em>)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 07:30       |            | *A neurologically compromised child: the choice of nutrition support*  
|             |            | Thomais Karagiozoglou-Lampoudi, Greece      |
| 07:30 – 08:30 | MC 3.4     | Clinical Cases: Nutrition 2 (*Ticket Required*) |
| 07:30       |            | *Assessment of malnutrition in a child with Crohn’s disease*  
|             |            | Konstantinos Gerasimidis, United Kingdom    |
| 08:45 – 09:30 | Room 1     | Opening Session                            |
| 09:30 – 10:00 | Room 1     | State of the Art Lecture                   |
| 09:30       |            | *The secret pathways from stress to inflammation*  
|             |            | George Chrousos, Greece                    |
### Plenary Session – Highest Scoring Abstracts

**Chairs** Berthold Koletzko, Germany · Eleftheria Roma, Greece

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td>G-O-004</td>
<td>Investigating the metabolic fingerprint of Celiac Disease – a prospective approach in the PreventCD cohort</td>
<td>Franca Kirchberg, Germany</td>
</tr>
<tr>
<td>10:40</td>
<td>G-O-005</td>
<td>Natural history of tissue transglutaminase autoantibodies in the TEDDY cohort</td>
<td>Satu Simell, Finland</td>
</tr>
<tr>
<td>10:50</td>
<td>H-O-002</td>
<td>Neonatal sclerosing cholangitis; a liver ciliopathy</td>
<td>Tassos Grammatikopoulos, United Kingdom</td>
</tr>
<tr>
<td>11:00</td>
<td>N-O-003</td>
<td>Effect of fermented milk with Lactobacillus paracasei CBA L74 on gastrointestinal and respiratory infections in children: multicenter randomized controlled trial</td>
<td>Roberto Berni Canani, Italy</td>
</tr>
<tr>
<td>11:10</td>
<td>G-O-006</td>
<td>Oats in the Diet of Children with Celiac Disease: a Double-Blind, Randomized, Placebo-Controlled Multicenter Trial</td>
<td>Elena Lionetti, Italy</td>
</tr>
<tr>
<td>11:20</td>
<td>G-O-007</td>
<td>The Impact of “Crohn’s Disease-TReatment-with-EATing” Diet (CD-TREAT Diet) and Exclusive Enteral Nutrition on Healthy Gut Bacteria</td>
<td>Vaios Svolos, United Kingdom</td>
</tr>
<tr>
<td>11:30</td>
<td>H-O-003</td>
<td>Common variant p.D19H of the hepatobiliary sterol transporter ABCG5/8 increases the risk of gallstone disease in children</td>
<td>Marcin Krawczyk, Germany</td>
</tr>
<tr>
<td>11:40</td>
<td>N-O-004</td>
<td>Children with eating disorders secondarily to artificial nutrition in the neonatal period have specific food preferences and saliva composition</td>
<td>Noel Peretti, France</td>
</tr>
</tbody>
</table>

All presentations are supposed to include adequate times for discussion

---

**Chlorological Programme**

- **10:00 – 10:30** Coffee Break
- **10:00 – 12:30** ELZ / MLZ (Level –1)
- **10:00 – 12:00** Room 1 (Level 0)

> Details on page 121

Thursday 26 May 2016

www.espgghancongress.org
### Keynote Lecture: Hepatology

**Chair** Ulrich Baumann, Germany

**12:00 – 12:30 Room 1 (Level 0)**

*The future of multivisceral transplantation*  
Andreas Tzakis, USA

---

**12:30 – 14:15 Lunch Break**

---

### Lunchtime Symposium

**13:00 – 14:00 Room 2 (Level -1)**

**Industry sponsored > Details on page 129**

---

**13:00 – 14:00 Room 5 (Level 1)**

**Industry sponsored > Details on page 130**

---

**13:00 – 14:00 Room 6 (Level 0)**

**Industry sponsored > Details on page 130**

---

### ELZ Session 2 + MLZ Session 2 (*Ticket Required*)

**14:00 – 16:30 ELZ / MLZ (Level -1)**

*Details on page 121*
### Parallel Symposium: When anti-TNF fails?

**Chairs** Genevieve Veereman, Belgium · Jorge Amil Dias, Portugal

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:15</td>
<td>The future is here: vedolizumab, ustekinumab and thalidomide in practice</td>
<td>Athos Bousvaros, USA</td>
</tr>
<tr>
<td>14:40</td>
<td>The availability of calcineurin inhibitors and infliximab in acute severe colitis have reduced colectomy rates in 283 children admitted during 1990-2012</td>
<td>Dan Turner, Israel</td>
</tr>
<tr>
<td>14:50</td>
<td>The environment and IBD: what can we alter to treat and avoid the disease</td>
<td>Eytan Wine, Canada</td>
</tr>
<tr>
<td>15:15</td>
<td>Early immunization and increased risk of serious adverse events during Infliximab mono- versus combotherapy.</td>
<td>Bénédicte Pigneur, France</td>
</tr>
<tr>
<td>15:25</td>
<td>Preventing post-operative recurrence in Crohn’s disease: when to scope and when to introduce anti TNF?</td>
<td>Paolo Lionetti, Italy</td>
</tr>
<tr>
<td>15:50</td>
<td>When anti TNF’s are only partially effective</td>
<td>Frank Ruemmele, France</td>
</tr>
</tbody>
</table>

### Parallel Symposium: Liver transplantation

**Chairs** Björn Fischler, Sweden · Nedim Hadzic, United Kingdom

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:15</td>
<td>Immune dysregulation after liver transplantation</td>
<td>Francoise Smets, Belgium</td>
</tr>
<tr>
<td>14:40</td>
<td>Liver transplantation for young people with biliary atresia and academic outcome of long-term survivors</td>
<td>Vandana Jain, United Kingdom</td>
</tr>
<tr>
<td>14:50</td>
<td>What are the contraindications to paediatric liver transplantation?</td>
<td>Martin Burdelski, Saudi Arabia</td>
</tr>
<tr>
<td>15:15</td>
<td>Serum autoantibodies are associated with chronic hepatitis and graft fibrosis after pediatric liver transplantation</td>
<td>Jeremy Rajanayagam, United Kingdom</td>
</tr>
<tr>
<td>15:25</td>
<td>Withdrawal of immunosuppression after liver transplantation</td>
<td>Sandy Feng, USA</td>
</tr>
<tr>
<td>15:50</td>
<td>Assessing children for combined liver and kidney transplantation</td>
<td>Marianne Samyn, United Kingdom</td>
</tr>
</tbody>
</table>
## Parallel Symposium: Short bowel syndrome

**Chairs** Frédéric Gottrand, France · Ioanna Panayotou, Greece

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:15</td>
<td>How to promote intestinal adaptation?</td>
<td>Laura Merras-Salmio, Finland</td>
</tr>
<tr>
<td>14:40</td>
<td>Early detection of necrotizing enterocolitis and late onset sepsis by intestinal microbiota analysis</td>
<td>Tim de Meij, The Netherlands</td>
</tr>
<tr>
<td>14:50</td>
<td>Metabolic consequences and their management</td>
<td>Susan Hill, United Kingdom</td>
</tr>
<tr>
<td>15:15</td>
<td>Safety and tolerability of teduglutide in the treatment of short bowel syndrome in children</td>
<td>Susan Hill, United Kingdom</td>
</tr>
<tr>
<td>15:25</td>
<td>Diagnosis and management of anastomotic ulcers and Crohns like disease</td>
<td>Jean-Pierre Hugot, France</td>
</tr>
<tr>
<td>15:50</td>
<td>The role of surgeon in SBS</td>
<td>Antonino Morabito, United Kingdom</td>
</tr>
</tbody>
</table>

## Parallel Symposium: Controversies in paediatric PN

**Chairs** Jessie Hulst, The Netherlands · Hans van Goudoever, The Netherlands

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:15</td>
<td>Venous access</td>
<td>Iva Hojsak, Croatia</td>
</tr>
<tr>
<td>14:40</td>
<td>Soluble mediators from Lactobacillus rhamnosus GG improve intestinal barrier function in a rat model of short bowel syndrome</td>
<td>Jiang Wu, China</td>
</tr>
<tr>
<td>14:50</td>
<td>Lipid emulsions</td>
<td>Alexandre Lapillonne, France</td>
</tr>
<tr>
<td>15:15</td>
<td>Maternal high dietary linoleic acid during gestation and lactation impairs rat offspring gut and metabolic homeostasis.</td>
<td>Gaelle Boudry, France</td>
</tr>
<tr>
<td>15:25</td>
<td>Early vs late PN for critically ill children (results from the PEPANIC trial)</td>
<td>Koen Joosten, The Netherlands</td>
</tr>
<tr>
<td>15:50</td>
<td>Iodine in PN</td>
<td>Fiona Williams, United Kingdom</td>
</tr>
</tbody>
</table>
### Chronological Programme

**16:15 – 16:45** Coffee Break

**16:45 – 17:45** Room 1 (Level 0)

**Clinical Practice in Hepatology**

**Chairs** Piotr Socha, Poland · Thomas Casswall, Sweden

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:45</td>
<td>H-O-006</td>
<td>Pediatric CLIF-SOFA score is the best predictor of 28-day mortality</td>
<td>Rishi Bolia</td>
<td>India</td>
</tr>
<tr>
<td></td>
<td></td>
<td>in children with decompensated chronic liver disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:55</td>
<td>H-O-007</td>
<td>Chronic liver disease in young people; what has mental health got to</td>
<td>Anna Hames</td>
<td>United Kingdom</td>
</tr>
<tr>
<td></td>
<td></td>
<td>do with it?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:05</td>
<td>H-O-008</td>
<td>Long-term outcome of juvenile autoimmune liver disease: what has</td>
<td>Angelo Di Giorgio</td>
<td>United Kingdom</td>
</tr>
<tr>
<td></td>
<td></td>
<td>changed since 1997?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:15</td>
<td>H-O-009</td>
<td>Diagnosis of monogenetic metabolic hepatopathies in children by</td>
<td>Amelie Stalke</td>
<td>Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td>next generation sequencing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:25</td>
<td>H-O-010</td>
<td>Clinical, histopathological and molecular genetics of children in</td>
<td>Abdulrahman Al-Hussaini</td>
<td>Saudi Arabia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>with inborn errors of bile acid synthesis and liver disease: results</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>from an eight years prospective study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:35</td>
<td>H-O-011</td>
<td>Mitochondrial nuclear gene mutations in aetiology of acute liver</td>
<td>Nik Nazimah Nik Mahmood</td>
<td>United Kingdom</td>
</tr>
<tr>
<td></td>
<td></td>
<td>failure of infancy</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**All presentations are supposed to include adequate times for discussion**

Thursday 26 May 2016

www.espghancongress.org

47
### Gastroenterology Parallel Session 2

**Chairs**
Rok Orel, Slovenia · Javier Martin de Carpi, Spain

16:45 **G-O-012** Reference values of fecal calgranulin C (S100A12) in school aged children and teenagers  
Anke Heida, The Netherlands

16:55 **G-O-013** A prospective 24-week mucosal healing and deep remission assessment of small bowel and colonic Crohn's Disease as detected by colon capsule endoscopy  
Salvatore Oliva, Italy

17:05 **G-O-014** Utility of proposed modified simple endoscopic score in upper gastrointestinal Crohn’s Disease  
Oren Ledder, Israel

17:15 **G-O-015** Validation of small intestine digital histomorphometry for celiac disease  
Alina Popp, Romania

17:25 **G-O-016** A noninvasive follow-up of pediatric ulcerative colitis by using colon capsule endoscopy and ultrasonography  
Salvatore Oliva, Italy

17:35 **G-O-017** Brain responses to uncertainty about upcoming visceral pain in quiescent Crohn’s disease – a fMRI study  
Amandine Rubio, France

### Gastroenterology Parallel Session 1

**Chairs**
Paolo Lionetti, Italy · George Chouliaras, Greece

16:45 **G-O-018** Genetic polymorphism in cannabinoid receptor 2 contributes to the risk of pediatric IBD  
Caterina Strisciuglio, Italy

16:55 **G-O-019** Cyclic enteral nutrition for the maintenance of remission in pediatric Crohn’s Disease patients  
Sara Nóbrega, France

17:05 **G-O-020** Enteral nutrients delay onset, reduce severity and promote recovery of induced colitis via calcium-sensing receptor  
Sam Cheng, USA

17:15 **G-O-021** Complications and disease recurrence after primary ileocecal resection in pediatric Crohn’s disease: a multicenter cohort analysis  
Marc Benninga, The Netherlands

17:25 **G-O-022** Rapid infliximab infusion in children: a multicenter cohort study  
Raffi Lev-Tzion, Israel

17:35 **G-O-023** New trends in biologic use in paediatric IBD in the UK: significantly less co-immunosuppression, milder disease and more patients!  
Rafeeq Muhammed, United Kingdom
# Nutrition Parallel Session 1

**Chair**  
Staffan Berglund, Sweden

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Code</th>
<th>Title</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:45</td>
<td>N-O-007</td>
<td>Probiotic supplementation in VLBW preterm infants improves feeding tolerance and reduces risk of gram negative sepsis</td>
<td>Deepa Hariharan, India</td>
</tr>
<tr>
<td>16:55</td>
<td>N-O-008</td>
<td>Dairy lipids in infant formula: impact on the Omega-3 fatty acid content in membrane phospholipids of red blood cells in healthy term infants</td>
<td>Charlotte Baudry, France</td>
</tr>
<tr>
<td>17:05</td>
<td>N-O-009</td>
<td>Delayed vs early cord clamping in small for gestational age infants &gt;35 weeks gestation: a randomized controlled trial</td>
<td>Abhisek Chopra, India</td>
</tr>
<tr>
<td>17:15</td>
<td>N-O-010</td>
<td>A partly fermented infant formula containing scGOS/lcFOS supports adequate growth in healthy, term infants: the life study</td>
<td>Alfonso Rodriguez-Herrera, Spain</td>
</tr>
<tr>
<td>17:25</td>
<td>N-O-011</td>
<td>Plasma metabolome in infants fed formula supplemented with milk fat globule membranes</td>
<td>Tove Grip, Sweden</td>
</tr>
<tr>
<td>17:35</td>
<td>N-O-012</td>
<td>Evaluation of Hepcidin as iron status indicator at 4 months of age</td>
<td>Staffan Berglund, Sweden</td>
</tr>
</tbody>
</table>

**18:00 – 19:30 Room 5 (Level 1)**

## Evening Symposium

Industry sponsored > Details on page 132
<table>
<thead>
<tr>
<th>Time</th>
<th>Room 1</th>
<th>Room 2</th>
<th>Room 3</th>
<th>Room 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30</td>
<td>Breakfast Symposium</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 132</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:45</td>
<td><strong>Hepatology</strong></td>
<td><strong>Joint Symposium:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Plenary Session</strong></td>
<td><strong>Clinical trials in paediatrics - current challenges</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 52</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15</td>
<td><strong>Keynote Lecture:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Nutrition</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 54</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td></td>
<td><strong>Coffee Break</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15</td>
<td><strong>Clinical Practice in Gastroenterology</strong></td>
<td><strong>Nutrition Parallel Session 2</strong></td>
<td><strong>Hepatology Parallel Session 2</strong></td>
<td><strong>Gastroenterology Parallel Session 3</strong></td>
</tr>
<tr>
<td></td>
<td>see page 55</td>
<td>see page 56</td>
<td>see page 56</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td><strong>Gastroenterology Parallel Session 6</strong></td>
<td><strong>Nutrition &amp; Gastroenterology Parallel Session</strong></td>
<td><strong>Hepatology Parallel Session 3</strong></td>
</tr>
<tr>
<td></td>
<td>see page 55</td>
<td></td>
<td>see page 56</td>
<td>see page 56</td>
</tr>
<tr>
<td>13:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td><strong>Lunch Break / Poster Sessions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:15</td>
<td><strong>ESPGHAN guidelines: answered and unanswered questions</strong></td>
<td><strong>Basic Science Symposium: From bench to bedside in paediatric gastroenterology</strong></td>
<td><strong>New developments in complementary feeding</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 60</td>
<td>see page 60</td>
<td></td>
<td>see page 61</td>
</tr>
<tr>
<td>17:30</td>
<td><strong>ESPGHAN AGM</strong></td>
<td><strong>(Members Only)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 24</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Programme Overview

**Room 5**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45</td>
<td>Hepatology Plenary Session</td>
</tr>
<tr>
<td>11:15</td>
<td>Keynote Lecture: Nutrition</td>
</tr>
<tr>
<td>15:15</td>
<td>ESPGHAN guidelines: answered and unanswered questions</td>
</tr>
</tbody>
</table>

**Room 6**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45</td>
<td>Plenary Session: Joint Symposium: Clinical trials in paediatrics - current challenges</td>
</tr>
<tr>
<td>10:15</td>
<td>Parallel Session 2: Gastroenterology</td>
</tr>
<tr>
<td>15:15</td>
<td>Parallel Session 5: Gastroenterology</td>
</tr>
</tbody>
</table>

**MC 3.2**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30</td>
<td>Breakfast Symposium</td>
</tr>
<tr>
<td>08:45</td>
<td>Plenary Session: Hepatology</td>
</tr>
<tr>
<td>10:45</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>13:30</td>
<td>Lunch Break / Poster Sessions</td>
</tr>
<tr>
<td>14:00</td>
<td>Satellite Symposium: Working Group</td>
</tr>
<tr>
<td>17:30</td>
<td>ESPGHAN AGM (Members Only)</td>
</tr>
</tbody>
</table>

**MC 3.4**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45</td>
<td>Plenary Session: Nutrition</td>
</tr>
<tr>
<td>10:45</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>15:15</td>
<td>Parallel Session 4: Gastroenterology</td>
</tr>
</tbody>
</table>

---

### Gastroenterology Parallel Sessions

- **Room 5**
  - See page 134
- **Room 6**
  - See page 52
- **MC 3.2**
  - See page 52
- **MC 3.4**
  - See page 52

### Coffee Break

- **Room 5**
  - See page 54
- **Room 6**
  - See page 53
- **MC 3.2**
  - See page 54
- **MC 3.4**
  - See page 53

### Lunch Break / Poster Sessions

- **Room 5**
  - See page 62
- **Room 6**
  - See page 63

### ELZ / MLZ (Level –1)

- **Session 3**
  - 10:00 – 12:30
  - See page 121
- **Session 4**
  - 14:00 – 16:30
  - See page 121

---

**Legend**

- **Other**
- **Parallel Symposium**
- **Satellite Symposium**
- **Working Group**
Friday, 27 May 2016 · Megaron Athens

<table>
<thead>
<tr>
<th>07:30 – 08:30</th>
<th>Room 4 (Level –2)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Breakfast Symposium</strong></td>
<td></td>
</tr>
<tr>
<td>Industry sponsored &gt; Details on page 132</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>07:30 – 08:30</th>
<th>Room 6 (Level 0)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Breakfast Symposium</strong></td>
<td></td>
</tr>
<tr>
<td>Industry sponsored &gt; Details on page 134</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>07:30 – 08:30</th>
<th>MC 3.2 (Level –1)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical Cases: Gastro/IBD 1 (Ticket Required)</strong></td>
<td></td>
</tr>
<tr>
<td>07:30</td>
<td>An adolescent boy with cachexia, short stature and delayed puberty</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>07:30 – 08:30</th>
<th>MC 3.4 (Level –1)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical Cases: Gastro/IBD 2 (Ticket Required)</strong></td>
<td></td>
</tr>
<tr>
<td>07:30</td>
<td>Sudden vision impairment in a girl with steroid refractory UC</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>08:45 – 10:15</th>
<th>Room 1 (Level 0)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hepatology Plenary Session</strong></td>
<td></td>
</tr>
<tr>
<td>Chairs</td>
<td>Deirdre Kelly, United Kingdom · Aglaia Zellos, Greece</td>
</tr>
<tr>
<td>08:45</td>
<td>H-O-012</td>
</tr>
<tr>
<td>08:55</td>
<td>H-O-013</td>
</tr>
<tr>
<td>09:05</td>
<td>H-O-014</td>
</tr>
</tbody>
</table>
**Chronological Programme**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:25</td>
<td>H-O-016</td>
<td>C3d DSA with high MFI is associated with a higher rate of graft loss in a pediatric cohort of LT patients</td>
<td>Eduardo Couchonnal, France</td>
</tr>
<tr>
<td>09:35</td>
<td>H-O-017</td>
<td>Evaluating risk of esophageal variceal bleed in children with cirrhosis and waitlisted for liver transplantation</td>
<td>Xavier Stephenne, Belgium</td>
</tr>
<tr>
<td>09:45</td>
<td>H-O-018</td>
<td>Clinico-pathological features of liver disease following paediatric bone marrow transplantation</td>
<td>Lorenzo D’Antiga, Italy</td>
</tr>
<tr>
<td>09:55</td>
<td>H-O-019</td>
<td>Prevalence and prognosis of patients with autoimmune liver disease in a population based childhood-onset inflammatory bowel disease cohort from northern Stockholm County</td>
<td>Petter Malmborg, Sweden</td>
</tr>
</tbody>
</table>

**Joint Symposium: Clinical trials in paediatrics – current challenges**

**Chairs** Berthold Koletzko, Germany · Raanan Shamir, Israel

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45</td>
<td>Room 4</td>
<td>Public private collaboration in clinical research - current concepts</td>
<td>Hans van Goudoever, The Netherlands</td>
</tr>
<tr>
<td>09:08</td>
<td>N-O-013</td>
<td>A randomised trial to test the effectiveness of maternal relaxation therapy during breastfeeding: effects on infant behaviour</td>
<td>Nurul Husna M Shukri, United Kingdom</td>
</tr>
<tr>
<td>09:18</td>
<td></td>
<td>Limits of using placebo controls in paediatric patients</td>
<td>Dan Turner, Israel</td>
</tr>
<tr>
<td>09:41</td>
<td>N-O-014</td>
<td>A micronutrient-fortified young child formula improves the iron and vitamin D status of healthy young European children: a randomised double-blind controlled trial</td>
<td>Marjolijn Akkermans, The Netherlands</td>
</tr>
<tr>
<td>09:51</td>
<td></td>
<td>Sharing data from clinical trials for secondary research purposes</td>
<td>Berthold Koletzko, Germany</td>
</tr>
</tbody>
</table>

*Oral abstract presentations have been selected by highest score not by topic.*
**Nutrition Plenary Session**

**Chairs**  Sanja Kolacek, Croatia · Thomais Karagiozoglou-Lampoudi, Greece

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45</td>
<td>Optimising nutrition to improve growth and reduce neurodisabilities in neonates at risk of neurological impairment</td>
<td>Morag Andrew, United Kingdom</td>
</tr>
<tr>
<td>08:55</td>
<td>6th annual Paediatric Nutrition Week: e-Pinut 2015</td>
<td>Arnaud De Luca, France</td>
</tr>
<tr>
<td>09:05</td>
<td>Impact of pasteurization of human milk on its gastric digestion: an in vivo study in the preterm infant</td>
<td>Samira De Oliveira, France</td>
</tr>
<tr>
<td>09:15</td>
<td>Human milk short chain fatty acid composition is associated with infancy adiposity outcomes</td>
<td>Philippa Prentice, United Kingdom</td>
</tr>
<tr>
<td>09:25</td>
<td>Effect of early protein supply on body fat deposition during infancy and childhood: a randomized trial</td>
<td>Martina Weber, Germany</td>
</tr>
<tr>
<td>09:35</td>
<td>Aberrant adipose tissue partitioning with abdominal obesity, defined by MRI, is a hallmark of paediatric Crohn’s Disease</td>
<td>Dhamyanthi Thangarajah, United Kingdom</td>
</tr>
<tr>
<td>09:45</td>
<td>Placental MFSD2A transporter is related to decreased DHA in cord blood of women with gestational diabetes</td>
<td>Elvira Larque, Spain</td>
</tr>
<tr>
<td>09:55</td>
<td>Effect of prebiotic inulin-type fructans on health parameters and intestinal microbiota composition in children aged 3 to 6 years: a randomized, double-blind, placebo-controlled explorative study</td>
<td>Tamás Decsi, Hungary</td>
</tr>
</tbody>
</table>

**Keynote Lecture: Nutrition**

**Chair**  Mary Fewtrell, United Kingdom

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15</td>
<td>Exosomes in breast milk</td>
<td>Bo Lonnerdal, USA</td>
</tr>
</tbody>
</table>

10:45 – 11:15  Coffee Break
### Clinical Practice in Gastroenterology

**Chairs** Jernej Dolinšek, Slovenia · Panayota Kafritsa, Greece

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15</td>
<td>Epidemiology of EoE in Europe: pEEr data</td>
<td>Jorge Amil Dias, Portugal</td>
</tr>
<tr>
<td>11:39</td>
<td>IBS: Current treatment strategies</td>
<td>Marc Benninga, The Netherlands</td>
</tr>
<tr>
<td>12:03</td>
<td>Optimal management of belching, aerophagia, hiccups and rumination</td>
<td>André Smout, The Netherlands</td>
</tr>
<tr>
<td>12:27</td>
<td>Tandem talk: management of upper GI bleeding - variceal bleeding</td>
<td>Patrick McKiernan, United Kingdom</td>
</tr>
<tr>
<td>12:39</td>
<td>Tandem talk: management of upper GI bleeding - non variceal bleeding</td>
<td>Mike Thomson, United Kingdom</td>
</tr>
<tr>
<td>12:51</td>
<td>Gastrointestinal polyps in childhood: predictive testing and surveillance</td>
<td>Warren Hyer, United Kingdom</td>
</tr>
</tbody>
</table>

### Nutrition Parallel Session 2

**Chairs** Olle Hernell, Sweden · Nataša Fidler Mis, Slovenia

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15</td>
<td>N-O-023 Infant feeding is associated with growth trajectory patterns in childhood and body composition in adulthood.</td>
<td>Wendy Oddy, Australia</td>
</tr>
<tr>
<td>11:25</td>
<td>N-O-024 The effect of different protein concentration in infant formula on growth, body composition, and later risk of obesity: a systematic review</td>
<td>Bernadeta Patro-Gołąb, Poland</td>
</tr>
<tr>
<td>11:35</td>
<td>N-O-025 Longitudinal fat mass and visceral fat during the first 6 months after birth in healthy infants: support for a critical window for adiposity in early life</td>
<td>Laura Breij, The Netherlands</td>
</tr>
<tr>
<td>11:45</td>
<td>N-O-026 Serum lipid profile in infants fed formula supplemented with a bovine milk fat globule membrane fraction</td>
<td>Tove Grip, Sweden</td>
</tr>
<tr>
<td>11:55</td>
<td>N-O-027 The ability of body mass index and serum leptin to predict body composition in 8 year old Spanish children.</td>
<td>Veronica Luque, Spain</td>
</tr>
<tr>
<td>12:05</td>
<td>N-O-028 Safe discharge of perterm infants at &lt;34 weeks PCA, weight less than 1.8 kg by aggressive paladai feeding in Indian NICU</td>
<td>Deepa Hariharan, India</td>
</tr>
</tbody>
</table>

All presentations are supposed to include adequate times for discussion.

www.espgghancongress.org
## Hepatology Parallel Session 2

**Chair:** Ekkehard Sturm, Germany

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker, Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15</td>
<td>H-O-020</td>
<td>Successful identification of high risk young people with biliary atresia using the Mayo PSC risk score</td>
<td>Deepak Joshi, United Kingdom</td>
</tr>
<tr>
<td>11:25</td>
<td>H-O-021</td>
<td>DEFI-ALPHA Cohort: phenotype of liver disease in children with alpha-1 antitrypsin deficiency in France</td>
<td>Mathias Ruiz, France</td>
</tr>
<tr>
<td>11:35</td>
<td>H-O-022</td>
<td>Early onset LAL deficiency mimicking haemophagocytic lymphohistiocytosis.</td>
<td>Maja Klaudel-Dreszler, Poland</td>
</tr>
<tr>
<td>11:45</td>
<td>H-O-023</td>
<td>Brain MRI and Spectroscopy in the diagnosis of early neurological involvement in Wilson’s disease in children</td>
<td>Hatem Hussein, Egypt</td>
</tr>
<tr>
<td>11:55</td>
<td>H-O-024</td>
<td>What coagulation parameters define a safe liver biopsy in children?</td>
<td>Winita Hardikar, Australia</td>
</tr>
<tr>
<td>12:05</td>
<td>H-O-025</td>
<td>Reference values for exchangeable copper and rec, new promising biomarkers for diagnosis and treatment-monitoring of Wilson Disease</td>
<td>Anne Sophie Brunet, France</td>
</tr>
</tbody>
</table>

## Gastroenterology Parallel Session 3

**Chairs:** Sibylle Koletzko, Germany · Constantinos Siafakas, Greece

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker, Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15</td>
<td>G-O-024</td>
<td>Distressed behavior and GER in infants: new insights</td>
<td>Silvia Salvatore, Italy</td>
</tr>
<tr>
<td>11:25</td>
<td>G-O-025</td>
<td>Laryngeal inflammation and gastroesophageal reflux: two sides of the same or two different coins?</td>
<td>Silvia Salvatore, Italy</td>
</tr>
<tr>
<td>11:35</td>
<td>G-O-026</td>
<td>Influence of percutaneous endoscopic gastrostomy on gastro-esophageal reflux disease</td>
<td>Madeleine Gottrand, France</td>
</tr>
<tr>
<td>11:45</td>
<td>G-O-027</td>
<td>Neuroglioplastic changes induce functional repercussions in the remaining ‘healthy’ bowel in Hirschsprung disease.</td>
<td>Anne Dariel, France</td>
</tr>
</tbody>
</table>
### Gastroenterology Parallel Session 4

**Chairs** Carmen Ribes Koninckx, Spain · Maria Fotoulaki, Greece

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15</td>
<td>G-O-030</td>
<td>Mode of delivery and risk of celiac disease in at-family-risk infants prospectively investigated from birth: the CELIPREV study</td>
<td>Elena Lionetti</td>
<td>Italy</td>
</tr>
<tr>
<td>11:25</td>
<td>G-O-031</td>
<td>Accuracy of three commercially available point-of-care tests in monitoring celiac disease</td>
<td>Sabine Vriezinga</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>11:35</td>
<td>G-O-032</td>
<td>Degradation of immunogenic gluten epitopes from wheat by sourdough lactobacilli.</td>
<td>Roberta Moretti</td>
<td>Italy</td>
</tr>
<tr>
<td>11:45</td>
<td>G-O-033</td>
<td>Role of the gluten-free diet on neurological-EEG findings and sleep disordered breathing in children with celiac disease</td>
<td>Chiara Maria Trovato</td>
<td>Italy</td>
</tr>
<tr>
<td>12:05</td>
<td>G-O-035</td>
<td>Serum hepcidin levels are not increased in anemic children with celiac disease.</td>
<td>Monika Kowalczuk-Kryston</td>
<td>Poland</td>
</tr>
</tbody>
</table>

### Gastroenterology Parallel Session 6

**Chairs** Michael Wilschanski, Israel · Stavroula Karyda, Greece

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30</td>
<td>G-O-036</td>
<td>The role of Myo5B and Syntaxin 3 in cargo-selective apical exocytosis in Microvillus Inclusion Disease</td>
<td>Georg-Friedrich Vogel</td>
<td>Austria</td>
</tr>
<tr>
<td>12:40</td>
<td>G-O-037</td>
<td>Effectiveness of double-balloon enteroscopy-facilitated polypectomy in paediatric patients with Peutz-Jeghers syndrome</td>
<td>Dalia Belsha</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>12:50</td>
<td>G-O-038</td>
<td>The role of anatomic anomalies of pancreatic duct in pediatric chronic pancreatitis.</td>
<td>Grzegorz Oracz</td>
<td>Poland</td>
</tr>
<tr>
<td>13:00</td>
<td>G-O-039</td>
<td>Nasogastric or nasojejunal tube feeding in pediatric acute pancreatitis: a clinical, randomized pilot study</td>
<td>Jinxan Lou</td>
<td>China</td>
</tr>
<tr>
<td>13:10</td>
<td>G-O-040</td>
<td>Helicobacter pylori infection in children with Coeliac disease.</td>
<td>Nevzet Aykut Bayrak</td>
<td>Turkey</td>
</tr>
<tr>
<td>13:20</td>
<td>G-O-041</td>
<td>First report of a lethal infantile autosomal recessive ITGB6V343M disorder correlating with impaired integrin αVβ6 receptor dimerization in intestinal epithelia</td>
<td>Jan Postberg</td>
<td>Germany</td>
</tr>
</tbody>
</table>
### Nutrition & Gastroenterology Parallel Session

**Chairs** Olivier Goulet, France · Iva Hojsak, Croatia

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30</td>
<td>N-O-029</td>
<td>Growth during early infancy and anthropometry at 4 years of age: follow-up of the BeMIM study.</td>
<td>Manja Fleddermann, Germany</td>
</tr>
<tr>
<td>12:40</td>
<td>N-O-030</td>
<td>A symbiotic mixture of scGOS/lcFOS and bifidobacterium breve M-16V is able to restore the delayed colonization of bifidobacterium observed in C-section delivered infants</td>
<td>Chua Mei Chien, Singapore</td>
</tr>
<tr>
<td>12:50</td>
<td>N-O-031</td>
<td>Maternal CD does not influence human milk macronutrients, lipids and hormones</td>
<td>Maria Grunewald, Germany</td>
</tr>
<tr>
<td>13:00</td>
<td>G-O-042</td>
<td>Use of vitamin D, omega-3 fatty acids, and iron supplements during pregnancy is not associated with the risk of celiac disease in offspring: the TEDDY Study</td>
<td>Jimin Yang, USA</td>
</tr>
<tr>
<td>13:10</td>
<td>G-O-043</td>
<td>Gluten Free diet leads to an obesogenic lifestyle</td>
<td>Eyal Shteyer, Israel</td>
</tr>
<tr>
<td>13:20</td>
<td>G-O-044</td>
<td>Industrial food additive microbial transglutaminase is immunogenic in children with celiac disease</td>
<td>Torsten Matthias, Germany</td>
</tr>
</tbody>
</table>

### Hepatology Parallel Session 3

**Chairs** Emmanuel Gonzales, France · Marianne Hørby Jørgensen, Denmark

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30</td>
<td>H-O-026</td>
<td>NK cells phenotype as a risk marker of posttransplant lymphoproliferative disease in liver transplanted children</td>
<td>Francoise Smets, Belgium</td>
</tr>
<tr>
<td>12:40</td>
<td>H-O-027</td>
<td>Similarities and differences in allocation policies for pediatric liver transplantation across the world</td>
<td>Björn Fischler, Sweden</td>
</tr>
<tr>
<td>12:50</td>
<td>H-O-028</td>
<td>The histological quantification of alpha-smooth muscle actin predicts future graft fibrosis in pediatric liver transplant recipients</td>
<td>Sharat Varma, Belgium</td>
</tr>
<tr>
<td>13:00</td>
<td>H-O-029</td>
<td>Risk factors for auto-immune hemolytic anemia after pediatric liver transplantation.</td>
<td>Nathalie Rock, Switzerland</td>
</tr>
<tr>
<td>13:10</td>
<td>H-O-030</td>
<td>Long term outcome of biliary atresia into adult life</td>
<td>Javaid Sadiq, United Kingdom</td>
</tr>
<tr>
<td>13:20</td>
<td>H-O-031</td>
<td>Mortality of young biliary atresia patients listed for liver transplantation: results from the Eurotransplant registry.</td>
<td>Hubert van der Doef, The Netherlands</td>
</tr>
</tbody>
</table>
### Gastroenterology Parallel Session 5

**Chairs**: Michela Tempia, Switzerland · Jean-Pierre Hugot, France

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30</td>
<td>G-O-045</td>
<td>Results of the ESPGHAN Endoscopy Training Survey</td>
<td>Ilse Broekaert, Germany</td>
</tr>
<tr>
<td>12:40</td>
<td>G-O-046</td>
<td>Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease</td>
<td>Katrine Carlsen, Denmark</td>
</tr>
<tr>
<td>12:50</td>
<td>G-O-047</td>
<td>Risk of serious infection in pediatric inflammatory bowel disease: results from the DEVELOP registry</td>
<td>Johanna Escher, The Netherlands</td>
</tr>
<tr>
<td>13:00</td>
<td>G-O-048</td>
<td>Evolution of disease phenotype in paediatric-onset Crohn's disease after more than 10 years follow up</td>
<td>Firas Rinawi, Israel</td>
</tr>
<tr>
<td>13:10</td>
<td>G-O-049</td>
<td>Incidence of bowel surgery and associated risk factors in paediatric onset Crohn's disease</td>
<td>Firas Rinawi, Israel</td>
</tr>
<tr>
<td>13:20</td>
<td>G-O-050</td>
<td>The prevalence of irritable bowel syndrome-type symptoms in pediatric inflammatory bowel disease and the relationship with biochemical markers of disease activity</td>
<td>Marc Benninga, The Netherlands</td>
</tr>
</tbody>
</table>

### Nutrition Parallel Session 3

**Chairs**: Frédéric Gottrand, France · Elena Kornienko, Russia

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30</td>
<td>N-O-032</td>
<td>Associating nutritional risk with clinical outcomes in pediatric patients: an appraisal of different tools</td>
<td>Nara Elizabeth Lara Pompa, United Kingdom</td>
</tr>
<tr>
<td>12:40</td>
<td>N-O-033</td>
<td>Despite lower serum 25-hydroxy vitamin D concentrations, bone density was higher in dark than fair skinned children</td>
<td>Pia Karlsland-Akeson, Sweden</td>
</tr>
<tr>
<td>12:50</td>
<td>N-O-034</td>
<td>Protein intakes and their nutritional sources during the first two years of life in 5 European countries.</td>
<td>Louiza Damianidi, Germany</td>
</tr>
<tr>
<td>13:00</td>
<td>N-O-035</td>
<td>Micronutrient intake and prevalence of adequacy in European children, from birth to 8 years.</td>
<td>Marta Zaragoza-Jordana, Spain</td>
</tr>
<tr>
<td>13:10</td>
<td>N-O-036</td>
<td>Duration of breastfeeding is an independent contributor to BMI z-score decrease after 12 months of lifestyle intervention in overweight and obese children</td>
<td>Elke Dorenbos, The Netherlands</td>
</tr>
<tr>
<td>13:20</td>
<td>N-O-037</td>
<td>Circulating salicylic acid and metabolic profile in obese children: a case-control study</td>
<td>Elvira Verduci, Italy</td>
</tr>
</tbody>
</table>
### Parallel Symposium: ESPGHAN guidelines – answered and unanswered questions

**Chairs**  
Raanan Shamir, Israel · Alexandra Papadopoulou, Greece

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Author, Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15</td>
<td>HP infection</td>
<td>Sibylle Koletzko, Germany</td>
</tr>
<tr>
<td>15:40</td>
<td>Variability of human anti-transglutaminase assay across Mediterranean countries</td>
<td>Andrea Smarrazzo, Italy</td>
</tr>
<tr>
<td>15:50</td>
<td>CIPO</td>
<td>Nikhil Thapar, United Kingdom</td>
</tr>
<tr>
<td>16:15</td>
<td>Assessment of ESPGHAN criteria for diagnosis of coeliac disease in New Zealand children</td>
<td>Jonathan Bishop, New Zealand</td>
</tr>
<tr>
<td>16:25</td>
<td>Esophageal atresia</td>
<td>Frédéric Gottrand, France</td>
</tr>
<tr>
<td>16:50</td>
<td>Gluten introduction</td>
<td>Hania Szajewska, Poland</td>
</tr>
</tbody>
</table>

### Basic Science Symposium: From bench to bedside in paediatric gastroenterology

**Chairs**  
Riccardo Troncone, Italy · Christos Tzivinikos, United Kingdom

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Author, Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15</td>
<td>Genetics of intestinal inflammation - implications for patient care</td>
<td>Holm Uhlig, United Kingdom</td>
</tr>
<tr>
<td>15:40</td>
<td>In vitro hepatogenic differentiation of umbilical cord matrix stem cells enables Hepatitis B entry by modulating the expression of the Sodium Taurocholate Cotransporter Polypeptide</td>
<td>Camillo Sargiacomo, Belgium</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Title</td>
</tr>
<tr>
<td>--------</td>
<td>----------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>15:50</td>
<td>Innate and adaptive immune responses in the intestine</td>
<td>Janneke Samsom, The Netherlands</td>
</tr>
<tr>
<td>16:15</td>
<td>G-O-054</td>
<td>The 3-dimentional structures of human and microbial transglutaminases complexed to gliadin are similar</td>
</tr>
<tr>
<td>16:25</td>
<td></td>
<td>Influence of the microbiome on host gut function and physiology</td>
</tr>
<tr>
<td>16:50</td>
<td></td>
<td>Targeted metabolomic analysis and data evaluation: opportunities and limitations</td>
</tr>
</tbody>
</table>

**Parallel Symposium: New developments in complementary feeding**

Chairs: Flavia Indrio, Italy · Nick Embleton, United Kingdom

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15</td>
<td>Complementary feeding and allergy risk</td>
<td>Michael Perkin, United Kingdom</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:40</td>
<td>N-O-038</td>
<td>Nutrition in preschool children and later risk of obesity: a systematic review and meta analysis</td>
<td>Julie Lanigan, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>15:50</td>
<td></td>
<td>Genetic versus environmental influences on food preferences and eating behaviour - data from the Gemini twin cohort</td>
<td>Claire Llewellyn, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>16:15</td>
<td>N-O-039</td>
<td>Protein intake and source during complementary feeding and growth up to 6 years of age, secondary data evaluation from the European Childhood Obesity Project.</td>
<td>Louiza Damianidi, Germany</td>
<td></td>
</tr>
<tr>
<td>16:25</td>
<td></td>
<td>Does protein intake and source during complementary feeding influence later health and obesity risk?</td>
<td>Kim F. Michaelsen, Denmark</td>
<td></td>
</tr>
<tr>
<td>16:50</td>
<td></td>
<td>Gluten - is the amount important?</td>
<td>Magnus Domellöf, Sweden</td>
<td></td>
</tr>
</tbody>
</table>

Oral abstract presentations have been selected by highest score not by topic.
**Parallel Symposium:**
*Porto group 3 most recent guidelines on paediatric IBD*

**Chairs**  Dan Turner, Israel · Annamaria Staiano, Italy

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15</td>
<td>Endoscopy in paediatric IBD - when and how</td>
<td>Salvatore Cucchiara, Italy</td>
</tr>
<tr>
<td>15:40</td>
<td>G-O-055 Fecal calprotectin concentration reflects disease severity but not disease extent in pediatric patients with new onset ulcerative colitis. The PROTECT Study</td>
<td>Thomas Walters, Canada</td>
</tr>
<tr>
<td>15:50</td>
<td>IBD-unclassified - how to diagnose and how to treat</td>
<td>Richard Russell, United Kingdom</td>
</tr>
<tr>
<td>16:15</td>
<td>G-O-056 Reliability assessment of endoscopic disease severity using central video review of colonoscopies in paediatric patients with Crohn’s Disease: data from the Canadian Children IBD Network.</td>
<td>Nicholas Carman, Canada</td>
</tr>
<tr>
<td>16:25</td>
<td>Surgery in Crohn’s disease</td>
<td>Kaija Kolho, Finland</td>
</tr>
<tr>
<td>16:50</td>
<td>5 years, 6 Porto group guidelines in paediatric IBD... what have I learned?</td>
<td>Anne Griffiths, Canada</td>
</tr>
</tbody>
</table>
Parallel Symposium: Novelties in paediatric hepatology

Chairs
Henkjan Verkade, The Netherlands · Jörg Jahnel, Austria

15:15 – 17:15 Room 6 (Level 0)

15:15 Clinical manifestation of TJP2 gene mutation
Richard Thompson, United Kingdom

15:40 H-O-032 Long-term follow up of childhood autoimmune liver disease: the importance of resolving nomenclature
Jeremy Rajanayagam, United Kingdom

15:50 Bileacid receptor FXR and the hormones F6, F19 in the management of paediatral liver disease
Antonio Moschetta, Italy

16:15 H-O-033 Adenosine kinase deficiency is a new cause of infantile cholestasis with a severe neurological phenotype
Christian Staufner, Germany

16:25 Hepatitis E in childhood
Dominique Debray, France

16:50 Histopathological approach of focal lesions in the liver
Brigitte Le Bail, France

17:30 – 19:45 Room 2 (Level –1)

ESPGHAN Annual General Meeting (Members Only)

Registration and pre-session drinks from 17:00 onwards.
Details on page 24
**Venue** **Megaron Athens**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room 1</th>
<th>Room 2</th>
<th>Room 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td>Dilemmas in coeliac disease diagnosis management</td>
<td>Parents and Patients Association Symposium: Quality of care from the patient’s perspective</td>
<td>Africa goes ESPGHAN</td>
</tr>
<tr>
<td></td>
<td>see page 66</td>
<td>see page 67</td>
<td>see page 67</td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>Gastroenterology Plenary Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 69</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>Keynote Lecture: Gastroenterology</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 70</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>Closing Session &amp; Awards</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 70</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Venue** **Hilton Athens**

<table>
<thead>
<tr>
<th>Time</th>
<th>Thalia 1</th>
<th>Thalia 3+4</th>
<th>Santorini 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td>Porto Group: A Position Paper on Nutrition in Paediatric IBD <em>(Invite Only)</em></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td>see page 71</td>
</tr>
<tr>
<td>14:30</td>
<td>ESPGHAN goes Africa Workshop</td>
<td>Monkey See, Monkey Do &amp; Monkey Business</td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 71</td>
<td>see page 72</td>
<td></td>
</tr>
</tbody>
</table>
### Saturday, 28 May 2016

**Programme Overview**

<table>
<thead>
<tr>
<th>Room 4</th>
<th>Room 5</th>
<th>Room 6</th>
<th>MC 3.2</th>
<th>MC 3.4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breakfast Symposium</td>
<td>Clinical Cases: Hepatology 1</td>
<td>Clinical Cases: Hepatology 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>see page 134</td>
<td>see page 66</td>
<td>see page 66</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clinical management of obesity and non-alcoholic fatty liver disease in childhood</th>
<th>Food allergy</th>
<th>Vascular liver disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>see page 68</td>
<td>see page 68</td>
<td>see page 69</td>
</tr>
</tbody>
</table>

### Coffee Break

<table>
<thead>
<tr>
<th>Management and later outcomes in children with intestinal failure</th>
</tr>
</thead>
<tbody>
<tr>
<td>see page 70</td>
</tr>
</tbody>
</table>
Saturday, 28 May 2016 · Megaron Athens

07:15–08:15 Room 4 (Level –2)

Breakfast Symposium

Industry sponsored > Details on page 134

07:30–08:30 MC 3.2 (Level –1)

Clinical Cases: Hepatology 1 *(Ticket Required)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30</td>
<td>Diagnostic approach to early onset cholangiopathies</td>
<td>Tassos Grammatikopoulos, Finland</td>
</tr>
</tbody>
</table>

07:30–08:30 MC 3.4 (Level –1)

Clinical Cases: Hepatology 2 *(Ticket Required)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30</td>
<td>4 month old infant presenting with jaundice, chronic diarrhea and a large anterior fontanelle</td>
<td>Aglaia Zellos, Greece</td>
</tr>
</tbody>
</table>

08:30–10:30 Room 1 (Level 0)

Parallel Symposium:
Dilemmas in coeliac disease diagnosis management

Chairs: Steffen Husby, Denmark · Thomais Karagiozoglou-Lampoudi, Greece

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Lessons from the ProCeDe</td>
<td>Katharina Werkstetter, Germany</td>
</tr>
<tr>
<td>08:55</td>
<td>Constitutive alterations of the intracellular vesicular trafficking in CD (Celiac Disease) enterocytes and fibroblasts: relationship with stress/innate immune response to gliadin</td>
<td>Maria Vittoria Barone, Italy</td>
</tr>
<tr>
<td>09:05</td>
<td>Duodenal biopsies revisited, standardisation possible?</td>
<td>Markku Mäki, Finland</td>
</tr>
<tr>
<td>09:30</td>
<td>Short gluten challenge in the wide spectrum of genetic gluten intolerance.</td>
<td>Luigina De Leo, Italy</td>
</tr>
<tr>
<td>09:40</td>
<td>E-Health in coeliac disease</td>
<td>Sabine Vriezinga, The Netherlands</td>
</tr>
<tr>
<td>10:05</td>
<td>Non celiac gluten hypersensitivity</td>
<td>Carlo Catassi, Italy</td>
</tr>
</tbody>
</table>

Oral abstract presentations have been selected by highest score not by topic.
### Chronological Programme

#### Parents and Patients Association Symposium: Quality of care from the patient’s perspective

**Chairs** Luisa Mearin, The Netherlands · Maria Fotoulaki, Greece

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>The mirror method to learn from patients</td>
<td>Maria Mul, The Netherlands</td>
<td>Room 2</td>
</tr>
<tr>
<td>08:55</td>
<td>What matters</td>
<td>Alison Taylor, United Kingdom</td>
<td>Room 2</td>
</tr>
<tr>
<td>09:20</td>
<td>What the patients want? - The parents’ perspective</td>
<td>Voula Tsetsi, Belgium</td>
<td>Room 2</td>
</tr>
<tr>
<td>09:35</td>
<td>What the patients want? - The patients’ perspective</td>
<td>Iris Mittman, Greece</td>
<td>Room 2</td>
</tr>
<tr>
<td>09:50</td>
<td>Parental challenges in the feeding of preterm infants after discharge - the need for adequate information</td>
<td>Silke Mader, Germany</td>
<td>Room 2</td>
</tr>
<tr>
<td>10:15</td>
<td>Panel discussion with representatives of the parents and patients associations</td>
<td></td>
<td>Room 2</td>
</tr>
</tbody>
</table>

#### Africa goes ESPGHAN

**Chairs** Michael Lentze, Germany · Jan Taminiau, The Netherlands

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Tb and HIV of the intestine</td>
<td>Etienne Nel, South Africa</td>
<td>Room 3</td>
</tr>
<tr>
<td>09:00</td>
<td>G-O-059 Clinico-epidemilogic features and genotypes of rotavirus acute gastroenteritis in Egyptian children: a single tertiary care center study</td>
<td>Ahmed Megahed, Egypt</td>
<td>Room 3</td>
</tr>
<tr>
<td>09:10</td>
<td>Challenges managing liver disease in a developing country</td>
<td>Elizabeth Goddard, South Africa</td>
<td>Room 3</td>
</tr>
<tr>
<td>09:40</td>
<td>H-O-034 Hepatic sinusoidal obstruction syndrome due to herbal ingestion in South African children – a 7 year review</td>
<td>Lesley Hendricks, South Africa</td>
<td>Room 3</td>
</tr>
<tr>
<td>09:50</td>
<td>Chronic malnutrition during childhood – impact on adult health</td>
<td>Ahmed Laving, Kenya</td>
<td>Room 3</td>
</tr>
<tr>
<td>10:20</td>
<td>G-O-060 Prevalence and predisposing factors of functional constipation in adolescent Nigerians</td>
<td>Ekong Udoh, Nigeria</td>
<td>Room 3</td>
</tr>
</tbody>
</table>

All presentations are supposed to include adequate times for discussion.
**08:30 – 10:30 Room 4 (Level -2)**

### Parallel Symposium: Clinical management of obesity and non-alcoholic fatty liver disease in childhood

**Chairs**: Mary Fewtrell, United Kingdom · Anil Dhawan, United Kingdom

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Non-surgical management of child obesity</td>
<td>Cristina Campoy, Spain</td>
</tr>
<tr>
<td>08:55</td>
<td>Effect of sebelipase alfa on survival and liver function in infants with rapidly progressive lysosomal acid lipase deficiency: 2-year follow-up data</td>
<td>Simon A. Jones, United Kingdom</td>
</tr>
<tr>
<td>09:05</td>
<td>NAFLD as an indications for bariatric surgery in children</td>
<td>Valerio Nobili, Italy</td>
</tr>
<tr>
<td>09:30</td>
<td>Gut and Liver Inflammation in obese children: a dangerous vicious circle.</td>
<td>Maurizio Mennini, Italy</td>
</tr>
<tr>
<td>09:40</td>
<td>Ethical consideration in the treatment of obese children</td>
<td>Jennifer Baker, Denmark</td>
</tr>
<tr>
<td>10:05</td>
<td>Outcomes and nutritional care of adolescents after bariatric surgery</td>
<td>Claude Marcus, Sweden</td>
</tr>
</tbody>
</table>

**08:30 – 10:30 Room 5 (Level 1)**

### Parallel Symposium: Food allergy

**Chairs**: Yvan Vandenplas, Belgium · Eleftheria Roma, Greece

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Allergy and the GI tract (epidemiology, mechanisms)</td>
<td>Simon Murch, United Kingdom</td>
</tr>
<tr>
<td>08:55</td>
<td>FOXP3 epigenetic features in children with cow milk allergy</td>
<td>Lorella Paparo, Italy</td>
</tr>
<tr>
<td>09:05</td>
<td>Induction of immune tolerance</td>
<td>Nikolaos Papadopoulos, Greece</td>
</tr>
<tr>
<td>09:30</td>
<td>STAT3 gain of function mutation causes IPEX-like autoimmune enteropathy due to excessive IL-17 production.</td>
<td>Nicolette Moes, The Netherlands</td>
</tr>
<tr>
<td>09:40</td>
<td>Pitfalls in the management of food allergy</td>
<td>Neil Shah, United Kingdom</td>
</tr>
<tr>
<td>10:05</td>
<td>Controversies in food allergy diagnosis</td>
<td>Christophe Dupont, France</td>
</tr>
</tbody>
</table>
## Parallel Symposium: Vascular liver disease

**Chairs** Valérie McLin, Switzerland · Piotr Czubkowski, Poland

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Diagnostic and etiology of microvascular liver disease</td>
<td>Dominique Cazals-Hatem, France</td>
</tr>
<tr>
<td>08:55</td>
<td>H-O-036 A new prediction tool of portal hypertension in cirrhotic children</td>
<td>Peter Witters, United Kingdom</td>
</tr>
<tr>
<td>09:05</td>
<td>Budd Chiari Syndrome in children: management modalities</td>
<td>Surender Kumar Yachha, India</td>
</tr>
<tr>
<td>09:30</td>
<td>H-O-037 Acute variceal bleeding (AVB) in children causes significant morbidity: a 15 year retrospective study</td>
<td>Marta Moura, Canada</td>
</tr>
<tr>
<td>09:40</td>
<td>Hepatic dysfunction in children with congenital heart disease</td>
<td>Luis Garcia-Guereta, Spain</td>
</tr>
<tr>
<td>10:05</td>
<td>Diagnosis, therapy and pitfalls in congenital portosystemic shunts</td>
<td>Jean de Ville de Goyet, Italy</td>
</tr>
</tbody>
</table>

### Coffee Break

#### Gastroenterology Plenary Session

**Chairs** Nikhil Thapar, United Kingdom · Ioanna Panayotou, Greece

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>G-O-063 Analysis of the early infantile gliadin antibody response by recombinant food allergen microarray and prospective evaluation of a protective role</td>
<td>Ilma Rita Korponay-Szabo, Hungary</td>
</tr>
<tr>
<td>11:10</td>
<td>G-O-064 The use of concomitant immunomodulators with adalimumab therapy in pediatric Crohn’s Disease</td>
<td>Richard Colletti, USA</td>
</tr>
<tr>
<td>11:20</td>
<td>G-O-065 Loop formation in paediatric population</td>
<td>Dalia Belsha, United Kingdom</td>
</tr>
<tr>
<td>11:30</td>
<td>G-O-066 Targeted next generation sequencing: a powerful and sensitive tool for molecular diagnosis in monogenic enteropathies.</td>
<td>Fabienne Charbit-Henrion, France</td>
</tr>
<tr>
<td>11:40</td>
<td>G-O-067 Coeliac Disease across Mediterranean Countries: a prospective study</td>
<td>Andrea Smarrazzo, Italy</td>
</tr>
</tbody>
</table>
11:50  G-O-068  Anti-neo-epitope tTg complexed to gliadin are more reliable than tTg for celiac disease diagnosis  
Sandra Neidhöfer, Germany

12:00  G-O-069  Once versus twice daily mesalazine to induce remission in pediatric ulcerative colitis: an investigator-initiated randomized controlled trial  
Dan Turner, Israel

12:10  G-O-070  Gliadin an alimentary protein, regulated the INF-alpha immune response in celiac small intestine and in an enterocytes cell line  
Merlin Nanayakkara, Italy

11:00 – 12:20  Room 5 (Level 1)

Clinical Practice in Nutrition: Management and later outcomes in children with intestinal failure

Chairs  Christian Mølgaard, Denmark · Jiri Bronsky, Czech Republic

11:00  Management of children with intestinal failure  
Julian Thomas, United Kingdom

11:25  N-O-041  The impact of taurolidine-citrate locks implementation in a large pediatric cohort on home parenteral nutrition  
Cecile Lambe, France

11:35  Long-term outcomes  
Judith Pichler, Austria

12:00  Quality of life in children on home parenteral nutrition - online monitoring  
Merit Tabbers, The Netherlands

12:30 – 13:00  Room 1 (Level 0)

Keynote Lecture: Gastroenterology

Chair  Nikhil Thapar, United Kingdom

12:30  Intestinal tissue engineering  
Paolo de Coppi, United Kingdom

13:00 – 14:00  Room 1 (Level 0)

Closing Session & Awards
### Chronological Programme

#### 14:00–17:00  Santorini 2 (Hilton Athens)

**Porto Group: A Position Paper on Nutrition in Paediatric IBD (Invite Only)**

**Chair**  
Dan Turner, Israel

---

#### 14:30–17:30  Thalia 1 (Hilton Athens)

**ESPGHAN goes Africa Workshop**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30</td>
<td>Introduction of Faculty and Participant</td>
<td>Michael Lentze, Germany</td>
</tr>
<tr>
<td>15:00</td>
<td>Session 1: Research on the prevalence of GI diseases in developing countries: opportunities for establishing registries, lessons learned and future opportunities</td>
<td>Ronalda De Lacy, South Africa</td>
</tr>
<tr>
<td>15:30</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td>Session 2: Lessons learned from nutritional research in Africa (Burkina Faso, Ethiopia, Uganda)</td>
<td>Kim F. Michaelsen, Denmark · Christian Mølgaard, Denmark</td>
</tr>
<tr>
<td>16:15</td>
<td>Session 3: Research into complementary feeding as an example of designing a simple study</td>
<td>Mary Fewtrell, United Kingdom · Etienne Nel, South Africa · Jan Taminiau, The Netherlands</td>
</tr>
<tr>
<td>16:45</td>
<td>Information on funding opportunities for research in Africa</td>
<td>Berthold Koletzko, Germany</td>
</tr>
<tr>
<td>17:00</td>
<td>Information on corresponding ESPGHAN membership</td>
<td>Berthold Koletzko, Germany</td>
</tr>
<tr>
<td>17:10</td>
<td>Any other business</td>
<td></td>
</tr>
</tbody>
</table>

---

#### 14:30–18:00  Thalia 3+4 (Hilton Athens)

**Monkey see, Monkey do & Monkey Business**

*Details on page 72*
**Lecture**

**Monkey see, Monkey do**

**Improving communication and cooperation in the paediatric praxis:**

*Why is communication and cooperation so difficult? And for what reason do we fail to improve these processes?*

Behavioural biologist Patrick van Veen takes you on a guided tour through his virtual zoo to explain the social processes in our clinical praxis. The social behaviour of primates is used as a mirror to explain why we fail and succeed. In a world which is getting more complicated our primal instincts still have influence on our professional behaviour. Learn why we should groom our colleagues or why sacred cows obstruct cooperation.

This lecture is not only entertaining, it also gives you input for thoughts and improvements.

**Learning objectives**

- Understanding social dynamics
- Improving communication
- Improving cooperation

**Workshop**

**Monkey Business**

**Your career and professional life from a different perspective**

*How does your own behaviour influence the behaviour of your colleagues? Can you influence your own career?*

Learn what chimpanzees and baboons can show us about our own behaviour.

During this workshop we will find out which methods are effective in influencing behaviour and why the experience we gain in a zoo also has effect at the workplace.

The social structure in clinical practice is a more complicated than an average company, therefore the understanding of social dynamics are crucial. In this workshop we will discuss how to implement this knowledge and how this can be of use within your own career building.

**Learning objectives**

- Improving communication, avoiding miscommunication
- Career building
- Influencing behaviour

---

**Please note**

- The participation is complimentary for all ESPGHAN participants
- The session is already fully booked. Please refer to the registration desk for further information
Connect with the speakers – join the speakers to ask questions, discuss hot topics or give your feedback on a talk. Some speakers of the following sessions will be available in the respective room at the end of the session:

**Thursday, 26 May 2016 · 16:45 – 17:45 · Room 1 (Level 0)**

**Clinical Practice in Hepatology**

**Chairs**
- Piotr Socha, Poland
- Thomas Casswall, Sweden

**Speakers**
- Ino Kanavaki, Switzerland
- Antal Dezsofi, Hungary

Details on page 47

**Friday, 27 May 2016 · 11:15 – 13:15 · Room 1 (Level 0)**

**Clinical Practice in Gastroenterology**

**Chairs**
- Jernej Dolinšek, Slovenia
- Panayota Kafritsa, Greece

**Speakers**
- Jorge Amil Dias, Portugal
- Marc Benninga, The Netherlands
- André Smout, The Netherlands
- Patrick McKiernan, United Kingdom
- Mike Thomson, United Kingdom
- Warren Hyer, United Kingdom

Details on page 55

**Saturday, 28 May 2016 · 11:00 – 12:20 · Room 5 (Level 1)**

**Clinical Practice in Nutrition: Management and later outcomes in children with intestinal failure**

**Chairs**
- Christian Mølgaard, Denmark
- Jiri Bronsky, Czech Republic

**Speakers**
- Julian Thomas, United Kingdom
- Cecile Lambe, France
- Judith Pichler, Austria
- Merit Tabbers, The Netherlands

Details on page 70
List of Invited Speakers, Chairpersons, Tutors and Poster Judges

Haralabos Agakidis, Greece
Aspasia Angelakopoulou, Greece
Jorge Amil Dias, Portugal
Protima Amon, United Kingdom
Andraz Arato, Hungary
Urs Arun, United Kingdom
Marcus Auth, United Kingdom
Theodora Bachou, Greece
Jennifer Baker, Denmark
Alastair Baker, United Kingdom
Claire Barnes, United Kingdom
Ulrich Baumann, Germany
Dominique Belli, Switzerland
Marc Benninga, The Netherlands
Staffan Berglund, Sweden
Osvaldo Borrelli, United Kingdom
Athos Bousvaros, USA
Ilse Broekaert, Germany
Efrat Broide, Israel
Jiri Bronsky, Czech Republic
Elaine Buchanan, United Kingdom
Stephan Buderus, Germany

Gordana Bukovina, Croatia
Martin Burdelski, Saudi Arabia

Cristina Campoy, Spain
Thomas Casswall, Sweden
Carlo Catassi, Italy
Dominique Cazals-Hatem, France
Ioanna Charoniti, Greece
George Chouliaras, Greece
George Chrousos, Greece
Nicholas Croft, United Kingdom
Hannah Cronin, United Kingdom
Salvatore Cucchiara, Italy
Piotr Czubkowski, Poland

Lorenzo D’Antiga, Italy
Paolo de Coppi, United Kingdom
Ronaldia de Lacy, South Africa
Lissy de Ridder, The Netherlands
Jean de Ville de Goyet, Italy
Dominique Debray, France
Tamás Decsi, Hungary
Antal Dezsofi, Hungary
List of Invited Speakers, Chairpersons, Tutors and Poster Judges

Anil Dhawan, United Kingdom
Juan Jose Diaz Martin, Spain
Konstantina Dimakou, Greece
Jernej Dolinšek, Slovenia
Magnus Domellöf, Sweden
Ester Donat, Spain
Christophe Dupont, France
Marcin Dziekiewicz, Poland

Mohamed El Guindi, Egypt
Mamoun Elawad, United Kingdom
Maria Elia, Greece
Muftah Eltumi, United Kingdom
Nick Embleton, United Kingdom
Johanna Escher, The Netherlands

Simona Faraci, Italy
Sandy Feng, USA
Smaragdi Fessatou, Greece
Mary Fewtrell, United Kingdom
Nataša Fidler Mis, Slovenia
Yigael Finkel, Sweden
Björn Fischler, Sweden
Maria Fotoulaki, Greece

Rafael Galera Martínez, Spain
Luis Garcia-Guereta, Spain
Konstantinos Gerasimidis, United Kingdom
Liz Goddard, South Africa
Emmanuel Gonzales, France
Frédéric Gottrand, France
Olivier Goulet, France
Tassos Grammatikopoulos, United Kingdom
Luigi Greco, Italy

Anne Griffiths, Canada
Nedim Hadzic, United Kingdom
Ioanna Haroniti, Greece
Almuthe Christina Hauer, Austria
Christian Hellmuth, Germany
Olle Hernell, Sweden
Susan Hill, United Kingdom
Jonathan Hind, United Kingdom
Iva Hojsak, Croatia
Matjaz Homan, Slovenia
Jean-Pierre Hugot, France
Jessie Hulst, The Netherlands
Steffen Husby, Denmark
Warren Hyer, United Kingdom

Flavia Indrio, Italy
Giuseppe Indolfi, Italy

Jörg Jahnel, Austria
Irena Jankowska, Poland
Huw Jenkins, United Kingdom
Koen Joosten, The Netherlands
Marianne Hørby Jørgensen, Denmark

Panayota Kafritsa, Greece
Ino Kanavaki, Switzerland
Thomais Karagiozoglou-Lampoudi, Greece
Paraskevi Karanika, Greece
Stavroula Karyda, Greece
Franca Kirchberg, Germany
Brigitte Kochavi, Israel
Sanja Kolacek, Croatia
Berthold Koletzko, Germany
Sibylle Koletzko, Germany
Kaija-Leena Kolho, Finland
<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evangelia Kolias</td>
<td>Greece</td>
</tr>
<tr>
<td>Elena Kornienko</td>
<td>Russia</td>
</tr>
<tr>
<td>Kallirroi Kotilea</td>
<td>Greece</td>
</tr>
<tr>
<td>Stamatiki Kritas</td>
<td>Greece</td>
</tr>
<tr>
<td>Janusz Ksiazyk</td>
<td>Poland</td>
</tr>
<tr>
<td>Florence Lacaille</td>
<td>France</td>
</tr>
<tr>
<td>Alexandre Lapillonne</td>
<td>France</td>
</tr>
<tr>
<td>Nara Elizabeth Lara-Pompa</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Elvira Larque</td>
<td>Spain</td>
</tr>
<tr>
<td>Peter Lauenstein</td>
<td>Germany</td>
</tr>
<tr>
<td>Ahmed Laving</td>
<td>Kenya</td>
</tr>
<tr>
<td>Brigitte Le Bail</td>
<td>France</td>
</tr>
<tr>
<td>Michael Lentze</td>
<td>Germany</td>
</tr>
<tr>
<td>Arie Levine</td>
<td>Israel</td>
</tr>
<tr>
<td>Keith Lindley</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Paolo Lionetti</td>
<td>Italy</td>
</tr>
<tr>
<td>Claire Llewellyn</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Bo Lonnerdal</td>
<td>USA</td>
</tr>
<tr>
<td>Sarah Macdonald</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Silke Mader</td>
<td>Germany</td>
</tr>
<tr>
<td>Markku Maki</td>
<td>Finland</td>
</tr>
<tr>
<td>Gerassimos Mantzaris</td>
<td>Greece</td>
</tr>
<tr>
<td>Maria Maragkoudaki</td>
<td>Austria</td>
</tr>
<tr>
<td>Claude Marcus</td>
<td>Sweden</td>
</tr>
<tr>
<td>Javier Martin de Carpi</td>
<td>Spain</td>
</tr>
<tr>
<td>Patrick McKiernan</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Valérie McLin</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Luisa Mearin</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Laura Merras-Salmo</td>
<td>Finland</td>
</tr>
<tr>
<td>Rosan Meyer</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Kim F. Michaelsen</td>
<td>Denmark</td>
</tr>
<tr>
<td>Erasmo Miele</td>
<td>Italy</td>
</tr>
<tr>
<td>Walter Mihatsch</td>
<td>Germany</td>
</tr>
<tr>
<td>Iris Mittman</td>
<td>Greece</td>
</tr>
<tr>
<td>Christian Mølgaard</td>
<td>Denmark</td>
</tr>
<tr>
<td>Antonino Morabito</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Antonio Moschetta</td>
<td>Italy</td>
</tr>
<tr>
<td>Tatiani Moudiou</td>
<td>Greece</td>
</tr>
<tr>
<td>Yael Mozer-Glassberg</td>
<td>Israel</td>
</tr>
<tr>
<td>Thomas Mueller</td>
<td>Austria</td>
</tr>
<tr>
<td>Maria Mul</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Simon Murch</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Mohamed Mutalib</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Priya Narula</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Victor Manuel Navas Lopez</td>
<td>Spain</td>
</tr>
<tr>
<td>Etienne Nel</td>
<td>South Africa</td>
</tr>
<tr>
<td>Anthal Nemeth</td>
<td>Sweden</td>
</tr>
<tr>
<td>Tena Niseteo</td>
<td>Croatia</td>
</tr>
<tr>
<td>Valerio Nobili</td>
<td>Italy</td>
</tr>
<tr>
<td>Salvatore Oliva</td>
<td>Italy</td>
</tr>
<tr>
<td>Rok Orel</td>
<td>Slovenia</td>
</tr>
<tr>
<td>Ioanna Panayotou</td>
<td>Greece</td>
</tr>
<tr>
<td>John Papaconstantinou</td>
<td>Greece</td>
</tr>
<tr>
<td>Nikolaos Papadopoulos</td>
<td>Greece</td>
</tr>
<tr>
<td>Alexandra Papadopoulos</td>
<td>Greece</td>
</tr>
<tr>
<td>Bernadetta Patro</td>
<td>Poland</td>
</tr>
<tr>
<td>Ender Pehlivanoglu</td>
<td>Turkey</td>
</tr>
<tr>
<td>Michael Perkin</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Judith Pichler</td>
<td>Austria</td>
</tr>
<tr>
<td>Olena Platonova</td>
<td>Ukraine</td>
</tr>
<tr>
<td>Prithviraj Rao</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>David Rawat</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Carmen Ribes Koninckx</td>
<td>Spain</td>
</tr>
</tbody>
</table>
Nathalie Rock, Switzerland
Maria Rogalidou, Greece
Eleftheria Roma, Greece
Claudio Romano, Italy
Erminia Romeo, Italy
Frank Ruemmele, France
Richard Russell, United Kingdom
Ania Rybak, United Kingdom

Efstratios Saliakellis, Greece
Janneke Samsom, The Netherlands
Marianne Samyn, United Kingdom
Ian Sanderson, United Kingdom
Daniela Serban, Romania
Neil Shah, United Kingdom
Raanan Shamir, Israel
Constantinos Siafakas, Greece
Maria Skouroliaikou, Greece
Francoise Smets, Belgium
André Smout, The Netherlands
Piotr Socha, Poland
Anna Solovyeva, Russian Federation
Amelie Stalke, Germany
Annamaria Staiano, Italy
Ekkehardt Sturm, Germany
Hania Szajewska, Poland

Merit Tabbers, The Netherlands
Jan Taminiau, The Netherlands
Alison Taylor, United Kingdom
Michela Tempia, Switzerland
Nikhil Thapar, United Kingdom
Julian Thomas, United Kingdom
Richard Thompson, United Kingdom
Mike Thomson, United Kingdom

Patrick Tounian, France
Riccardo Troncone, Italy
Voula Tsetsi, Belgium
Dan Turner, Israel
Andreas Tzakis, USA
Christos Tzivinikos, United Kingdom

Holm Uhlig, United Kingdom
Arun Urs, United Kingdom

Hans van Goudoever, The Netherlands
Patrick van Rheenen, The Netherlands
Michiel Van Wijk, The Netherlands
Yvan Vandenplas, Belgium
Genevieve Veereman, Belgium
Krishnappa Venkatesh, United Kingdom
Gábor Veres, Hungary
Henkjan Verkade, The Netherlands
Sabine Vriezinga, The Netherlands

Martina Weber, Germany
Batya Weiss, Israel
Katharina Werkstetter, Germany
Fiona Williams, United Kingdom
Michael Wilschanski, Israel
David Wilson, United Kingdom
Eytan Wine, Canada

John Xinias, Greece
Surender Kumar Yachha, India

Bartlomiej Zalewski, Poland
Aglia Zellos, Greece
Theodoros Ziambaras, Greece
The ePosters will be presented in the ePoster Session on Friday, 27 May 2016, at 13:45.

**Session 1**

**Chairs:** Steffen Husby, Denmark
Alexandra Papadopoulou, Greece

**GASTROENTEROLOGY**

**G-eP-001**
Effect of calcium and vitamin D supplementation in celiac disease
*Paola Sgaramella, Italy*

**G-eP-002**
Epitopes of human and microbial transglutaminases are similarly recognized by celiac disease sera
*Patricia Jeremias, Germany*

**G-eP-003**
Outside the normal limits: False positive/negative of anti TG2 autoantibodies
*Aaron Lerner, Israel*

**G-eP-004**
Epigenetic of Coeliac Disease: Expression in epithelial cells and cells of the lamina propria
*Donatella Cielo, Italy*

**G-eP-005**
Differential constitutive distribution of type 2 transglutaminase in skin derived-fibroblasts from celiac disease patients and from healthy subjects
*Maria Vittoria Barone, Italy*

**G-eP-006**
The role of functional platelet indices in childhood coeliac disease
*Nevzat Aykut Bayrak, Turkey*

**G-eP-007**
Critical appraisal of the 2012 ESPGHAN diagnosis criteria. Spanish Working Group on Celiac Disease
*Enriqueta Román Riechmann, Spain*

**G-eP-008**
Tissue transglutaminase Antibody cut-off and diagnosis of celiac disease
*Gloria Raimondi, Italy*

**G-eP-009**
Clinicopathological features of gastrointestinal and liver GVHD in children with allogeneic stem cell transplantation
*Zarife Kuloğlu, Turkey*

**G-eP-010**
A single center experience with endoscopic and surgical gastrostomy in pediatric patients: A 10 year review
*Jiyoung Kim, Rep. of South Korea*

**G-eP-011**
Solitary rectal ulcer syndrome in children: a case series study
*Kinga Kowalska-Duplaga, Poland*
G-eP-012
Esophageal Savary Dilation Is an Effective and Safe Treatment For Esophageal Narrowing Associated With Pediatric Eosinophilic Esophagitis

Abdulrahman Al-Hussaini, Saudi Arabia

G-eP-013
Ursodeoxycholic Acid Treatment is associated with improvement of liver stiffness in cystic fibrosis patients

Hubert van der Doef, The Netherlands

G-eP-014
Low sodium status is associated with decreased growth parameters in patients with cystic fibrosis

Peter Heinz-Erian, Austria

G-eP-015
RNA-based MAFA over-expression is sufficient to drive human pancreatic duct-derived cells toward a b-cell-like phenotype

Elisa Corritore, Belgium

G-eP-016
Lipid spectrum in paediatric patients with cystic fibrosis

Dorothea A. Schulkes, The Netherlands

G-eP-017
Clinical Course of Chronic Pancreatitis in Children with CFTR Mutation.

Aleksandra Marach, Poland

G-eP-018
Comparative effects of Clostridium difficile toxins on transepithelial chloride secretion and epithelial structure in in-vitro and ex-vivo human epithelium.

Vittoria Buccigrossi, Italy

G-eP-019
The Accuracy of the Three Dehydration Scales in Children with Acute Gastroenteritis in a Developing Country of Kosovo.

Teuta Hoxha-Kamberi, Kosovo

G-eP-020
Differences in cytokines response during acute infection of bacterial and viral gastroenteritis.

King Jun Koh, Taiwan

G-eP-021
Congenital diarrhea with predominant protein losing enteropathy is associated with two different biallelic mutations in DGAT1, the enzyme that catalyze triglyceride synthesis

Yael Haberman, Israel

G-eP-022
BAC treatment of the rectosigmoid in piglet: a reproducible model of partial aganglionosis in a large animal

Gaëlle Boudry, France

G-eP-024
In vitro assessment of the influence of intestinal pH and enzyme/substrate ratio on fats digestion in Cystic Fibrosis patients

Joaquim Calvo Lerma, Spain

G-eP-025
Primary eosinophilic gastrointestinal disorders after food oral immunotherapy

Sonia Fernández Fernández, Spain

G-eP-026
Peculiarities of the abdominal and digestive system manifestations in Armenian children with familial Mediterranean fever

Gayane Amaryan, Armenia

G-eP-027
An International Individual Participant Data Meta-Analysis (IPDMA) to Assess if Lactobacillus reuteri DSM 17938 Effective for the Treatment of Infant Colic

Michael Cabana, USA
**G-eP-028**
Long-term efficacy of proton pump inhibitor therapy in proton pump inhibitor-responsive Esophageal Eosinophilia
*Sonia Fernández Fernández, Spain*

**G-eP-029**
The incidence of eosinophilic esophagitis and treatment efficacy in children with dyspeptic symptoms
*Vlatka Konjik, Croatia*

**G-eP-030**
Gastric lipase and other lipolytic enzymes activity in the preterm infant fed raw, pasteurized or pasteurized-homogenized human milk
*Samira De Oliveira, France*

**G-eP-031**
Autoimmunity towards parietal cells in pediatric patients with Type 1 diabetes
*Agata Chobot, Poland*

**G-eP-032**
Treatment of children with intestinal failure associated bone fractures with pamidronate
*Esther Neelis, The Netherlands*

**G-eP-033**
Bone health in children with intestinal failure measured by dual energy X-ray absorptiometry and hand radiography
*Esther Neelis, The Netherlands*

**G-eP-034**
Diagnosis of non–coeliac gluten sensitivity: first double blind placebo controlled cross over trial in pediatrics.
*Antonia Gentile, Italy*

**G-eP-035**
Filaggrin and Periostin in Children with Eosinophilic Esophagitis.
*Aspasia Angelakopoulou, Greece*

**G-eP-036**
Cholesterol and bile acid synthesis in pediatric patients with short bowel syndrome
*Florian Gothe, Germany*

---

**Session 4**
Chairs: Sanja Kolacek, Croatia
Paolo Lionetti, Italy

**GASTROENTEROLOGY**

**G-eP-037**
Self-administered telemedicine empowers paediatric and adolescent patients with Inflammatory Bowel Disease
*Katrine Carlsen, Denmark*

**G-eP-038**
Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomized clinical study
*Katrine Carlsen, Denmark*

**G-eP-039**
Incidence and phenotype at diagnosis in very early compared to later-onset pediatric inflammatory bowel disease: a population-based study
*Emeline Bequet, Belgium*

**G-eP-040**
Mucosa-associated microbiome in paediatric patients with inflammatory bowel disease and the influence of treatment on its composition
*Rok Orel, Slovenia*

**G-eP-041**
Abdominal obesity in Paediatric Crohn’s disease is associated with adipokine dysregulation
*Dhamyanthi Thangarajah, United Kingdom*

**G-eP-042**
Cyclosporin A efficacy in a paediatric ulcerative colitis - a retrospective single center study.
*Marcin Osiecki, Poland*

**G-eP-043**
Tailored step-up approach results in beneficial long-term disease outcome in the prospective Belgian registry of paediatric Crohn’s disease (BELCRO)
*Lucas Wauters, Belgium*
| G-eP-044 | Type of treating physician is associated with long-term disease outcome in the prospective Belgian paediatric Crohn’s disease registry (BELCRO)  
Lucas Wauters, Belgium |
| --- | --- |
| G-eP-045 | Presence and severity of ulcerations in Crohn Disease does not contribute to response for induction therapy with infliximab in children  
Maciej Dadalski, Poland |
| G-eP-046 | Therapeutic drug monitoring in 45 children with IBD on maintenance infliximab treatment  
Helena Rolandsdotter, Sweden |
| G-eP-047 | Anti-TNF treatment in pediatric crohn´s disease... just a question of time?  
Patricia Domínguez Sánchez, Spain |
| G-eP-048 | Enterocytes and dendritic cells both contribute to the intestinal inflammation in pediatric inflammatory bowel diseases  
Caterina Strisciuglio, Italy |

**Session 5**

Chairs:  
Sibylle Koletzko, Germany  
Yvan Vandenplas, Belgium

**GASTROENTEROLOGY**

| G-eP-049 | Bacterial richness and the ratio of Bacteroidetes to Gammaproteobacteria are decreased in the colonic mucosa of pediatric ulcerative colitis  
Marko Kalliomäki, Finland |
| --- | --- |
| G-eP-050 | Clinical outcomes in paediatric ulcerative colitis: a single-centre cohort study  
Vivien Wong-Spracklen, United Kingdom |
| G-eP-051 | Fecal microbiota transplantation for CMV infection in pediatric patients with IBD  
Katarzyna Karolewska-Bochenek, Poland |
Silvia Ghione, Italy |
| G-eP-053 | Quality of life in pediatric Crohn’s disease: Data from Imagekids study  
Victor Manuel Navas López, Spain |
| G-eP-054 | Mucosal Healing in a cohort of IBD pediatric patients in clinical remission  
Francesca Paola Giugliano, Italy |
| G-eP-055 | Comparison of Efficacy and Safety of Biosimilar Infliximab to Originator Infliximab in Children with Inflammatory Bowel Disease  
Corinne Legeret, United Kingdom |
| G-eP-056 | Efficacy of oral Tacrolimus-as a concomitant rescue therapy in children with biologic refractory IBD  
Babu Vadamalayan, United Kingdom |
| G-eP-057 | Assessment of disease activity with Magnetic Resonance Enterography in Paediatric Crohn’s Disease  
Giovanna Zuin, Italy |
| G-eP-058 | Irritable bowel syndrome (IBS) like symptoms in pediatric patients with Crohn’s disease: functional symptoms or organic disease?  
Sara Isoldi, Italy |
| G-eP-059 | Fecal Calprotectin and Haematochezia in Colicky Infants.  
Francesco Savino, Italy |
| G-eP-060 | Intestinal permeability is increased in children with history of Irritable Bowel Syndrome  
Valentina Giorgio, Italy |
HEPATOLOGY

H-eP-001
“Atypical” bile acids are typical in the newborn infant
Jörg Jahnel, Austria

H-eP-002
Nuclear localization of hepatitis B virus cccDNA, X protein and epigenetic modifications and their relevance for chronification and carcinogenesis
Kai Hensel, Germany

H-eP-003
Vertical transmission of hepatitis C is not influenced by IL28B genotype in children
Afrodite Psaros Einberg, Sweden

H-eP-004
Serum Zinc levels discriminate “indeterminate” acute liver failure from “Wilson disease” acute liver failure
Palittiya Sintusek, United Kingdom

H-eP-005
Effect of demographic characteristics and underlying disease on cellular markers of immunity at time of liver transplantation - an analysis within the ChilSFree study
Ulrich Baumann, Germany

H-eP-006
Risk factors and impact of viremia on liver transplant outcomes in children undergoing preemptive therapy for Cytomegalovirus
Valeria Casotti, Italy

H-eP-007
Psychosocial outcome after paediatric liver transplantation
Katrin Mayer, Germany

H-eP-008
HHV-6 virus in children undergoing clinically-indicated liver biopsy following liver transplantation.
Ino Kanavaki, Switzerland

H-eP-009
Effect of treatment with ganciclovir and of pretransplant serologic status on EBV viremia after pediatric liver transplantation
Anniken Østensen, Norway

H-eP-010
Histopathological evaluation of the native liver in propionic acidaemia
Napat Angkathunyakul, United Kingdom

H-eP-011
Allograft inflammation and fibrosis among maintenance pediatric liver transplant recipients – genetic predisposition and antibodies, connecting the missing links
Sharat Varma, Belgium

H-eP-012
Cardiovascular risk factors after pediatric liver transplantation
Piotr Czubkowski, Poland

Session 7

Chair: Francoise Smets, Belgium
Giuseppe Indolfi, Italy

HEPATOLOGY

H-eP-013
Liver Disease In Pediatric Patients With Ataxia Telangiectasia: A Novel Report
Batia Weiss, Israel

H-eP-014
Very good response to hepatitis B virus vaccine in patients on treatment for latent tuberculosis
Björn Fischler, Sweden

H-eP-015
Poor long-term results of internal biliary diversion in patients with PFIC
Antal Nemeth, Sweden
H-eP-016
Biliary Atresia Splenic Malformation may not be indicative of bad prognosis? 
Sanjay Rajwal, United Kingdom

H-eP-017
Pediatric hepatocellular adenoma: benign hepatic tumors that may transform 
Isabelle Scheers, Belgium

H-eP-018
Non-adherence in young people with autoimmune liver disease: it’s about more than not taking medications 
Marianne Samyn, United Kingdom

H-eP-019
Gut microbiota composition and metabolism in infants with biliary atresia after hepatoportoenterostomy compared to healthy controls 
Ewa Orłowska, Poland

H-eP-020
Prophylactic endoscopic therapy in children with portal hypertension 
Harry Sutton, United Kingdom

H-eP-021
Semiquantitative evaluation of liver histology in children with Wilson’s disease 
Magdalena Naorniakowska, Poland

H-eP-022
Hepatokines in children with nonalcoholic fatty liver disease 
Marta Flisiak-Jackiewicz, Poland

H-eP-023
Evolution of incidence and characteristics of autoimmune liver diseases in children over 24 years in a French region 
Delphine Hivert, France

H-eP-024
Measurement of liver stiffness by Share Wave Elastography imaging technic in predicting oesophageal varices in portal hypertensive paediatric patients 
Didem Gulcu, Turkey

Session 8
Chairs: Florence Lacaille, France
Maria Rogalidou, Greece

HEPATOLOGY

H-eP-025
A urinary metabolomic signature of pediatric obesity related liver disease 
Jacopo Troisi, Italy

H-eP-026
Clinical practices among healthcare professionals concerning neonatal jaundice and pale stools 
Helena Moreira Silva, Portugal

H-eP-027
Tissue copper concentrations are lower in children with non-alcoholic fatty liver disease, but only in those with more advanced disease 
Emer Fitzpatrick, United Kingdom

H-eP-028
Autoimmune sclerosing cholangitis (AISC) in two cohorts in Europe and North America (NA): presentation of disease and follow-up 
Philip Bufler, Germany

H-eP-029
The role of plasma oxysterol measurement in the diagnosis of Niemann Pick C Disease in Children in Infantile Liver Disease 
Marumbo Mtegha, United Kingdom

H-eP-030
Study of Familial Tendency and PNPLA3 Polymorphism in Pediatric Non Alcoholic Fatty Liver Disease 
Vikrant Sood, India
<table>
<thead>
<tr>
<th>Session 9</th>
<th>Chairs: George Chouliaras, Greece Walter Mihatsch, Germany</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NUTRITION</strong></td>
<td></td>
</tr>
<tr>
<td><strong>N-eP-001</strong> Nutritional status in neurologically impaired children and its relation with bone mineralization</td>
<td><strong>N-eP-008</strong> A nutritional supplement beverage with and without probiotics during the third trimester of pregnancy and lactation show benefit on infant growth up to 12 months of age in the Philippines</td>
</tr>
<tr>
<td>Francesca Penagini, Italy</td>
<td>Sophie Pecquet, Switzerland</td>
</tr>
<tr>
<td><strong>N-eP-002</strong> Neurocognitive functions in infants with malnutrition; and its association with micronutrients, LC-PUFA and brain metabolits</td>
<td><strong>N-eP-009</strong> Bone status in preterm infants: influences of maternal factors and nutritional regimens</td>
</tr>
<tr>
<td>Murat Cakir, Turkey</td>
<td>Paola Gaio, Italy</td>
</tr>
<tr>
<td><strong>N-eP-003</strong> Eating behaviour and macronutrient intake before and during growth hormone treatment in short children born small for gestational age</td>
<td><strong>N-eP-010</strong> Extremely preterm infants experience hyperglycemia beyond the first days of life</td>
</tr>
<tr>
<td>Koen Huysentruyt, Belgium</td>
<td>Itay Zamir, Sweden</td>
</tr>
<tr>
<td><strong>N-eP-004</strong> Results of the ESPGHAN Nutrition Training Survey</td>
<td><strong>N-eP-011</strong> Sialyllactose and galacto-oligosaccharides differentially modulate microbiota composition, intestinal epithelium gene expression, and dendritic cell development</td>
</tr>
<tr>
<td>Jörg Jahnel, Austria</td>
<td>Laurien Ulfman, The Netherlands</td>
</tr>
<tr>
<td><strong>N-eP-005</strong> Does exclusive enteral nutrition affect the clinical course in paediatric Crohn’s disease patients?</td>
<td><strong>N-eP-012</strong> Detection of bovine proteins in human milk and amniotic fluid using proteomics</td>
</tr>
<tr>
<td>Elena Scarpato, Italy</td>
<td>Shay Phillips, USA</td>
</tr>
<tr>
<td><strong>N-eP-006</strong> Is obesity due to precocious antibiotic therapy an iceberg phenomenon?</td>
<td><strong>N-eP-013</strong> Protective effects of Milk Fat Globule Membrane and L. fermentum CECT 5716 on gut functions and on T cells response in a newborn rat model</td>
</tr>
<tr>
<td>Luminita Dobrota, Romania</td>
<td>Tiphaine Vanhaecke, France</td>
</tr>
<tr>
<td><strong>N-eP-007</strong> Growth assessment of preterm infants using detailed anthropometry</td>
<td><strong>N-eP-014</strong> High amino acid and energy intake influence the levels of zinc in the preterm neonate</td>
</tr>
<tr>
<td>James Ashton, United Kingdom</td>
<td>Maria Di Chiara, Italy</td>
</tr>
<tr>
<td><strong>N-eP-008</strong></td>
<td><strong>N-eP-015</strong> Systematic review: early infant feeding practices and the risk of wheat allergy</td>
</tr>
<tr>
<td></td>
<td>Ania Chmielewska, Poland</td>
</tr>
<tr>
<td></td>
<td><strong>N-eP-016</strong> Synaptic maturation in newborn piglets is dependent on immunoglobulins</td>
</tr>
<tr>
<td></td>
<td>Kateryna Goncharova, Sweden</td>
</tr>
</tbody>
</table>
N-eP-017
Lactobacillus rhamnosus GG derived soluble mediators modulate adaptive immunity in vitro
Sarmauli Manurung, The Netherlands

N-eP-018
Antibody-independent detection of bovine β-lactoglobulin derived peptides in human milk
Rosita Aitoro, Italy

Session 10
Chairs: Tamás Decsi, Hungary
Smaragdi Fessatou, Greece

NUTRITION

N-eP-019
Dysbalanced polynsaturated fatty acids metabolism in cow milk allergy: new clues for pathogenesis understanding and dietary treatment in food allergy
Lorella Paparo, Italy

N-eP-020
Growth of Infants Born to Obese Women: PREOBE Project
Liliana Ladino, Colombia

N-eP-021
Attitudes and practices of coaches concerning rapid weight loss in competitive judo and taekwondo athletes
Tali Sinai, Israel

N-eP-022
Visual evoked potentials in offspring born to mothers with overweight, obesity and gestational diabetes
Staffan K. Berglund, Sweden

N-eP-023
Antidiarrhoeal activity of milk derived compounds with enkephalinase inhibitory activity in a castor oil-induced diarrhoea in rats.
Maria Rodriguez-Palmero, Spain

N-eP-024
Rice protein hydrolysate and probiotic bifidobacterium breve combined with omega-3 fatty acids prevent weight gain and associated metabolic changes in a porcine model of prepuberal obesity
Maria Rodriguez-Palmero, Spain

N-eP-025
Nutritional and antibiotic intervention during lactation attenuates development of offspring measured by novel developmental score for mice, the “mouse-D-score”.
Wim van Hartingsveldt, The Netherlands

N-eP-026
Effectiveness of a primary prevention program of overweight in 0-3 year old children, the BBOFT+ study; a cluster randomized trial.
Eline Vlasblom, The Netherlands

N-eP-027
Extensively hydrolyzed casein formula containing L.rhamnosus GG prevents the occurrence of other allergic manifestations in children with cow’s milk allergy: 3-year randomized controlled trial
Roberto Berni Canani, Italy

N-eP-028
Dietary influence on epigenetic mechanisms in children with IgE-mediated cow’s milk allergy
Roberto Berni Canani, Italy

N-eP-029
Effect of different hydrolyzed formulas and soy formula on tolerance acquisition in children with cow’s milk allergy
Enza D’Auria, Italy

N-eP-030
Pediatric intestinal failure patients dependent on parenteral nutrition are at risk of biochemical essential fatty acid deficiency
Riikka Gunnar, Finland
Poster Exhibition

Poster Presentations

The presenters of the posters are requested to set-up their posters in the Poster Area on Thursday morning, 26 May, from 07:30 and to take them down by Saturday, 28 May, 14:00. Any posters not removed by this time will be disposed of by the meeting organisers. Please note that missing poster numbers in this programme have been previously withdrawn.

Poster Session

The Poster Session will take place on Friday, 27 May 2016, 13:30 – 15:15. All poster presenters should stand by their posters during this session in order to talk about their research work with other delegates.

During this session all poster presenters will be visited by designated Poster Judges. The Poster Judges will be glad to involve all presenters and delegates in an interactive discussion about the posters. The best poster presentations of each topic will be awarded by the Poster Judges. The presenters of the best posters will receive a certificate. Please find the names of the Poster Judges in the Faculty List on page 74 of this programme brochure.
BASIC SCIENCE

**G-P-001**
Crosstalk between BMP and Notch signaling in intestinal epithelial cell fate decision after massive small bowel resection in a rat
*Drora Berkowitz, Israel*

**G-P-002**
Precocious gastrointestinal maturation can be induced in T-cell deficient athymic (nude) suckling rats
*Ester Arevalo Sureda, Sweden*

**G-P-003**
Information for Minors Participating in Research Projects: Current Practice and Evaluation of a New Format
*Sabine Vriezinga, The Netherlands*

COELIAC DISEASE

**G-P-004**
Gluten free diet may improve obstructive sleep apnea related symptoms in children with celiac disease
*Anat Yerushalmy Feler, Israel*

**G-P-005**
Patients with mild enteropathy have apoptotic injury of enterocytes similar to that in advanced enteropathy in celiac disease: Implications on the treatment
*Anil Kumar Verma, Italy*

**G-P-006**
I-FABP as an early marker of coeliac disease in the paediatric risk groups – preliminary study
*Anna Rybak, United Kingdom*

**G-P-007**
Specific antibodies for celiac disease in patients with Crohn’s disease - preliminary report
*Anna Szaflarska-Poplawska, Poland*

**G-P-008**
Characterizing Combined Esophageal Eosinophilia and Celiac Disease in Children
*Noam Zevit, Israel*

**G-P-009**
Raising the cut-off value for anti-tissue transglutaminase antibodies decreased the number of unnecessary biopsies in children with type 1 diabetes
*Anouk Velthuis, The Netherlands*

**G-P-010**
An Evaluation of Psychiatric Disorders such as Quality of Life, Anxiety and Depression in Celiac Patients
*Aylin Yücel, Turkey*

**G-P-011**
Bone mineral density and vitamin K in children with celiac disease: Is there a link?
*Burcu Volkan, Turkey*

**G-P-012**
Pubertal development in children diagnosed with Celiac Disease
*Burcu Volkan, Turkey*

**G-P-013**
First Epidemiological Study on Celiac Disease in Children in Colombia. A Study on the Prevalence of Celiac Disease in Children with Type I Diabetes and Controls
*Carlos Alberto Velasco-Benitez, Colombia*

**G-P-014**
Positive celiac serology at onset of diabetes and spontaneous normalization – Analysis of predictive factors
*Claudia Banzato, Italy*

**G-P-015**
Iodine and autoimmune diseases. Urinary iodine concentration in children affected by coeliac disease or thyroiditis
*Claudia Banzato, Italy*

**G-P-016**
Severe rhabdomyolysis and celiac disease association
*Claudia Mandato, Italy*
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>G-P-017</td>
<td>Prevalence of eosinophilic esophagitis in children with celiac disease</td>
<td>Derya Altay, Turkey</td>
</tr>
<tr>
<td>G-P-018</td>
<td>Does type 1 diabetes mellitus increase the risk of gastritis in coeliac disease?</td>
<td>Elisabetta Manzali, Italy</td>
</tr>
<tr>
<td>G-P-019</td>
<td>The Relationship between Vitamin D and Quality of Life in Children with Celiac Disease</td>
<td>Eylem Sevinç, Turkey</td>
</tr>
<tr>
<td>G-P-020</td>
<td>Psychopathology, Quality of Life, and Associated Factors in children with Celiac Disease</td>
<td>Eylem Sevinç, Turkey</td>
</tr>
<tr>
<td>G-P-021</td>
<td>Internalizing symptoms and parental mental health problems in untreated children with celiac disease</td>
<td>Giorgos Giannakopoulos, Greece</td>
</tr>
<tr>
<td>G-P-022</td>
<td>Emotional/behavioral problems and frustration caused by gluten free diet compliance in treated patients with coeliac disease</td>
<td>Giorgos Giannakopoulos, Greece</td>
</tr>
<tr>
<td>G-P-023</td>
<td>Spectrum of autoimmunity at diagnosis of Celiac Disease</td>
<td>Irene Rutigliano, Italy</td>
</tr>
<tr>
<td>G-P-024</td>
<td>Prevalence of coeliac disease is not increased in hyperkinetic disorder in NE Slovenia</td>
<td>Jernej Dolinšek, Slovenia</td>
</tr>
<tr>
<td>G-P-025</td>
<td>Related factors to quality of life in celiac children</td>
<td>Josefa Barrio Torres, Spain</td>
</tr>
<tr>
<td>G-P-026</td>
<td>The effect of synbiotic use on the levels of anti-tissue transglutaminase IgA autoantibodies</td>
<td>Kaan Demiroren, Turkey</td>
</tr>
<tr>
<td>G-P-027</td>
<td>Celiac disease and Down syndrome mortality: a nationwide case-control study</td>
<td>Karl Márild, Norway</td>
</tr>
<tr>
<td>G-P-028</td>
<td>Vitamin D status in cord blood and later risk of celiac disease</td>
<td>Ketil Stordal, Norway</td>
</tr>
<tr>
<td>G-P-029</td>
<td>The value of a questionnaire based screening in identification of children at high risk for celiac disease</td>
<td>Laura Trandafir, Romania</td>
</tr>
<tr>
<td>G-P-030</td>
<td>Prevalence of increased liver values and their association with the clinical and histological features in children with celiac disease</td>
<td>Linnea Äärelä, Finland</td>
</tr>
<tr>
<td>G-P-031</td>
<td>IL-15 gene polymorphism in celiac disease patient and their healthy siblings.</td>
<td>Makbule Eren, Turkey</td>
</tr>
<tr>
<td>G-P-032</td>
<td>Measuring diet compliance in coeliac children and adolescents: is there an easier way than the dietary interview?</td>
<td>Margreet Wessels, The Netherlands</td>
</tr>
<tr>
<td>G-P-033</td>
<td>Implementation of the 2012 ESPGHAN guideline and the diagnostic algorithm of Celiac Disease in children. Results of a retrospective study in the Netherlands.</td>
<td>Marjolijn Landman, The Netherlands</td>
</tr>
<tr>
<td>G-P-034</td>
<td>Administration of Bifidobacterium breve decreases the production of TNF-α and faecal fermentation index in children with celiac disease</td>
<td>Martina Klemenak, Slovenia</td>
</tr>
<tr>
<td>G-P-035</td>
<td>The evaluation of muscle power in children patients with celiac disease and the effects of gluten free diet and exercise program on to muscle power</td>
<td>Hasan Ali Yüksekkaya, Turkey</td>
</tr>
</tbody>
</table>
| G-P-036 | Vitamin-D receptor gene polymorphism in celiac disease  
| Meltem Gumus, Turkey |
| G-P-037 | Examination of the Presence of Dental Enamel Defects and Oral Manifestation in Children with Celiac Disease  
| Merve Usta, Turkey |
| G-P-038 | HLA Genotypes in Czech Children with Coeliac Disease  
| Peter Szitanyi, Czech Republic |
| G-P-039 | Prevalence of Helicobacter pylori infection in pediatric patients with celiac disease  
| Nafiye Urganci, Turkey |
| G-P-040 | Prevalence of Asthma and Allergic Rhinitis in Children with Celiac Disease  
| Nafiye Urganci, Turkey |
| G-P-041 | Infrequent out-patient visits have deleterious effects on growth and nutritional status of children with Coeliac disease.  
| Nevzat Aykut Bayrak, Turkey |
| G-P-042 | Assessment of Liver Injuries Among Children With Celiac Disease  
| Oana Belei, Romania |
| G-P-043 | Maternal and postnatal exposure to antibiotics and the risk of developing celiac disease  
| Olof Sandström, Sweden |
| G-P-044 | Treatment of HCT116 cells with gliadin, transglutaminases and complexes thereof imitating celiac disease  
| Patricia Jeremias, Germany |
| G-P-045 | Longitudinal study in celiacs relatives patients typing HLA DQ related to celiac disease  
| Raquel Furnes, Argentina |
| G-P-046 | Extraintestinal symptoms in celiac disease: prevalence and impact to the disease presentation  
| Samuli Nurminen, Finland |
| G-P-047 | Comparison of the reliability of celiac disease serology to reflect intestinal damage  
| Sandra Neidhöfer, Germany |
| G-P-048 | Bone mineral density in children with screening-detected celiac disease: a case-control study  
| Sara Björck, Sweden |
| G-P-049 | Evaluation of the correlation between tTG-IgA titer and duodenal biopsy findings in children with suspected celiac disease  
| Seyed Mohsen Dehghani, Iran |
| G-P-050 | Barriers to implementing the revised ESPGHAN guidelines for coeliac disease in children – a national cross-sectional survey across the paediatric units in England  
| Siba Paul, United Kingdom |
| G-P-051 | Validation of the Diagnosis of Coeliac Disease by Linkage of National Patient and Pathology Registers, and Presence of Antibodies  
| Stine Dydensborg Sander, Denmark |
| G-P-052 | Anaemia in children with celiac disease: association with the clinical, serological and histological findings and response to the gluten-free diet  
| Teemu Rajalahti, Finland |
| G-P-053 | HoxD12 is a potential disease biomarker in pediatric celiac disease  
| Theodora Katsila, Greece |
**ENTEROPATHY (OTHER THAN COELIAC DISEASE)**

**G-P-054**
Microvillous inclusion disease (MVID): a regional centre experience
*Anjum Grewal, United Kingdom*

**G-P-055**
Highly diverse digestive presentation of stat3 gain-of-function mutation in four affected members of the same family
*Fabienne Charbit-Henrion, France*

**G-P-056**
Unnecessary Abdominal Exploration in Neonates with Congenital Chloride Losing Diarrhea
*Haifa Al Awadhi, Saudi Arabia*

**G-P-057**
Non-syndromic congenital tufting enteropathy results from cell contractility defects
*Julie Salomon, France*

**G-P-058**
Prevalence of cows’ milk allergy (CMA) in infants could be influenced by socioeconomic factors: report of a Chilean cohort experience
*Maria Eugenia Arancibia, Chile*

**G-P-059**
Clinical Presentation and Food Allergens Associated with Food Protein-Induced Enterocolitis Syndrome – a Frequently Misdiagnosed Rare Form of Gastrointestinal Food Hypersensitivity
*Roslyn Tarrant, Ireland*

**G-P-060**
Half cow’s milk-induced food protein induced enterocolitis syndrome (FPIES) require amino acid feeding
*Sibylle Blanc, France*

**G-P-061**
Our cases with sucrase isomaltase deficiency
*Sirmen Kizilcan, Turkey*

**G-P-062**
An Italian study assessing the population prevalence of self-reported gluten sensitivity
*Valentina Gasparre, Italy*

**G-P-063**
An Atypical presentation of Systemic Lupus Erythematosus
*Viswanathan Sivaramakrishnan, India*

**G-P-064**
The preliminary investigation of fecal microbiota transplantation for pediatric recurrent chronic bowel disease and literary review
*Youhong Fang, China*

**G-P-065**
MicroRNA expression in the colonic mucosa of pediatric patients with eosinophilic colitis
*Zoltán Kiss, Hungary*

**CYSTIC FIBROSIS AND PANCREATIC DISORDERS**

**G-P-066**
Isolated Polycystic Pancreatic Disease In An Adolescent Of 14 Years Old Case Report And Review Of Literature
*Abdul-Monem Badran, France*

**G-P-067**
Analysis of Pediatric Pancreatitis (APPLE trial): Pre-study protocol of a multinational prospective clinical trial.
*Andrea Párniczky, Hungary*

**G-P-068**
Observational Clinical Trial About Pain IN EArly phase of Pediatric Pancreatitis (PINEAPPLE)
*Dóra Mosztbacher, Hungary*

**G-P-069**
Alpha1-antitripsin deficiency and pancreatitis in children.
*Elwira Kolodziejczyk, Poland*

**G-P-070**
Microbial Colonization of Pancreatic Stents – Accidental Discovery or Reason for Concern?
*Elwira Kolodziejczyk, Poland*

**G-P-071**
New ultrasonographic protocol for early diagnosis of Cystic Fibrosis liver disease
*Eyal Shteyer, Israel*
G-P-072
Genetic testing, MRT and Pancreatic function tests are essential in the investigation of Chronic and Recurrent Pancreatitis in Children
Fredrik Lindgren, Sweden

G-P-073
Clinical experience of management of Acute Pancreatitis in children: needs to revise diagnostic criteria?
Luigi Martemucci, Italy

G-P-074
Combined Liver Pancreas transplant in an adolescent patient with Cystic Fibrosis – first Australasian experience
Jonathan Bishop, New Zealand

G-P-075
Analysis of causes and clinical course of chronic pancreatitis in children with the early-onset of the disease.
Karolina Wejnarska, Poland

G-P-076
The clinical presentation of chronic pancreatitis in children with SPINK1 gene mutations
Karolina Wejnarska, Poland

G-P-077
Obesity among Greek children with Cystic Fibrosis
Konstantina Vasilaki, Greece

G-P-078
Association of TNF-α Gene Variants With Clinical Manifestation of Cystic Fibrosis Patients of Iranian Azeri Turkish Ethnicity
Mandana Rafeey, Iran

G-P-079
Gender gap in clinical presentation of cystic fibrosis patients in Azeri Turkish populations
Mandana Rafeey, Iran

G-P-080
Clinical practice in acute pancreatitis in a prospectively collected pediatric cohort.
Natalia Lasztity, Hungary

G-P-081
Pancreaticobiliary maljunction in children presenting with severe abdominal pain and icterus
Neslihan Gürcan Kaya, Turkey

G-P-082
Genetic influence over vitamin d deficiency and bone lose in patients with cystic fibrosis
Tatjana Jakska-Maretti, Macedonia

ENDOSCOPY

G-P-083
Videocapsule endoscopy confirms the presence of active Crohn’s disease in children where magnetic resonance enteroscopy is normal or inconclusive, resulting in subsequent changes of disease management
Alexandra Bobarnac, Belgium

G-P-084
Emergency upper gastrointestinal endoscopy in children in district general hospitals in the UK... time for a rethink?
Amit Saha, United Kingdom

G-P-085
Biopsy-induced duodenal hematoma is a rare complication favored by hematological disorders
Anais Sierra, France

G-P-086
A Rare Cause of Iron Deficiency Anemia: Phacomatosis Pigmentovascularis
Asuman Karhan, Turkey

G-P-087
Granular cell tumor of Esophagus in pediatric population of a single center
Bauraind Olivia, Belgium

G-P-088
Use of percutaneous endoscopic gastrostomy in children with primary neurologic disease in the last 10 years
Carlos Ruiz Hernández, Spain

G-P-089
Esophageal eosinophilia in pediatrics endoscopies after ten years of analysis
Erica Rezende, Brazil
**G-P-090**
Guideline for wireless capsule endoscopy in children and adolescents: A consensus document by the SEGHNP (Spanish Society for Pediatric Gastroenterology, Hepatology, and Nutrition) and the SEPD (Spanish Society for Digestive Diseases)
*Ester Donat, Spain*

**G-P-091**
Bowel Preparation For Elective Paediatric Procedures
*Fiona Tyacke, United Kingdom*

**G-P-092**
Gastrointestinal bleeding associated with pharmacologic treatment of patent ductus arteriosus in preterm neonates
*Gianluca Terrin, Italy*

**G-P-093**
Impact of ethnicity and atopic status on treatment response to Eosinophilic Oesophagitis
*Mashood Ayaz, United Kingdom*

**G-P-094**
A tertiary care center experience in feasibility and safety of ERCP in infants, children and adolescents
*Jasmin Felix, Germany*

**G-P-095**
Flexible endoscopic procedure in children with foreign bodies in the upper gastrointestinal tract
*Kaan Demiroren, Turkey*

**G-P-096**
Service Evaluation of Bristol Endoscopy
*Lakshmipriya Selvarajan, United Kingdom*

**G-P-097**
Endoscopic Findings in Children with Isolated Rectal Bleeding
*Manar Matar, Israel*

**G-P-098**
Experience of 19 years in Percutaneous Endoscopic Gastrostomy in children
*Marcela Alarcón Gamarra, Spain*

**G-P-099**
Duodenal–Jejunal Bypass Liner- Primary Experience in Morbidly Obese Adolescents, Safety and Efficacy
*Matjaz Homan, Slovenia*

**G-P-100**
Inventory on primary prophylaxis in portal hypertension in children in France, Belgium, French speaking Canada and Switzerland
*Odile Malet, France*

**G-P-101**
Diagnostic yield of Colonoscopy in Children: A Single Center Experience in Turkey
*Selim Dereci, Turkey*

**G-P-102**
Bowel Preparation before Colonoscopy for Children: Comparison of Efficacy of Three Different Methods
*Seyed Mohsen Dehghani, Iran*

**G-P-103**
Small Bowel Diaphragmatic Disease
*Shishu Sharma, United Kingdom*

**G-P-104**
Use of oesophageal stent and trans thoracic T-tube in a case of oesophageal perforation post button battery ingestion.
*Shishu Sharma, United Kingdom*

**G-P-105**
A comparison of the sedation with midazolam-ketamine versus propofol-fentanyl during upper GI endoscopy in children
*Ulas Emre Akbulut, Turkey*

**G-P-106**
Evaluation of esophageal pathology in children who underwent esophagogastroduodenoscopy
*Ulas Emre Akbulut, Turkey*

---

**PEPTIC DISEASE AND HELICOBACTER PYLORI**

**G-P-107**
Endoscopic and Histological Findings in Children with Recurrent Abdominal Pain with and without Helicobacter Pylori Infection
*Danijela Jojkic-Pavkov, Serbia*
How much is the effect of helicobacter pylori in children with gastrointestinal hemorrhage?
*Derya Altay, Turkey*

Are there any factors associated with chronic helicobacter pylori negative gastritis?
*Efrat Broide, Israel*

Associations between Helicobacter pylori infection and Body Mass Index in children: Any relation between Obesity and Helicobacter pylori?
*Esra Polat, Turkey*

Antibiotic resistance by Helicobacter pylori in a Portuguese pediatric population
*Gisela Silva, Portugal*

Complaints, endoscopic and histopathological findings in patients with helicobacter pylori infection and their correlation with each other
*Gunsel Kutluk, Turkey*

Correlation between helicobacter pylori colonization and obesity in pediatric population
*Hadar Lev, Israel*

Inhaled air analyzer Helicosens – a new device for detection of Helicobacter pylori infection
*Kawtar Driouiche, Morocco*

Heart rhythm and conduction disorders in children with complicated duodenal ulcer
*Kseniya Yurchyk, Belarus*

Helicobacter pylori in the pediatric population in the health area of a tertiary hospital: microbiological diagnosis and antimicrobial susceptibility
*MCarмен Rivero de la Rosa, Spain*

Helicobacter pylori in the oral cavity of children
*Merve Usta, Turkey*

Validation of quick Helicobacter pylori stool antigen test in children
*Nicolas Kalach, France*

Vitamin B12 (Cobalamin) deficiency and Helicobacter Pylori infection in children.
*Sarit Peleg, Israel*

High Helicobacter pylori resistance to clarithromycin and metronidazole in Turkish Children
*Sevim Cakar, Turkey*

Detection of Clarithromycin Resistance and 23S rRNA Gene Point Mutations Using the Method Polymerase Chain Reaction at Paraffin Blocks for Children with Helicobacter Pylori Infection in Manisa Region, Western Turkey
*Yeliz Cagan Appak, Turkey*

The Effect of Helicobacter pylori Eradication on Functional Dyspepsia in Turkish Children: Cost of Diagnosis and Treatment
*Aysel Ünlüsoy Aksu, Turkey*

Pollen count and incidence of oesophageal eosinophilia in southwestern area of the region of Madrid: is there a relationship?
*Enrique La Orden Izquierdo, Spain*

Clinical profile of oesophageal eosinophilia: multicenter study of the southwest area of Madrid.
*Sonia Fernández Fernández, Spain*
G-P-125
Evaluation of patient/parent satisfaction of a newly established Paediatric Gastroenterology Ambulatory Unit (PGAU).
Aikaterini Kakotrichi, United Kingdom

G-P-126
Non-communicable chronic diseases: the role of neonatal characteristics
Antonio Dimauro, Italy

G-P-127
Clinical Features of Appendicitis in Early Childhood: Comparison with Late Childhood Onset
Chun Woo Song, Rep. of South Korea

G-P-128
Availability of low dose CT in the diagnosis of appendicitis in childhood and comparison of abdominal USG and standard dose CT
Dae Yong Yi, Rep. of South Korea

G-P-129
Anastomotic ulcerations in short bowel syndrome: an unsolved problem
Filippo Torroni, Italy

G-P-130
Screen Postpartum Depression in Pediatric Gastroenterology: Time Has Come.
Gokhan Baysoy, Turkey

G-P-131
The burden of gastrointestinal diseases on admissions to general paediatrics: 15-years follow-up of 4500 children.
Jake Mann, United Kingdom

G-P-132
Non-invasive monitoring of regional tissue oxygenation in newborn using near-infrared spectroscopy
Laura Olariu, Romania

G-P-133
Ten years after a successful intestinal transplantation: what is their life?
Lorenzo Norsa, France

G-P-134
Specificity of infant gastric digestive conditions: new in vivo data from preterm
Samira De Oliveira, France

G-P-135
Evaluation of microencapsulated sodium butyrate effects in young patients with newly diagnosed IBD – preliminary results.
Agnieszka Gawronska, Poland

G-P-136
Efficacy of a micronised, dispersible ferric pyrophosphate in children with anemia associated with inflammatory bowel disease
Agnieszka Wegner, Poland

G-P-137
Natural history of paediatric Inflammatory Bowel Disease- Unclassified: single tertiary UK centre experience
Ahmed Kadir, United Kingdom

G-P-138
Faecal Calprotectin as a Biomarker of Intestinal Inflammation in Children younger than 5 years old.
Aikaterini Kakotrichi, United Kingdom

G-P-139
Maintenance of remission in paediatric Crohn disease using mesalazine monotherapy: a single centre experience
Amit Saha, United Kingdom

G-P-140
Prevalence of thromboembolism in pediatric patients with inflammatory bowel disease-data from the CEDATA-GPGE registry
Andrea Deutschmann, Austria

G-P-141
Diagnostic and prognostic value of auto and anti - microbial antibody profiles in paediatric inflammatory bowel disease patients
Anna Maria Peter, Switzerland

G-P-142
The role of environmental exposure and nutritional habits in development of inflammatory bowel disease in pediatric population
Anna Stochel-Gaudyn, Poland
| G-P-143 | Assessment of IMPACT III Emotional and Social Functioning Domain Scores in Adalimumab-Treated Paediatric Patients with Crohn’s Disease |
| G-P-144 | Malignancy and mortality in paediatric onset inflammatory bowel disease |
| G-P-145 | The Effect of Colectomy in the Course of Inflammatory Bowel Disease |
| G-P-146 | Laparoscopic Colectomy for Ulcerative Colitis with Associated Auto-Immune Liver Disease and Portal hypertension |
| G-P-147 | Usefulness of Magnetic Resonance Enterography in Assessment of Small Bowel Diseases in Children with Crohn’s Disease |
| G-P-148 | Combination of 2 biologicals in pediatric Crohn’s disease with paradoxical psoriasis due to TNF alfa inhibitors. |
| G-P-149 | Adalimumab treatment for luminal inflammatory pediatric Crohn’s disease: Long-term single center experience |
| G-P-150 | Similarity of Clinical Outcomes and Golimumab Pharmacokinetics in Adult and Pediatric Patients with Moderate to Severe Ulcerative Colitis Treated with Subcutaneous Administered Golimumab |
| G-P-151 | Osteopontin in paediatric patients with IBD |
| G-P-152 | Effectiveness of induction therapy of ulcerative colitis in children with biosimilar infliximab – 1,5 year of experience. |
| G-P-153 | Immunogenicity of biosimilar infliximab in children with colitis ulcerosa- single centre experience |
| G-P-154 | Value of laboratory parameters in determining of endoscopic exacerbation of Crohn’s disease in children |
| G-P-155 | Transition clinic in inflammatory bowel disease: a two centre model |
| G-P-156 | Pancreas and bowel: a causal or random linkage? |
| G-P-157 | Aminosalicylates and pediatric UC: use and efficacy at one year from diagnosis, results from the Pediatric IBD Italian registry. |
| G-P-158 | Mortality and cancer in paediatric inflammatory bowel disease in Scotland 2005-2013 |
| G-P-159 | The prevalence of growth failure and short stature in paediatric onset Crohn´s disease |
| G-P-160 | Investigating the small bowel in pediatric Crohn’s disease: prospective comparative study between small intestine contrast ultrasonography and magnetic resonance imaging |
| G-P-161 | Accuracy of non-invasive tests in the initial diagnostic work-up of pediatric inflammatory bowel diseases  
*Fortunata Civitelli, Italy* |
| G-P-162 | Health care transition of patients with pediatric onset Inflammatory Bowel Disease: a Pilot Survey.  
*Giovanna Alfano, Italy* |
| G-P-163 | Evaluation of Autonomic Nervous System Functions in Children with Inflammatory Bowel Disease in Remission Phase  
*Gunsel Kutluk, Turkey* |
| G-P-164 | Prevalence and Evaluation of Predictors of Poor Outcome in Paediatric Crohn’s Disease Patients – data from the CEDATA-GPGE registry  
*Jan de Laffolie, Germany* |
| G-P-165 | Patient Registry CEDATA-GPGE – a collaborative development of an enhanced online platform to facilitate quality improvement  
*Jan de Laffolie, Germany* |
| G-P-166 | Tolerance and effectivity of preparation to magnetic resonance enterography with 3% sorbitol solution in children with IBD.  
*Joanna Sieczkowska, Poland* |
| G-P-167 | Efficacy of biosimilar infliximab induction therapy in paediatric patients with Crohn’s disease – 1,5 year of experience.  
*Joanna Sieczkowska, Poland* |
| G-P-168 | Immunogenicity after switching from reference infliximab to biosimilar in children with Crohn disease.  
*Joanna Sieczkowska, Poland* |
| G-P-169 | Immunogenicity of pertussis booster vaccination in adolescents with inflammatory bowel disease: a controlled study  
*Katarzyna Karolewska-Bochenek, Poland* |
| G-P-170 | Clinical response and reported experience of adolescent newly diagnosed Crohn’s Disease patients treated with exclusive enteral nutrition: A single centre experience  
*Katie Keetarut, United Kingdom* |
| G-P-171 | Circulating inflammatory cytokine profiles in children with newly diagnosed ibd: determining trends in ulcerative colitis and crohn’s disease patients  
*Kevan Jacobson, Canada* |
| G-P-172 | Fermentation capacity of gut microbiota of patients with inflammatory bowel disease compared with healthy controls  
*Konstantinos Gerasimidis, United Kingdom* |
| G-P-173 | Comparison between calprotectin and high motility group box 1 (HMGB1) protein as fecal biomarkers of intestinal inflammation in pediatric and adult patients with inflammatory bowel disease  
*Laura Stronati, Italy* |
| G-P-174 | Oral implementation of exclusive enteral nutrition (EEN) with Modulen IBD is good tolerated method of therapy to induce remission and to normalize nutritional status and growth velocity in children with active Crohn’s disease (CD)  
*Malgorzata Matuszczyk, Poland* |
| G-P-175 | Listeria meningitis in a child with Crohn’s disease: An important complication of immunosuppression  
*Maria Ioannidou, Greece* |
| G-P-176 | Feasibility and effectiveness of a psycho-educational program in adolescents with Inflammatory Bowel Disease (IBD)  
*Maria Maragkoudaki, Greece* |
| G-P-177 | Predicting outcome of pediatric Crohn’s disease: role of clinical, endoscopic and imaging findings at the diagnosis  
*Marina Aloi, Italy* |
| G-P-178 | Assessing iron status in children with inflammatory bowel disease: beyond absolute iron deficiency  
Marjolijn Akkermans, The Netherlands |
| G-P-179 | Ileo-cecal Crohn's disease is associated with early stricturing and poor medical outcomes in children  
Massimo Martinelli, Italy |
| G-P-180 | Assessing mucosa state in children with Crohn's disease using faecal calprotectin  
Monika Meglicka, Poland |
| G-P-181 | Evaluation of the nutritional status in our pediatric patients with inflammatory bowel disease at diagnosis  
Natàlia Egea, Spain |
| G-P-182 | 5-year review of IBD management in children with autoimmune liver disease; a single-centre experience  
Natalia Nedelkopoulou, United Kingdom |
| G-P-183 | Adalimumab as First Line Biologic Therapy is Effective and Well Tolerated by Children with Crohn's Disease  
Nkem Onyeador, United Kingdom |
| G-P-184 | Altered mucosal expression of microRNAs in pediatric patients with inflammatory bowel disease  
Nóra Judit Béres, Hungary |
| G-P-185 | Young IBD patients should receive a combotherapy (IS and IFX) until the 3rd infusion of Infliximab to reduce the risk of acute infusion reactions.  
Olivier Courbette, France |
| G-P-186 | Tacrolimus has a transient efficacy for the treatment of refractory Crohn disease colitis in children  
Oriane Truffinet, France |
| G-P-187 | Serum hepcidin concentration in children with inflammatory bowel disease (IBD)  
Paulina Krawiec, Poland |
| G-P-188 | Outcomes in a prospective cohort of newly diagnosed children with Crohn's disease treated with exclusive enteral nutrition  
Protima Amon, United Kingdom |
| G-P-189 | Can infliximab treatment for pediatric inflammatory bowel disease be safely stopped? Results from a single center cohort retrospective study.  
Ron Shaoul, Israel |
| G-P-190 | Rapid Infliximab infusions are generally well-tolerated in children with inflammatory bowel disease - an Australian perspective.  
Rupert Hinds, Australia |
| G-P-191 | Pediatric Crohn’s Disease and its Disability Over Time: a Study Performed With a New Pediatric Lémann Index. Data from a Tertiary Pediatric IBD Center  
Serena Arrigo, Italy |
| G-P-192 | Neutrophil Extracellular Traps in Pediatric Inflammatory Bowel Disease  
Shlomi Cohen, Israel |
| G-P-193 | Audit on Thiopurine metabolites in children receiving Thiopurines for Inflammatory Bowel Disease  
Sian Copley, United Kingdom |
| G-P-194 | Incidence of both Crohn's disease and ulcerative colitis is continuing to rise and is higher in the city population  
Siba Paul, United Kingdom |
| G-P-195 | Not just another Crohn's disease  
Siba Paul, United Kingdom |
G-P-196  
Fecal calprotectin in monitoring IBD patients: useful or not?  
Silvia Salvatore, Italy

G-P-197  
Post surgical relapse of Crohn's disease in pediatric population of a tertiary center  
Simona Faraci, Italy

G-P-198  
Aseptic splenic abscesses can precede paediatric inflammatory bowel disease (pIBD) well before manifestation of the disease - 2 case report  
Tania Ahmad, United Kingdom

G-P-199  
An Audit of Exclusive Enteral Nutrition use in Crohn’s Disease  
Theo Wong, United Kingdom

G-P-200  
Variation in the treatment of new onset pediatric IBD among phenotypically similar patient subgroups in Canada: a cross-sectional analysis of the Canadian Children IBD Network Inception Cohort.  
Thomas Walters, Canada

G-P-201  
Faecal microbiomes of paediatric patients with inflammatory bowel disease  
Rok Orel, Slovenia

G-P-202  
NOX1 loss-of-function genetic variants in patients with inflammatory bowel disease  
Tobias Schwerd, United Kingdom

G-P-203  
Faecal calprotectin a useful non-invasive biologic marker for infliximab therapy in paediatric inflammatory bowel disease  
Tracee Reid, United Kingdom

G-P-204  
Non-invasive markers for diagnosis and determination of the severity of ulcerative colitis in children - preliminary study  
Urszula Daniluk, Poland

G-P-205  
Patient perceptions of food-based dietary treatment of Crohn’s Disease; A survey of paediatric patients previously treated with exclusive enteral nutrition  
Vaios Svolos, United Kingdom

G-P-206  
Vitamin D Metabolism-related Gene Polymorphisms in Crohn’s Disease  
Youyou Luo, China

G-P-207  
Diagnostic Accuracy of Resonance Imaging Enterography, Capsule Endoscopy and Ileocolonoscopy in Children with Crohn’ s Disease  
Youyou Luo, China

G-P-208  
A novel exonic mutation inducing aberrant splicing in the IL10RA gene and resulting in infantile-onset inflammatory bowel disease  
Yugo Takaki, Japan

GI-INFECTIONS

G-P-209  
Diagnostic accuracy of faecal calprotectin in less than six-year-olds with gastrointestinal symptoms in a tertiary paediatric gastroenterology centre  
Alexsandra Zambrano Perez, United Kingdom

G-P-210  
Epidemiology, clinical features and risk of recurrence of Clostridium difficile infection in children living in a low prevalence country  
Andrea Lo Vecchio, Italy

G-P-211  
Clinical evaluation of a synbiotic for children between 6 months and 2 years with acute viral diarrhea  
María José de Ibarondo Guerica-Echevarría, Spain

G-P-213  
Hyperlipasemia in Rotavirus Infection: why?  
Irene Rutigliano, Italy
G-P-214  Assessing the colonic microbiome in children: Effects of sample site and bowel preparation
Azelea Rushd, United Kingdom

G-P-215  Interrater variability of Amsterdam Infant Stool Scale: a single center study
Katarzyna Wojtyniak, Poland

G-P-216  Oral microbiota is not a cause of basal increased levels of expired hydrogen
Kris Van de Maele, Belgium

G-P-217  Gut dysbiosis in children affected by autism spectrum disorder
Lorella Paparo, Italy

G-P-218  Efficacy of an ORS enriched with L. reuteri DSM 17938 and zinc in infants with acute gastroenteritis: a double blind, placebo controlled trial
Maria Maragkoudaki, Greece

G-P-219  Faecal calprotectin and eosinophil-derived neurotoxin in healthy children
Maria Roca, Spain

G-P-220  The influence of cefotaxime sodium on gut microbiota in neonate
Mizu Jiang, China

G-P-222  Anisakid: a new threat coming from the sea
Ramón Tormo, Spain

G-P-223  Differences in Intestinal Microbiota of Infants between Vaginal Delivery and C-Section, in particular Alpha-Toxigenic and Enterotoxigenic Clostridium perfringens
Ravinder Nagpal, Japan

G-P-224  Features of Intestinal Microbiota of Young Adults born by C-section
Ravinder Nagpal, Japan

G-P-225  Development of the intestinal microbiota after short and long antibiotic treatment in late-preterm and term infants
Jan Knol, The Netherlands

G-P-226  Elevated troponin levels in infants with acute gastroenteritis: is it ischemia or Rota associated carditis
Sana Barakat, Egypt

G-P-227  Practical approach to acute gastroenteritis in Austria: a nationwide survey on intravenous rehydration
Sebastian Bauchinger, Austria

GI MOTILITY, GERD AND FUNCTIONAL GI DISORDERS

G-P-228  Gastric Functional Abnormalities in Children with Helicobacter Pylori Gastritis
Ahmed Megahed, Egypt

G-P-229  Efficacy of Synbiotic, Probiotic, and Prebiotic Treatments for Irritable Bowel Syndrome in Children: a randomized controlled trial
Ahmet Basturk, Turkey

G-P-230  The systematic effect of infant formulas on stool consistency proven by longitudinal statistical models
Alfonso Rodriguez-Herrera, Spain

G-P-231  Accuracy of the Strobel and Modified Strobel formulae in pH catheter placement in children: A prospective cohort study
Amit Saha, United Kingdom

G-P-232  Colonic manometry parameters can predict the outcome of the surgical ostomy formation in children with intractable constipation
Anna Rybak, United Kingdom
G-P-233
Efficiency and Immunologic Effects of Synbiotics in Children with Functional Abdominal Pain
Ayşegül Otuzbir, Turkey

G-P-234
Prevalence of small intestinal bacterial overgrowth in children with functional gastrointestinal disorders
Banu Bal Çermik, Turkey

G-P-235
Intragastric pressure measurement during nutrient intake: a novel minimally invasive method to measure gastric accommodation in functional dyspepsia.
Carbone Florencia, Belgium

G-P-236
Is anorectal manometry useful in a gastroenterology pediatric unit?: our 10 years experience in a tertiary hospital
César Sánchez Sánchez, Spain

G-P-237
How can we measure orocecal transit in critically ill children? Our hydrogen breath test lactulose experience
César Sánchez Sánchez, Spain

G-P-238
Probiotics for the management of chronic constipation in children: A Cochrane systematic review
Chris Wallace, United Kingdom

G-P-239
Do Italian pediatricians apply the 2014 NASPGHAN-ESPGHAN guidelines for the diagnosis and management of Functional Constipation?
Cinzia Ciullo, Italy

G-P-240
Transverse rectal diameter and thickness of the anterior wall of the rectum in children with and without functional constipation
Daniela Pop, Romania

G-P-241
Diagnosis and management of esophageal achalasia in children.
Dorota Jarzębicka, Poland

G-P-242
Do children just grow out of Irritable Bowel Syndrome?
Eleonora Giannetti, Italy

G-P-243
Analysis of gastric and duodenal eosinophilic children with abdominal pain related functional gastrointestinal disorders according to ROME III criteria
Eun Hye Lee, Rep. of South Korea

G-P-244
Combined multichannel intraluminal impedance-ph (MII-pH): a step forward towards reference values
Fernanda Cristofori, Italy

G-P-245
Functional gastrointestinal disorders in children from low socioeconomic status and Helicobacter pylori infection
Francisca Jaime, Chile

G-P-246
Functional gastrointestinal disorders in Greek children: Prevalence and significant socioeconomic correlates
George Chouliaras, Greece

G-P-247
Depression and Anxiety are Related to Various Functional Gastrointestinal Disorders in Adolescents
Gokhan Baysoy, Turkey

G-P-248
The importance of combined 24-hour multichannel intraluminal impedance-pH monitoring for children with gastrointestinal symptoms suggesting gastroesophageal reflux disease
Iva Hojsak, Croatia

G-P-249
Probiotics for the management of functional abdominal pain in children: A Cochrane systematic review
Joe Stone, United Kingdom
G-P-250
Endoscopic and histopathologic findings in patients with disphagia
Josefa Barrio Torres, Spain

G-P-251
Low impedance baseline values predict severe esophagitis.
Judith Cohen Sabban, Argentina

G-P-252
Excessive crying during infancy predisposes to behavioral problems in early childhood
Judith Zeevenhooven, The Netherlands

G-P-253
Treatment of functional gastrointestinal disorders with dietary exclusions in an adolescent population: Outcomes on „milk, egg, wheat and soya“ (MEWS) free diet versus Low „Fermentable Oligo-Di-Mono and Di-saccharide (FODMAP) Diet exclusions
Katie Keetarut, United Kingdom

G-P-254
Could be the Reactive Gastropathy an Explanation for Functional Abdominal Pain?
Kinga Cristina Slavescu, Romania

G-P-255
Primary Duodenogastric Reflux and Reactive Gastropathy – A Survey on Children in Romania
Kinga Cristina Slavescu, Romania

G-P-256
pH-Impedance Features of Gastro-Esophageal Reflux Inducing Respiratory Symptoms
Letizia Zenzeri, Italy

G-P-257
Childhood functional constipation—change in behavioral difficulties based on treatment outcomes
Line Modin, Denmark

G-P-258
The characteristic of gastroesophageal reflux disease in children with adenoid hypertrophy
Marcin Dziekiewicz, Poland

G-P-259
Frequency of gastroesophageal reflux disease and esophageal motility disorders in adolescents with anorexia nervosa
Marcin Dziekiewicz, Poland

G-P-260
Magnesium Alginate plus Simethicone versus Lansoprazole in children with poorly controlled asthma: preliminary results
Marco Maglione, Italy

G-P-261
Lactobacillus reuteri DSM 17938 for the management of functional abdominal pain (FAP) in children: a multicenter randomized controlled trial
Maria Maragkoudaki, Greece

G-P-262
Efficacy and safety of gastrojejunal feeding tubes in children
Marta German, Spain

G-P-263
Infant colic is associated with low-grade systemic inflammation
Anna Pärtty, Finland

G-P-264
Childrens’GERD May Be Linked to Mothers’ Psychopathology
Meltem Ugras, Turkey

G-P-265
High-resolution impedance manometry measurement of bolus flow time in pediatric achalasia
Michiel van Wijk, The Netherlands

G-P-266
Inter- and intraobserver reliability of the reflux finding score for infants (RFS-I) in flexible versus rigid laryngoscopy
Michiel van Wijk, The Netherlands

G-P-267
Effects of carob-bean gum thickened formulas on infants’ reflux, growth and tolerance indices
Miglena Georgieva, Bulgaria
G-P-268
Development of a core outcome set for infant colic
Nina Steutel, The Netherlands

G-P-269
Lactobacillus reuteri in the treatment of functional abdominal pain in children – randomized, double-blind, placebo-controlled study
Oleg Jadresin, Croatia

G-P-270
Long-term outcome of neonates with suspected Hirschsprung’s disease but normal rectal biopsy
Oren Ledder, Israel

G-P-271
The colo-anal reflex is mediated via an extrinsic neural pathway
Palittiya Sintusek, United Kingdom

G-P-272
Utility of antroduodenal manometry in predicting response to prokinetics children with upper gastrointestinal symptoms
Raquel Plácido Paisas, Spain

G-P-273
Hydrogen breath testing in children: A retrospective audit of practice in a tertiary paediatric unit
Rashad Hasanov, United Kingdom

G-P-274
Gastroesophageal reflux symptoms in healthy infants measured by the Infant Gastroesophageal Reflux Questionnaire Revised (I-GERQ-R): a cross-sectional study
Romy Koning, The Netherlands

G-P-275
An Importance of Magnesium Deficiency in the Formation of Vegetative Disadaptation in Children and Adolescents with Digestive Tract Pathology
Serhii Potapenko, Ukraine

G-P-276
Neonatal programming of functional gastrointestinal disorders in infants
Silvia Salvatore, Italy

G-P-277
Transanal irrigation in the treatment of children with intractable constipation
Sophie Kuizenga-Wessel, The Netherlands

G-P-278
Reporting on outcome measures of functional constipation in children
Sophie Kuizenga-Wessel, The Netherlands

G-P-279
Surgical management of children with functional constipation: What are we doing and are we doing it right?
Sophie Kuizenga-Wessel, The Netherlands

G-P-280
Gastric emptying and myoelectrical activity in children with Esophageal atresia-tracheoesophageal fistula
Usha Krishnan, Australia

G-P-281
Prevalence of Gastrointestinal functional disorders in a cohort of children affected by type II and III Spinal Muscular Atrophy
Valentina Giorgio, Italy
**BASIC SCIENCE**

**H-P-001**
Capturing t-cell receptors - a potential new modality for targeting hepatic tumours and post-transplantation lymphoproliferative disease (PTLD)
Nicola Ruth, United Kingdom

**H-P-002**
Ammonium affects expression of mRNA aquaporin 8 in hepatocytes
Karianne Vegheim, Norway

**H-P-003**
Leukocyte MMP-2, TIMP-2 and IGF-1R expression are preferentially increased in children with NAFLD as compared to their healthy obese counterparts
Wojciech Janczyk, Poland

**GENERAL HEPATOLOGY**

**H-P-004**
Further Evidence of Immune Mediation in Extrahepatic Biliary Atresia
Mohamed Shagrani, Saudi Arabia

**H-P-005**
Serum resitin elevation occurs specifically in the NAFLD in children
Aldona Wierzbicka, Poland

**H-P-006**
Iron Overload In The Liver of Two Children: Nonalcoholic Steatohepatitis and Juvenile Hemochromatosis
Aysel Ünlüsoy Aksu, Turkey

**H-P-007**
Autoimmune Liver disease in Children with Sickle Cell Disease
Suttiruk Jitraruch, United Kingdom

**H-P-008**
Kasai portoenterostomy in Biliary Atresia- single centre experience with adjuvant therapy
Sanjay Rajwal, United Kingdom

**H-P-009**
Long-term developmental outcome in extremely preterm infants with cholestasis
Jonas Teng, Sweden

**H-P-010**
Role of different cytokine polymorphisms in predicting the response to Pegylated interferon alfa-2a plus ribavirin in Egyptian children with chronic hepatitis C genotype 4
Sana Barakat, Egypt

**H-P-011**
Hepatoblastoma in Explanted Livers of Patients with Biliary Atresia
Achiya Amir, Israel

**H-P-013**
Efficacy and security of TIPS in children
Etna Masip, Spain

**H-P-014**
Postvaccination immunity against hepatitis B virus in children
Barbara Santangelo, Italy

**H-P-015**
Non-invasive assessment of liver fibrosis in children: correlations between transient elastography and biochemical markers
Tudor Lucian Pop, Romania

**H-P-016**
Hepatic lesions associated with McCune Albright Syndrome
Patrick McKiernan, United Kingdom

**H-P-017**
Analysis of Hepatic Steatosis in Children (a single center experience)
Asuman Karhan, Turkey
H-P-018  
Studies on gut liver axis dysfunction in obese children with and without hepatic complications  
Salvatore Guercio Nuzio, Italy

H-P-019  
Viraemic Relapse After Apparent Spontaneous Clearance in a Child Vertically Infected by Hepatitis C Virus  
Giuseppe Indolfi, Italy

H-P-020  
Improved adhesion and rolling of adult derived human liver stem cells (ADHLSC) cultured on thermosensitive polymer and attached with sialyl Lewis X.  
Pierre-Edouard Dollet, Belgium

H-P-021  
Development of an adherence self-help leaflet for the parents of children with liver disease.  
Faith Matcham, United Kingdom

H-P-022  
Predictives Factors of Positive Response to Interferon Treatment in Chronic B Active Hepatitis in Children  
Oana Belei, Romania

H-P-023  
Portal Vein Obstruction: The Challenge of Timely Diagnosis  
Dalia Belsha, United Kingdom

H-P-024  
Stool colour cards allow specific identification of infant cholestasis: results of a prospective, experimental, monocentric, non-profit pilot study  
Paola Gaio, Italy

H-P-025  
Clinical and immunological aspects of patients with chronic D hepatitis  
Corina Cazan, Romania

H-P-026  
A Hidden Cause of Toxic Hepatitis: Herbal Anti-Colic Remedies  
Asuman Karhan, Turkey

H-P-027  
A retrospective study of the outcomes for paediatric chronic hepatitis B infection post adefovir dipivoxil treatment  
Adam Arshad, United Kingdom

H-P-028  
An international survey regarding management of coagulopathy in children undergoing liver biopsy  
Björn Fischler, Sweden

H-P-029  
The impact of serum bile acid levels on the mRNA expression of pro- and anticoagulant proteins in liver tissue  
Antal Nemeth, Sweden

H-P-030  
Evolution of fulminant liver failure in mushroom poisoning in children  
Alina Grama, Romania

H-P-031  
Genotype-phenotype correlation in Wilson’s disease with haemolytic anaemia and acute liver failure in children  
Tudor Lucian Pop, Romania

H-P-032  
Prevalence of the ATP7B gene mutations among children with Wilson’s disease from North-Western Romania  
Tudor Lucian Pop, Romania

H-P-033  
APRI as a fibrosis marker in children with autoimmune hepatitis (AIH)  
Karolina Piwczyńska, Poland

H-P-034  
Biliary atresia outcome in greek children: a 14 year experience in a tertiary referral center  
Aglaia Zellos, Greece

H-P-035  
Autoimmune hepatitis in greek children: a 14 year experience in three tertiary referral centers  
Aglaia Zellos, Greece
<table>
<thead>
<tr>
<th>Paper ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-P-036</td>
<td>Evaluation Of Thyroid Hormones in Paediatric Acute Liver Failure Patients</td>
<td>Zeren Barış, Turkey</td>
</tr>
<tr>
<td>H-P-037</td>
<td>Predictors of liver steatosis and fibrosis measured by Fibroscan in children with Wilson’s disease.</td>
<td>Wojciech Janczyk, Poland</td>
</tr>
<tr>
<td>H-P-038</td>
<td>Portosystemic shunt surgery in children: Gazi university experience</td>
<td>Neslihan Bozbulut, Turkey</td>
</tr>
<tr>
<td>H-P-039</td>
<td>Use of the Paediatric End-stage Liver Disease Score for prediction of the evolution in fulminant liver failure caused by mushroom poisoning in children</td>
<td>Tudor Lucian Pop, Romania</td>
</tr>
<tr>
<td>H-P-040</td>
<td>Autoimmune hepatitis or Wilson’s disease or both? Analysis of challenging cases</td>
<td>Magdalena Naorniakowska, Poland</td>
</tr>
<tr>
<td>H-P-041</td>
<td>Role of plasmapheresis in acute liver failure of autoimmune etiology</td>
<td>Banu Bal Çermik, Turkey</td>
</tr>
<tr>
<td>H-P-042</td>
<td>Portal hypertensive biliopathy as a cause of cholestasis in children with congenital hepatic fibrosis</td>
<td>Neslihan Gürcan Kaya, Turkey</td>
</tr>
<tr>
<td>H-P-043</td>
<td>The Effect of Vitamin D Deficiency on Nonalcoholic Fatty Liver Disease Development in Obese Children</td>
<td>Makbule Eren, Turkey</td>
</tr>
<tr>
<td>H-P-044</td>
<td>Antenatal and postnatal clinical spectrum of congenital portosystemic shunts: experience from a university hospital with high patient turnover</td>
<td>Mustafa Serdar Cantez, Turkey</td>
</tr>
<tr>
<td>H-P-045</td>
<td>Novel Mutation of ABCB11 Heterozygote Associated with Transient Neonatal Intrahepatic Cholestasis</td>
<td>Jae Young Kim, Rep. of South Korea</td>
</tr>
<tr>
<td>H-P-046</td>
<td>Lysosomal acid lipase activity deficiency in children with liver disease: What Else Could It Be?</td>
<td>Giusy Ranucci, Italy</td>
</tr>
<tr>
<td>H-P-047</td>
<td>Liver ciliopathies in children; a single centre 20-year experience</td>
<td>Natalia Nedelkopoulou, United Kingdom</td>
</tr>
<tr>
<td>H-P-048</td>
<td>Subclinical neurological involvement does not develop if Wilson’s disease is treated early</td>
<td>Giusy Ranucci, Italy</td>
</tr>
<tr>
<td>H-P-049</td>
<td>The significance of portal hypertension in children with biliary atresia.</td>
<td>Maria Goliszek, Poland</td>
</tr>
<tr>
<td>H-P-050</td>
<td>Non Cirrhotic Portal Fibrosis in Pediatric Population- Breaking the Myths!!</td>
<td>Vikrant Sood, India</td>
</tr>
<tr>
<td>H-P-051</td>
<td>Revised scoring system for the diagnosis of Wilson disease in children</td>
<td>Palittiya Sintusek, United Kingdom</td>
</tr>
<tr>
<td>H-P-052</td>
<td>Native liver survival in children with biliary atresia and ascites</td>
<td>Sandra Maria Gonçalves Vieira, Brazil</td>
</tr>
<tr>
<td>H-P-053</td>
<td>One-Year Native Liver Loss after Spontaneous Bacterial Peritonitis in Pediatric Patients compared to Adults</td>
<td>Sandra Maria Gonçalves Vieira, Brazil</td>
</tr>
</tbody>
</table>
| H-P-054 | De novo autoimmune hepatitis in first high volume pediatric liver transplantation program in Saudi Arabia  
Kishwer Kumar, Saudi Arabia |
| H-P-055 | Liver transplantation from a donor with β-thalassemia intermedia is not contraindicated  
Ersin Gumus, Turkey |
| H-P-056 | Outcomes of Patients Recommended for Transplant In a Cohort of Infants Born Less Than 30 Weeks Gestation with Intestinal Failure  
Ann Anderson Berry, USA |
| H-P-057 | Survival after liver transplantation in metabolic diseases and congenital liver diseases  
Sirmen Kizilcan, Turkey |
| H-P-058 | Autoimmune BSEP disease after liver transplantation: effect of azathioprine  
Nicolette Moes, The Netherlands |
| H-P-059 | Plasmapheresis, intravenous immunoglobulin and rituximab successfully treat recurrent progressive familial intrahepatic cholestasis type 2 (PFIC-2) after liver transplantation  
Mohamed Shagrani, Saudi Arabia |
| H-P-060 | Adherence to treatment in adolescents after organ transplant and chronic disease and their psychological correlates.  
Marta A. Biernacka, Poland |
| H-P-062 | Sensorineural hearing loss in pediatric liver transplanted patients  
Yael Mozer - Glassberg, Israel |
| H-P-064 | Bone metabolism in children after liver transplantation  
Dolóresz Szabó, Hungary |
| H-P-055 | The Incidence, Risk Factors And Clinical Course of De Novo Hepatitis B Infection in Paediatric Living Donor Liver Transplantation  
Zeren Barış, Turkey |
| H-P-066 | Donor specific antibodies (DSA) in children, five years after liver transplantation  
Loreto Hierro, Spain |
| H-P-067 | Does antiviral prophylaxis prevent cytomegalovirus associated complications in paediatric liver transplant recipients?  
Palaniswamy Karthikeyan, United Kingdom |
| H-P-068 | Pulmonary function in children with cystic fibrosis (CF) after liver transplantation  
Sebastian Więckowski, Poland |
| H-P-069 | Bloodstream infections in children after living related liver transplantation. One center experience.  
Kishwer Kumar, Saudi Arabia |
| H-P-070 | Primary hyperoxaluria type 1 as an indication for liver-kidney transplantation – single center experience  
Irena Jankowska, Poland |
BASIC SCIENCE

N-P-001
The adhesion of S. pneumoniae to respiratory cells is reduced by bovine milk oligosaccharides
Mariarosaria Marotta, Ireland

N-P-002
IgG-binding Fc receptor (FcRn) expression in small intestine and brain in neonatal rats
Ester Arevalo Sureda, Sweden

N-P-003
Modulation of Serotonergic Stress Neurocircuitry by Dietary Prebiotics and Bioactive Milk Fractions
Brian Berg, USA

N-P-004
An Early Diet with Prebiotics and Bioactive Milk Fractions Modulates the Stress-Evoked Inflammatory Response
Maciej Chichlowski, USA

N-P-005
Lactobacillus rhamnosus GG (LGG) soluble mediators ameliorate visceral pain hypersensitivity induced by early life stress in rats
Gabriele Gross, USA

N-P-006
Free-living Glycemic Profiles of Children With Overweight and Obesity in Association With Cardiometabolic Risk
Jesse Rijks, The Netherlands

N-P-007
Direct effects of fermented rice with lactobacillus paracasei cba l74 on th1/th2 response in children with cow's milk allergy
Rosita Aitoro, Italy

N-P-008
Pituitary hyperresponsiveness to thyrotropin releasing hormone in children with overweight and obesity
Jesse Rijks, The Netherlands

N-P-009
The influence of phospholipids derived fatty acids to circulating non-esterified fatty acids
Felicitas Maier, Germany

N-P-010
The sources of pediatric nurses knowledge and skills in children feeding
Ewa Winnicka, Poland

N-P-011
Serum butyrate concentration in children affected by cow's milk allergy
Lorella Paparo, Italy

N-P-012
Gestational protein restriction impacts bulk 15N natural isotopic abundance from birth in mice offspring
Arnaud De Luca, France

N-P-013
Protein Oxydation as a Relevant Factor for Determining Protein Status is Adults
Gerlof Reckman, The Netherlands

N-P-014
Glycoside-hydrolase activity in the human gut microbiome
Cristina Campoy, Spain

CLINICAL NUTRITION

N-P-015
Simple dietary criteria to improve serum n-3 fatty acid levels of mothers and their infants one month after delivery
Ulla Hautero, Finland

N-P-016
Nutritional status of children with severe form of cerebral palsy fed by gastrostomy
Anija Orel, Slovenia

N-P-017
The role of Leptine Gene Polymorphisms 223 G/A in children's obesity
Marginean Cristina Oana, Romania

N-P-018
Nutritional support is useful in infant with congenital heart disease
Ignacio Ros, Spain
| N-P-019 | Role of Nutrition Management of Chylous Ascites Post Pediatric Liver Transplantation, Single Center Experience  
Sahar Madkhali, Saudi Arabia |
| N-P-020 | Current issue of nutrition status assessment in hospitalized children with chronic heart failure  
Natalia Zvonkova, Russian Federation |
| N-P-021 | Caffeine consumption in adolescents: from coffee to energy drinks and back again  
Barbara Santangelo, Italy |
| N-P-022 | Impact of nutritional status on prognosis factors and response to treatment of remission induction in children with acute lymphoblastic leukemia  
Luisa García-riosas Vázquez, Mexico |
| N-P-023 | Pediatric Parenteral Nutrition: Experience of a University Hospital with 178 Patients  
Asuman Karhan, Turkey |
| N-P-024 | Nutritional status assessment of children of SOS children’s villages Bata (Equatorial Guinea) regarding nutrition training program for cooperation team  
César Sánchez Sánchez, Spain |
| N-P-025 | Validation of Tanita BC-418 in a population of 8 year old Caucasian children, using deuterium oxide dilution as a reference technique  
Veronica Luque, Spain |
| N-P-026 | Nutrition assessment in 126 hospitalized children with hepatic disease  
Ting Zhang, China |
| N-P-028 | Association amongst anthropometric status, micronutrients deficiencies and bone mineral density in neurologically impaired children  
Elena Creuh-Gaudiza, Spain |
| N-P-029 | Accurate Estimation of Energy Requirements of Youth in Different Nutritional Status  
Xiaonan Li, China |
| N-P-030 | Nutritional intervention neurologically impaired children: a population-based study  
Claudio Romano, Italy |
| N-P-031 | Diabetic Ketoacidosis: What is changing  
Irene Rutigliano, Italy |
| N-P-032 | Acute metabolic complications and nutritional assessment in children and adolescents with anorexia nervosa  
Orjena Žaja, Croatia |
| N-P-033 | Lean Body Mass Measurement as a Part of Dietitian Assessment in Infants with Cholestatic Liver Disease before Liver Transplantation.  
Luba Marderfeld, Israel |
| N-P-034 | Effect of cyproheptadine on growth velocity in children with Silver-Russell syndrome  
Anaïs Lemoine, France |
| N-P-035 | Survey on dietary habits of a pediatric IBD population in Southern Italy: preliminary results.  
Massimo Martinelli, Italy |
| N-P-036 | Indications for using the hydrolyzed protein industrial formula in infants treated with the Home Enteral Nutrition (HEN) - not only in case of allergy.  
Małgorzata Matuszczyk, Poland |
| N-P-037 | The use of specialist medium chain triglyceride (MCT) formulas in infants with biliary atresia  
Deepa Kamat, United Kingdom |
<table>
<thead>
<tr>
<th>N-P-038</th>
<th>The Importance of Regional Body Composition when using DXA scan in Patients with End Stage Liver Disease (ESLD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eirini Kyrana, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>N-P-039</th>
<th>Pediatric Nutrition Week: The four editions – Colombia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maria Bages, Colombia</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>N-P-040</th>
<th>Vitamin E deficiency in children with chronic liver disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Juliana Roda, Portugal</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>N-P-041</th>
<th>The differences of food preference and physical fitness between children born low birth weight and children born normal birthweight are age- and gender-dependent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Muqing Cao, China</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>N-P-042</th>
<th>Wilkie’s syndrome admitted with acute abdomen: a case presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hasret Ayyildiz Civan, Turkey</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>N-P-043</th>
<th>Family history of atopy in infants with cow’s milk protein allergy: a french real lifestudy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicolas Kalach, France</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>N-P-044</th>
<th>Pooled analysis of the Cow’s Milk Symptom Score (CoMiSS) as a predictor for the diagnosis of cow’s milk allergy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yvan Vandenplas, Belgium</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Pretty, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>N-P-046</th>
<th>Gluten: essential for wheat survival but detrimental to human health</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aaron Lerner, Israel</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>N-P-047</th>
<th>A multi-component intervention programme for overweight and obese children</th>
</tr>
</thead>
<tbody>
<tr>
<td>Milena Morano, Italy</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>N-P-048</th>
<th>The relationship between nutrition and vitamin D sufficiency in infants and children under three years of age residing in the south of Russia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Victoria Kuryaninova, Russian Federation</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>N-P-049</th>
<th>Features of early physical development of overweight children aged 7-10 years old</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elena Roslavtseva, Russian Federation</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>N-P-050</th>
<th>Influence of calcium intake and of calcium intake adequacy to recommendations on bone mineral density.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marta Zaragoza-Jordana, Spain</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>N-P-051</th>
<th>Nutritional status and motor function in cerebral palsy in spanish regional hospital</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCarmen Rivero de la Rosa, Spain</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>N-P-052</th>
<th>Suger-sweetened beverages intake positively associated with the risks of abdominal obesity and increased triglyceride concentration among children aged 7-18 in China</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baoting He, China</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>N-P-053</th>
<th>Hepcidin and iron metabolism associated with cardiometabolic risk factors in children: a case-control study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baoting He, China</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>N-P-054</th>
<th>Vitamin D Deficiency in Moscow Teenagers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sugyan Narine, Russian Federation</td>
<td></td>
</tr>
</tbody>
</table>
| N-P-055 | Severe Vitamin D Deficiency Rickets in an infant Manifested as Hypocalcaemic Seizures a case report  
Biljana Vuletic, Serbia |
| N-P-056 | Liver disease and early vascular lesions in obese children  
Manon Goisbault, France |
| N-P-057 | Motivational aspects of alcohol consumption in sporting adolescents  
Thierry De Vreker, Belgium |
| N-P-059 | Bone microarchitecture in children with long term parenteral nutrition: a prospective pilot study.  
Typhaine Louazon, France |
| N-P-060 | Food safety in Infancy: are the Italian paediatricians informed enough?  
Michele di Toma, Italy |
| N-P-061 | The impact of nutritional status on oral health and lipid metabolism parameters in adolescents  
Paulina Krawiec, Poland |
| N-P-062 | Chronic malnutrition in pediatric cancer patients: incidence, risk factors and complications  
Amandine Rubio, France |
| N-P-063 | Cow’s milk allergy guidelines: the quality appraisal with the AGREE II instrument  
Piotr Dziechciarz, Poland |
| N-P-064 | Italian pediatric nutrition day  
Antonella Lezo, Italy |
| N-P-065 | Systematic review: early infant feeding and the prevention of type 1 diabetes  
Małgorzata Pieścik-Lech, Poland |
| N-P-066 | Development of Urinary Adiponectin and Fibroblast Growth Factor-21 Assay Tool for the Population-based Screening of Pediatric Metabolic Syndrome  
Jin Soo Moon, Rep. of South Korea |
| N-P-067 | A comparative study of the course and outcome of pregnancy and delivery, and the blood and colostrum content of hormones regulating energy homeostasis in Moscow women with normal and excessive body weight  
Nataliya Shilina, Russian Federation |
| N-P-068 | Obesity, but not metabolic syndrome, is associated with decreased trace elements in adolescents  
Szu-Ta Chen, Taiwan |
| N-P-069 | Are gluten free products available in Europe and in USA comparable?  
Paula Crespo Escobar, Spain |
| N-P-070 | Dietary fiber intake in children with inflammatory bowel disease  
Aleksandra Pituch-Zdanowska, Poland |
| N-P-071 | Iron deficiency -potential risk factor for febrile seizures  
Raluca Maria Costea, Romania |
| N-P-072 | Early feeding practices influence weight gain and gastrointestinal health in the STRONG Kids 2 cohort.  
Sharon Donovan, USA |
| N-P-073 | Obesity prevention project in preschool-age: the 3P-Project effectiveness in short- and medium-term  
Pietro Vajro, Italy |
| N-P-074 | BMI and food behavior in a cohort of Russian young children aged 12-35 months.  
Aleksandra Surzhik, Russian Federation |
| N-P-075 | The effect of breastfeeding and complementary feeding on growth and later health: a systematic review of systematic reviews  
Bartłomiej Zalewski, Poland |
| --- | --- |
| N-P-076 | A new approach to home artificial nutrition in children: a multidisciplinary process between a university hospital and local health authority (ASL-NA1) in Campania region  
Andrea Lo Vecchio, Italy |
| N-P-077 | Aetiology and outcome of long term hospital intestinal failure in 2015  
Vinod Sharma, United Kingdom |
| N-P-078 | Is the actual trend of eating habits among 5-12 years old children going in the right direction?  
Andreia Florina Nita, Romania |
| N-P-079 | Protein and fat intake in children up to 3 years and their effect on growth and later risk of overweight/obesity: a systematic review of systematic reviews  
Maciej Kołodziej, Poland |
| **NEONATAL AND INFANT NUTRITION** |  |
| N-P-080 | Profile of hypernatremic dehydration due to inadequate breastfeeding in a referral NICU in India: review of 76 cases  
Deepa Hariharan, India |
| N-P-081 | The early-life nutritional status and progress in nutritional support strategy of extremely low birth weight infants in China  
Meiying Quan, China |
| N-P-082 | The clinical study of growth retardation of 50 extremely low birth weight infants  
Meiying Quan, China |
| N-P-083 | Successful management of neonatal chylous ascites in extremely preterm infants a report on three cases and a literature review  
Meiying Quan, China |
| N-P-084 | Quality Initiative to Improve Expressed Breast Milk Use in Very Low Birth Weight Infants  
Anup Thakur, India |
| N-P-085 | In vivo Assessment of Lipophilic Nutrients Absorption Mechanisms using Human Milk and Infant Formula With Novel Mono- and Di-glycerides Based Emulsification Technologies  
Mustafa Vurma, USA |
| N-P-086 | Recommended intakes of protein for infants in Russian Federation: a debating point.  
Olga Lukoyanova, Russian Federation |
| N-P-087 | Nutritional Antioxidant Composition of Donor Milk  
Ann Anderson Berry, USA |
| N-P-088 | Serum Concentrations and Ratios of Alpha and Gamma Tocopherol in Newborn, Hospitalized Infants  
Ann Anderson Berry, USA |
| N-P-089 | The Impact of Maternal Intake of Sources of Vitamin A on Newborn Concentrations  
Ann Anderson Berry, USA |
| N-P-090 | Cow’s milk fat in infant nutrition; the importance of lipid structure  
Laurien Ulfman, The Netherlands |
| N-P-091 | Prevalence of Laboratory-Defined Malnutrition in Maternal-Infant Dyads During NICU Hospitalization in the USA  
Ann Anderson Berry, USA |
N-P-092  
Estimating the contribution on the reduction of the burden of Iron Deficiency Anemia from the current fortification strategy for commercial foods targeted to infants and toddlers in India  
Patrick Detzel, Switzerland

N-P-093  
Dairy lipids in infant formula: impact on growth and gastrointestinal tolerance in healthy infants  
Charlotte Baudry, France

N-P-094  
Sodium, Potassium, Calcium, and Phosphorus Content of Human Milk over the First Year of Lactation: a GEHM Study of Three Global Cohorts  
Michael Gray, USA

N-P-095  
Impacts of the structure of infant formulas on their digestive behaviour and hydrolysis: insights from in vitro studies and comparison with human milk  
Claire Bourlieu, France

N-P-096  
Impact of L.fermentum CECT 5716 and dairy lipids in maternal diet on fatty acid composition of cerebral and peripheral tissue in pups’ mice  
Corinne Joffre, France

N-P-097  
Dairy lipids during the perinatal period impact microglial phenotype and neuronal plasticity in CD1 mice  
Dinel Anne-Laure, France

N-P-098  
Dairy fat matrix diet could prevent cognitive decline at adulthood induced by lipopolysaccharide injection during perinatal period  
Dinel Anne-Laure, France

N-P-099  
Are current ESPGHAN recommendations for enteral nutrient supply for preterm infants also applicable for late preterm infants?  
Anne Schaafsma, The Netherlands

N-P-100  
Tolerance and efficacy of extensively hydrolyzed formula for infants with IgE-mediated cow’s milk Protein Allergy (CMPA) JUNGLO study – PART 2: Extensively hydrolyzed rice protein formula  
Jose Manuel Moreno, Spain

N-P-101  
ESPGHAN recommendations for DHA in preterm formulae do not seem to be sufficient for healthy late preterm infants to reach optimal DHA status within 8 postnatal weeks.  
Anne Schaafsma, The Netherlands

N-P-102  
Tolerance and efficacy of extensively hydrolyzed formula for infants with IgE-mediated cow’s milk Protein Allergy (CMPA) JUNGLO Study – PART 1: Extensively hydrolyzed casein formula  
Jose Manuel Moreno, Spain

N-P-103  
Gender effect on brain DHA level of 1.5%ALA-pure-vegetal formula can be abolished by 1.5%ALA-dairy fat incorporation which induces simultaneously a better increase of brain DHA level compared to DHA-supplemented vegetal formula  
Bernadette Delplanque, France

N-P-104  
Total protein, amino acids, and bioactive proteins in breast milk: a developmental perspective  
Bo Lonnerdal, USA

N-P-105  
Gestation Specific Reference Growth Chart for North Indian Infants  
Anup Thakur, India

N-P-106  
Use of partially hydrolyzed whey formula in the general infant population: effect on growth and allergy prevention  
Dunjin Chen, China
| N-P-107 | L. fermentum CECT 5716 protects and prevents from intestinal epithelial barrier hyperpermeability in a newborn rat model  
*Tiphaine Vanhaecke, France* |
| N-P-108 | Fat absorption of a new infant milk formula concept with large fat globules coated with phospholipids is comparable to the high fat absorption of current infant milk formula  
*Bert van de Heijning, The Netherlands* |
| N-P-109 | Influence of nutritional variables on the onset of necrotizing enterocolitis in preterm infants: A case-control study  
*Cecilia Martínez-Costa, Spain* |
| N-P-110 | Formula feeding by gastric port in preterm pigs as a model of enteral feeding in preterm infants  
*Anna Socha-Banasiak, Poland* |
| N-P-111 | Importance of accumulated protein intake for growth rate improvement  
*Masahiko Murase, Japan* |
| N-P-112 | Dairy fat for infant formula: history and new evaluation of impact on tissue DHA levels in animals  
*Bernadette Delplanque, France* |
| N-P-113 | Use of vitamin D and probiotics supplements in young children with genetic risk of type 1 diabetes  
*Jimin Yang, USA* |
| N-P-114 | Tolerance and growth in children with cow’s milk allergy fed a thickened extensively hydrolyzed casein-based formula  
*Christophe Dupont, France* |
| N-P-115 | Microbiota can be affected by the lipid composition of infant formulas  
*Isabelle Le Huërou-Luron, France* |
| N-P-116 | Feeding of very preterm infants: the results application of modern standardized approaches in the practices  
*Marina Narogan, Russian Federation* |
| N-P-117 | Applying TWORKAM methodology among medical staff to gain new skills of premature newborns oral feeding  
*Ewa Winnicka, Poland* |
| N-P-118 | Early life exposure of the developing fetus and newborn to the mycotoxin deoxynivalenol  
*Saskia Braber, The Netherlands* |
| N-P-119 | Food intake essential fatty acid sources in the third trimester of pregnancy  
*Raquel Furnes, Argentina* |
| N-P-120 | Amino acids’ 15N natural isotopic abundance in the umbilical artery and vein and in the venous blood of the mother at birth  
*Arnaud De Luca, France* |
| N-P-121 | Iron status at age 6 months in Colombian infants exclusively breast-fed for 4-6 versus 6 months  
*Gilma Olaya, Colombia* |
| N-P-122 | Frequency of feeding problems in infants with congenital diaphragmatic hernia  
*Kate Tavener, United Kingdom* |
| N-P-123 | An innovative infant formula with large, phospholipid-coated lipid droplets supports an adequate growth in healthy, term infants  
*Anita C.S. Hokken-Koelega, The Netherlands* |
| N-P-124 | Growth and nutritional sequelae in infants with congenital diaphragmatic hernia  
*Kate Tavener, United Kingdom* |
| N-P-125 | Maternal body mass index (BMI) and leptin, ghrelin in human milk  
*Lorenza Rossi, Italy* |
| N-P-126 | Complementary feeding practices in a group of Romanian mothers: physician recommendations versus maternal preferences  
*Corina Pienar, Romania*

| N-P-127 | Adequate iron supply in infants fed according to dietary guidelines?  
*Hermann Kalhoff, Germany*

| N-P-128 | The change from a soybean based to a mixed source lipid as first line parenteral lipid in infants born with gastroschisis improves bilirubin and enteral feeding outcomes  
*Perraju Bendapudi, United Kingdom*

| N-P-129 | Effects of postnatal overfeeding and fish oil diet on energy expenditure in rats  
*Xiaonan Li, China*

| N-P-130 | Milk feeding and first complementary foods during the first year of life in an international prospective TEDDY cohort study  
*Anne Riikonen, Finland*

| N-P-131 | Effect of high beta-palmitate infant formula supplemented with galacto-oligosaccharides on stool fatty acid soaps  
*Maroula Lambidou, Germany*

| N-P-132 | Nutritional status in premature neonates fed with extensively hydrolyzed protein formula  
*Yi Feng, China*

| N-P-133 | Social Factors Affecting Breastfeeding Rates: Mother’s Perception of Grandmother’s Attitude and Doctor Advices In East Delta of Egypt  
*Usama El Safy, Egypt*

| N-P-134 | Impact of an infant formula supplemented with Nutriexpert® factor regarding infections during the first 12 months of life  
*Cristina Campoy, Spain*

| N-P-135 | Nutritional intervention in early life influences the head circumference in healthy male children at 2.5 years  
*Cristina Campoy, Spain*

**NUTRITION IN INTESTINAL FAILURE**

| N-P-136 | TauroLock is effective in preventing catheter related bloodstream infection in post-surgical infants on HPN  
*Kajsa Waldenvik, Sweden*

| N-P-137 | Case Report: Complicated D-Lactic Acidosis in Short Bowel Syndrome  
*Lynette Forsythe, United Kingdom*

| N-P-138 | Growth and vitamin deficiencies in children with intestinal failure receiving long-term parenteral nutrition  
*Esther Neelis, The Netherlands*

| N-P-139 | Outcome of children with short bowel syndrome (SBS)  
*Francesca Barbieri, Italy*

| N-P-140 | Successful Management of Infants with Intestinal Failure over Two Decades  
*Helen Garrett, United Kingdom*

| N-P-141 | Iron deficiency anaemia in children with short bowel syndrome  
*Katarzyna Olszewska, Poland*
See you 2017 in Prague
The Mead Johnson Pediatric Nutrition Institute has just one goal: to advance the science of infant and child nutrition. Our global network of professionals connects with leading nutrition experts to develop innovative nutrition solutions for children.

From our groundbreaking research on the composition of human milk to the development of formulas targeting dietary allergies and metabolic disorders, our focus remains the same — to pioneer new discoveries in the field of infant nutrition.

Visit us at Booth 24
Industry Participation & Sponsoring

The Mead Johnson Pediatric Nutrition Institute has just one goal: to advance the science of infant and child nutrition. Our global network of professionals connects with leading nutrition experts to develop innovative nutrition solutions for children. From our groundbreaking research on the composition of human milk to the development of formulas targeting dietary allergies and metabolic disorders, our focus remains the same — to pioneer new discoveries in the field of infant nutrition.

Visit us at Booth 24

Committed to the Science of Caring
MIC-KEY® G-tube

THE MOST TRUSTED GASTROSTOMY FEEDING TUBE

DIGESTIVE HEALTH
We deliver easy and reliable Digestive Health solutions that help improve patient outcomes and quality of life, particularly for patients needing supplemental nutrition delivery with enteral feeding.

www.halyardhealth.co.uk

* Registered Trademark or Trademark of Halyard Health, Inc. or its affiliates. © 2016 HYH. All rights reserved.
Endoscopy and Motility Learning Zones

The 49th ESPGHAN Annual Meeting hosts this year two Learning Zones: an Endoscopy Learning Zone and for the first time at an Annual Meeting, a Motility Learning Zone.

ELZ / MLZ (Level –1)

Endoscopy Learning Zone

The Endoscopy Learning Zone will provide hands-on training in the following diagnostic and therapeutic endoscopy techniques:

• diagnostic upper GI endoscopy
• diagnostic ileocolonoscopy
• capsule endoscopy
• hemostasis techniques for bleeding varices (banding/injection)
• hemostatic techniques for bleeding ulcers (APC/clips/injection)
• polypectomies
• esophageal balloon dilatation
• foreign body removal
• gastrostomy placement

The training will be on biologic models and mannequins to achieve optimum simulation and interaction. The hands-on training will be supervised by some of the most experienced pediatric endoscopists in Europe.

Motility Learning Zone

The Motility Learning Zone will provide training in the following diagnostic and treatment motility techniques as follows:

• pH/impedance
• high resolution esophageal manometry
• high resolution anorectal manometry

The hands-on training in GI motility will be supervised by some of the most experienced specialists in pediatric motility in Europe. Analysis of GI motility studies will be performed in individual laptops.

The endoscopy and motility skill training sessions are restricted to a very limited number of places. If you have booked to attend one of the sessions please ensure that you show up on-time.

Biologic models handling (ELPEN Experimental Research Center)
Director: Apostrolos Papalois

<table>
<thead>
<tr>
<th>Thursday, 26 May 2016</th>
<th>Friday, 27 May 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nikolaos Psychalakis</td>
<td>Nikolaos Psychalakis</td>
</tr>
<tr>
<td>Evripidis Gerakis</td>
<td>Kalliopi Tsarea</td>
</tr>
<tr>
<td>Maria Karamperi</td>
<td>Eleftheria Karampela</td>
</tr>
<tr>
<td>Antonios Karaiskos</td>
<td>Georgios Stagias</td>
</tr>
</tbody>
</table>
## Endoscopy Learning Zone *(Ticket Required)*

<table>
<thead>
<tr>
<th>Thursday, 26 May 2016</th>
<th>10:00 – 12:30</th>
<th>14:00 – 16:30</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>APC/Gold Probes</strong></td>
<td>Rok Orel</td>
<td>Warren Hyer</td>
</tr>
<tr>
<td><strong>Polypectomies / Clips</strong></td>
<td>Erasmo Miele</td>
<td>Arun Urs</td>
</tr>
<tr>
<td><strong>Esophageal Variceal Banding</strong></td>
<td>Claudio Romano</td>
<td>Prithviraj Rao</td>
</tr>
<tr>
<td><strong>Gastric Varices Injections</strong></td>
<td>David Rawat</td>
<td>Mike Thomson</td>
</tr>
<tr>
<td><strong>Foreign Body Removal</strong></td>
<td>Jorge Amil Dias</td>
<td>Rok Orel</td>
</tr>
<tr>
<td><strong>Esophageal Balloon Dilatation</strong></td>
<td>Nicholas Croft</td>
<td>Simona Faraci</td>
</tr>
<tr>
<td><strong>Gastrostomy Placement</strong></td>
<td>Frederic Gottrand</td>
<td>Muftah Eltumi</td>
</tr>
<tr>
<td><strong>Capsule Endoscopy</strong></td>
<td>George Chouliaras</td>
<td>Erminia Romeo</td>
</tr>
<tr>
<td><strong>Endoscopy Simulators</strong></td>
<td>Krishnappa Venkatesh</td>
<td>Christos Tzivinikos</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Friday, 27 May 2016</th>
<th>10:00 – 12:30</th>
<th>14:00 – 16:30</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>APC/Gold Probes</strong></td>
<td>Simona Faraci</td>
<td>Mike Thomson</td>
</tr>
<tr>
<td><strong>Polypectomies / Clips</strong></td>
<td>Erasmo Miele</td>
<td>Gabor Veres</td>
</tr>
<tr>
<td><strong>Esophageal Variceal Banding</strong></td>
<td>Priya Narula</td>
<td>Priya Narula</td>
</tr>
<tr>
<td><strong>Gastric Varices Injections</strong></td>
<td>David Rawat</td>
<td>Claudio Romano</td>
</tr>
<tr>
<td><strong>Foreign Body Removal</strong></td>
<td>Jorge Amil Dias</td>
<td>Arun Urs</td>
</tr>
<tr>
<td><strong>Esophageal Balloon Dilatation</strong></td>
<td>Prithviraj Rao</td>
<td>Salvatore Oliva</td>
</tr>
<tr>
<td><strong>Gastrostomy Placement</strong></td>
<td>Marcus Auth</td>
<td>Muftah Eltumi</td>
</tr>
<tr>
<td><strong>Capsule Endoscopy</strong></td>
<td>George Chouliaras</td>
<td>Erminia Romeo</td>
</tr>
<tr>
<td><strong>Endoscopy Simulators</strong></td>
<td>Christos Tzivinikos</td>
<td>Krishnappa Venkatesh</td>
</tr>
</tbody>
</table>

## Motility Learning Zone *(Ticket Required)*

### Equipment Station

<table>
<thead>
<tr>
<th>Equipment Station</th>
<th>PH Impedance</th>
<th>Manometry Station</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Thursday, 26 May 2016 10:00 – 12:30</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hannah Cronin</td>
<td>Efstratios Saliakellis</td>
<td>Osvaldo Borrelli</td>
</tr>
<tr>
<td>Stamatiki Kritas</td>
<td>Michiel Van Wijk</td>
<td>Nikhil Thapar</td>
</tr>
<tr>
<td>Mohamed Mutalib</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Thursday, 26 May 2016 14:00 – 16:30</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Panayota Kafritsa</td>
<td>Keith Lindley</td>
<td>Marc Benninga</td>
</tr>
<tr>
<td>Stamatiki Kritas</td>
<td>Michiel Van Wijk</td>
<td></td>
</tr>
<tr>
<td><strong>Friday, 27 May 2016 10:00 – 12:30</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paraskevi Karanika</td>
<td>Efstratios Saliakellis</td>
<td>Osvaldo Borrelli</td>
</tr>
<tr>
<td>Stamatiki Kritas</td>
<td>Michiel Van Wijk</td>
<td>Keith Lindley</td>
</tr>
<tr>
<td>Ania Rybak</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Friday, 27 May 2016 14:00 – 16:30</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hannah Cronin</td>
<td>Mohamed Mutalib</td>
<td>Efstratios Saliakellis</td>
</tr>
<tr>
<td>Paraskevi Karanika</td>
<td>Keith Lindley</td>
<td>Osvaldo Borrelli</td>
</tr>
</tbody>
</table>
French Expertise in Infant Nutrition

UNIQUE INGREDIENTS WITH PROVEN BENEFITS

To find out more about our products visit us at our exhibition stand - Booth 32

Important information: Breastfeeding provides the best nutrition for babies. Infant and follow-on formulas should be used only on the advice of a healthcare professional.

* Lactobacillus Fermentum CECT5716
** Maldonado et al., JPGN 2012; 54:55-61
The Endoscopy and Motility Learning Zones are generously supported by the following companies to which we are very grateful for their contribution:

BIOSENSE is active for over 30 years, in the field of medical equipment and medical simulators. It has succeeded in becoming the partner of choice for the largest firms in the Field of Medical, Surgical and Training Equipment. The highly trained Sales and Customer Service staff, and fully equipped Technical Department, aim for the prompt customer support. BIOSENSE offers through its partner Simbionix, full Line of MIS Virtual Reality Simulators – the most advanced in the market, Simulator training curricula management system, and Patient Specific Simulation – Advanced procedure planning and rehearsing, as well as 3D printing solutions for patient-specific printed models.

As a family-owned and operated business, Erbe develops, manufactures and markets surgical systems for professional use in various medical disciplines all over the world. Erbe technology leads the market in many countries and is therefore an inherent part of the working processes in the OR. The products are thus helping to provide the best possible treatment for patients. The portfolio comprises devices and instruments for electrosurgery, vessel sealing, argon plasma coagulation (APC), cryosurgery and hydrosurgery. By combining these technologies, innovative applications become possible, particularly in general surgery, gastroenterology, gynecology, pulmonology and urology.

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.

Our products and technologies are used to diagnose or treat a wide range of medical conditions, including heart, digestive, pulmonary, vascular, urological, women’s health, and chronic pain conditions. We continue to innovate in these areas and are extending our innovations into new geographies and high-growth adjacency markets.

For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.

As a family-owned and operated business, Erbe develops, manufactures and markets surgical systems for professional use in various medical disciplines all over the world. Erbe technology leads the market in many countries and is therefore an inherent part of the working processes in the OR. The products are thus helping to provide the best possible treatment for patients.

The portfolio comprises devices and instruments for electrosurgery, vessel sealing, argon plasma coagulation (APC), cryosurgery and hydrosurgery. By combining these technologies, innovative applications become possible, particularly in general surgery, gastroenterology, gynecology, pulmonology and urology.

Erbe employs more than 900 people worldwide, over 550 of them in Germany. Approx. 120 employees work in research and development. The intensive collaboration with renowned users from medical schools and hospitals is the key to success with which Erbe successfully furthers developments in medicine.
The Experimental Research Center of Elpen Pharmaceuticals was established in 1996. It has developed a great progress and activities since 1996 (20 years) with lab facilities and equipment for biomedical and pharmaceutical research as well as for training and projects with other Institutions.

Activities:

1. **Scientific Partnerships** on innovative research ideas with clinics and laboratories of Greek Universities, the Greek National Health System and the private Hospital sector

2. **International Research Collaborations**

3. **Experimental Projects** of ELPEN with the General Secretariat for Research and Technology, the European Union and other bodies

4. **Preclinical (in vivo) Experimental Research** on new molecules where ELPEN retains exclusive rights

5. **Medical Training** for qualified specialists and young doctors and other scientists, in the form of certified workshops, Greek and international, properly organised (CME and certification) and run by acknowledged scientific Institutions

Fujifilm is known as the world’s largest imaging company and is pioneering in high-definition diagnostic imaging and information systems for health-care facilities. Dedicated research, highest quality demands and close working relationships with international specialists contribute to the advancement of culture, science, technology and industry, as well as improved health.

Fujifilm is always creating new opportunities in the world of endoscopy to provide top-quality products, excellent services, and highly customised business solutions.

Being one of the leading companies in the development of endoscope technology, Fujifilm regularly sets new benchmarks in the industry, for example with devices for double balloon endoscopy and endoscopic ultrasound systems.

Halyard Health is a medical technology company focused on advancing health and healthcare by delivering clinically-superior products and solutions in infection prevention, surgical solutions, respiratory health, digestive health, IV therapy and pain management.

Halyard sells its recognized brands and products in more than 100 countries, and holds leading market positions in multiple categories across the portfolio.

**DIGESTIVE HEALTH**

We developed the first balloon-retained low-profile feeding tube: MIC-KEY*. Today, we continue to lead the way with the HALYARD* Introducer Kit for gastric and intestinal access. Come and get a hands-on session at our booth.

For more information, visit www.halyardhealth.co.uk
Important notice: Breast milk is the ideal food for each baby. Good maternal nutrition is essential for preparing and maintaining breastfeeding. Infant formulas are intended to replace breastfeeding if it is not chosen, is not suitable, stopped prematurely or needs to be completed. Mixed feeding can interfere with breastfeeding and it is difficult to reverse the decision not to breastfeed. The socio-economic implications need to be considered in choosing the method of feeding. Inappropriate preparation and storage of any infant milk may lead to health hazards.

Document strictly reserved for use by health care professionals
Laborie offers MMS GERD diagnostic (Ohmega Ambulatory Impedance-pH recorder) and GI Motility products. Our Solar GI HRM/HRM/HRAM systems have revolutionary QuickView software for automatic study classification per Chicago Classification 3.0. HRM analysis becomes easier, quicker and better. HRM can be performed with solid state or single-use/multi-use water perfused catheters.

As a global leader in medical technology, services and solutions, Medtronic improves the lives and health of millions of people each year. We use our deep clinical, therapeutic and economic expertise to address the complex challenges faced by healthcare systems today. Let’s take healthcare Further, Together. Learn more at Medtronic.com.

PROTON S.A. was founded in 1992, and is currently operating within two major business areas: Health and Security Systems. In collaboration with international manufacturers, PROTON S.A. has developed into one of the major suppliers and providers of high-tech security systems and medical equipment & consumables. PROTON S.A. is one of the leading suppliers of medical equipment in the Greek market, providing Hospitals and Clinics with state-of-the-art medical devices, systems and consumables. Our company has managed to secure distributorship of the following Manufacturing Companies:

- OLYMPUS CORPORATION – MEDICAL SYSTEM GROUP
- TOSHIBA MEDICAL SYSTEMS - Ultrasound & Imaging Equipment
- ACCURAY - Radiotherapy Equipment
- SMITHS - HEIMANN SYSTEMS- Security & Control Systems
- Ceia SpA - Metal Detection Walkthrough Gates

- German manufacturer based in Dusseldorf
- 30 years of experience in the market
- Distribution network that spans more than 50 countries
- Registered on difficult foreign markets (i.e. China)
- Product portfolio of flexible endoscopic devices, instruments and implants
- Products for diagnostics and therapy, perfectly adjusted to the needs of their users; completely safe to operate
- Production certified in accordance with ISO standards
- Unique selling points
- Individual and needs-oriented customized productions
- Success achieved thanks to the many years of experience that our highly-qualified technicians have in the creation of prototypes and production (R&D Dept.)
NUTRICIA SATELLITE SYMPOSIUM

MICROBIOTA - IMMUNE INTERACTIONS IN ALLERGIC DISEASE

Chair: Prof. Nikolaos Papadopoulos (UK & Greece)

“The Gut Microbiota and its Role in Allergic Disease”
Dr Christina West (Sweden)

“Synbiotics can Target Microbial Dysbiosis in the Dietary Management of Cow’s Milk Allergy”
Dr Louise Michaelis (UK)

Date: Thursday, May 26, 2016
Time: 7:30 - 8:30 AM
Place: Room 4
Satellite Symposia – Information

Breakfast Symposium Thursday, 26 May 2016

Microbiota-Immune interactions in allergic disease

- Time: 07:30 – 08:30
- Room: Room 4
- Chair: Nikolaos Papadopoulos, Greece

07:30 The gut microbiota and its role in allergic disease
Christina West, Sweden

07:55 Synbiotics can target microbial dysbiosis in the dietary management of cow’s milk allergy
Louise Michaelis, United Kingdom

08:20 Q&A session
All faculty

Lunchtime Symposium Thursday, 26 May 2016

Challenging presentation in paediatric hepatic disease, what is your likely diagnosis?

- Time: 13:00 – 14:00
- Room: Room 2
- Chair: Valerio Nobili, Italy

13:00 Introduction
Valerio Nobili, Italy

13:05 Diagnostic dilemma; Failure to thrive with chronic malabsorption and liver disease?
John J. Gargus, USA

13:20 A challenging diagnosis with liver involvement, what do you suggest?
Valerio Nobili, Italy

13:35 Nutritional imperatives in an infant with LAL-D
Fiona White, United Kingdom

13:50 Complex diseases need seamless cross-functional collaboration: Panel discussion of key takeaways
All faculty
Lunchtime Symposium Thursday, 26 May 2016

Early Nutrition and Long-term Outcome

Time 13:00 – 14:00  
Room Room 5  
Chair Hania Szajewska, Poland

13:00  The global childhood obesity pandemic. The reasons why and how to react  
Ferdinand Haschke, Austria

13:30  Host-microbiota interactions – health benefit in infancy  
Erika Isolauri, Finland

Lunchtime Symposium Thursday, 26 May 2016

A comprehensive approach for managing pediatric Crohn’s disease

Time 13:00 – 14:00  
Room Room 6  
Chair Frank Ruemmele, Germany

13:00  Introduction  
Frank Ruemmele, France

13:05  Burden of disease in paediatric Crohn’s disease  
Frank Ruemmele, France

13:20  Focusing on a successful transition from the paediatric to the adult healthcare system  
Richard Russell, United Kingdom

13:35  Understanding the impact of sustained remission on patient outcomes  
Javier Martin de Carpi, Spain

13:50  Q&A and summary  
All faculty
A COMPREHENSIVE APPROACH TO MANAGING PAEDIATRIC CROHN’S DISEASE

49th Annual Congress of ESPGHAN
Athens, Greece

Thursday 26 May 2016, 13:00 – 14:00

Room 6 - Mitropoulos Hall
Megaron Athens International Conference Center
Athens

Chair
Professor Frank Rümmele
Paris, France

Faculty
Dr Richard Russell
Glasgow, UK

Dr. Javier Martín de Carpi
Barcelona, Spain
### Evening Symposium Thursday, 26 May 2016

**Early nutrition’s impact on the gut-brain-immune axis**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:00</td>
<td><strong>Impact of the gut microbiome on brain and behavior</strong>&lt;br&gt;John F. Cryan, Ireland</td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td><strong>Clinical benefits of feeding a milk fat globule membrane fraction to infants and young children</strong>&lt;br&gt;Olle Hernell, Sweden</td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td><strong>Impact of early nutrition on food tolerance and long term paediatric GI disease</strong>&lt;br&gt;Neil Shah, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>

### Breakfast Symposium Friday, 27 May 2016

**FGID; Functional Gastro-intestinal....Dilemmas?**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30</td>
<td><strong>Is the intestinal microbiota controlling our lives?</strong>&lt;br&gt;Carlos Lifschitz, Argentina</td>
<td></td>
</tr>
<tr>
<td>07:40</td>
<td><strong>Ferments, prebiotics and probiotics: not equal to each other</strong>&lt;br&gt;Hania Szajewska, Poland</td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td><strong>FGID: To be or not to be; Follow the guidelines of follow parental pressure?</strong>&lt;br&gt;Hugo Heymans, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>08:20</td>
<td><strong>Q&amp;A session</strong>&lt;br&gt;All faculty</td>
<td></td>
</tr>
</tbody>
</table>
NUTRICIA SATELLITE SYMPOSIUM

FGID: Functional Gastro-Intestinal ... Dilemmas?

FRIDAY
27 MAY 2016
7.30 – 8.30AM

ROOM 4, BANQUET HALL
MEGARON CONGRESS CENTER
ATHENS, GREECE

CHAIR
Prof. Carlos Lifschitz, Argentina

SPEAKERS
Prof. Carlos Lifschitz, Argentina
Is the intestinal microbiota contributing to IBS?

Prof. Hanna Szajewska, Poland
Hereditary, Prebiotics and Probiotics: not equal in each other?

Prof. Hugo Heymans, The Netherlands
IBS: To be aware to not follow the guidelines or follow parental pressure?

Breakfast will be provided
### Breakfast Symposium Friday, 27 May 2016

**Prevention through nutrition: Myths, Facts and Speculation**

<table>
<thead>
<tr>
<th>Time</th>
<th>07:30 – 08:30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room</td>
<td>Room 6</td>
</tr>
<tr>
<td>Chair</td>
<td>Hans van Goudoever, The Netherlands</td>
</tr>
</tbody>
</table>

07:30  | **“Low Protein”, “Wheat Belly”, “Grain Brain” & Co: Serious concepts or just popular trends?**  
       | Michael Lentze, Germany  

08:00  | **Infant gut microbiota and probiotics: What do we know and what can we expect?**  
       | Seppo Salminen, Finland  

### Breakfast Symposium Saturday, 28 May 2016

**Diagnosing cow’s milk protein allergy – Towards an earlier accurate diagnosis**

<table>
<thead>
<tr>
<th>Time</th>
<th>07:15 – 08:15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room</td>
<td>Room 4</td>
</tr>
<tr>
<td>Chair</td>
<td>Sibylle Koletzko, Germany</td>
</tr>
</tbody>
</table>

07:15  | **The CoMiSS as a predictor for the diagnosis of cow’s milk protein allergy**  
       | Yvan Vandenplas, Belgium  

07:45  | **Diagnosing cow’s milk protein allergy, how big is the gap between medical best-practice and reality?**  
       | Sibylle Koletzko, Germany  

---

134  ESPGHAN 49th Annual Meeting
Come to our Satellite Symposium

Prevention through nutrition: myths, facts and speculation

Friday, 27 May 2016
7:30 - 8:30 am
Megaron Athens
Hall 6 - Mitropoulos Hall

Chair:
Prof. Dr. Hans van Goudoever,
The Netherlands

Speakers:
Prof. Dr. Michael J. Lentze,
Germany

„Low Protein“, „Wheat Belly“, „Grain Brain“ & Co: serious concepts or just popular trends?

Prof. Dr. Seppo Salminen,
Finland

Infant gut microbiota and probiotics: what do we know and what can we expect?

Breakfast will be provided.
# Exhibitors List (Overview)

<table>
<thead>
<tr>
<th>COMPANY · COUNTRY</th>
<th>BOOTH No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott · United Kingdom</td>
<td>2</td>
</tr>
<tr>
<td>Advanced Lipids - A joint venture of AAK &amp; Enzymotec · Israel &amp; Sweden</td>
<td>19</td>
</tr>
<tr>
<td>Alexion Pharmaceuticals · Switzerland</td>
<td>17</td>
</tr>
<tr>
<td>Association of European Coeliac Societies (AOECS) · Belgium</td>
<td>40</td>
</tr>
<tr>
<td>Applied Medical Technology, Inc. · USA</td>
<td>3</td>
</tr>
<tr>
<td>Arla Food Ingredients · Denmark</td>
<td>18</td>
</tr>
<tr>
<td>Baxter Healthcare SA · Switzerland</td>
<td>6</td>
</tr>
<tr>
<td>Bedfont Scientific · United Kingdom</td>
<td>16</td>
</tr>
<tr>
<td>BioGaia AB · Sweden</td>
<td>9</td>
</tr>
<tr>
<td>Biostime Institute of Nutrition and Care · PR China</td>
<td>8</td>
</tr>
<tr>
<td>BÜHLMANN Laboratories AG · Switzerland</td>
<td>21</td>
</tr>
<tr>
<td>Cisbio Bioassays · France</td>
<td>7</td>
</tr>
<tr>
<td>Danone Nutricia Early Life Nutrition · The Netherlands</td>
<td>13</td>
</tr>
<tr>
<td>Nutricia Advanced Medical Nutrition · The Netherlands</td>
<td>13</td>
</tr>
<tr>
<td>DICOFARM · Italy</td>
<td>30</td>
</tr>
<tr>
<td>DSM Nutritional Products · Switzerland</td>
<td>5</td>
</tr>
<tr>
<td>Early Life Nutrition Network · United Kingdom</td>
<td>41</td>
</tr>
<tr>
<td>European Foundation for the Care of Newborn Infants (EFCNI) · Germany</td>
<td>38</td>
</tr>
<tr>
<td>European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)</td>
<td>1</td>
</tr>
<tr>
<td>Europital · Italy</td>
<td>20</td>
</tr>
<tr>
<td>FASSKA S.A. · Belgium</td>
<td>34</td>
</tr>
<tr>
<td>FrieslandCampina · The Netherlands</td>
<td>15</td>
</tr>
<tr>
<td>FrieslandCampina Ingredients · The Netherlands</td>
<td>23</td>
</tr>
<tr>
<td>HALYARD · Belgium</td>
<td>4</td>
</tr>
<tr>
<td>Hellenic Society of Crohn’s Disease’s and Ulcerative Colitis’ Patients (HELLESCC) · Greece</td>
<td>39</td>
</tr>
<tr>
<td>HiPP · Germany</td>
<td>12</td>
</tr>
<tr>
<td>Immundiagnostik AG · Germany</td>
<td>31</td>
</tr>
<tr>
<td>Journal of Pediatric Gastroenterology and Nutrition (JPGN)</td>
<td>43</td>
</tr>
<tr>
<td>Lactalis Nutrition · France</td>
<td>32</td>
</tr>
<tr>
<td>Mead Johnson Nutrition · USA</td>
<td>24</td>
</tr>
<tr>
<td>Mendes SA · Switzerland</td>
<td>22</td>
</tr>
<tr>
<td>Miris AB · Sweden</td>
<td>25</td>
</tr>
<tr>
<td>Nestlé · Switzerland</td>
<td>14</td>
</tr>
<tr>
<td>NOVALAC · France</td>
<td>33</td>
</tr>
<tr>
<td>NOVENTURE · Spain</td>
<td>11</td>
</tr>
<tr>
<td>Shire · Switzerland</td>
<td>10</td>
</tr>
<tr>
<td>TNO and TNO Triskelion · The Netherlands</td>
<td>26</td>
</tr>
<tr>
<td>Wisepress Medical Bookshop · United Kingdom</td>
<td>28</td>
</tr>
</tbody>
</table>

Status as of 29.04.2016
Exhibitors & Sponsors List
For over 125 years, we’ve been committed to helping people reach their potential through better health. Abbott’s nutrition business has become a leading partner in nutrition by developing teams of scientists and clinical specialists to create products and services that help improve the health and wellbeing of infants, children and adults worldwide.

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

Advanced Lipids is a joint venture of AAK and Enzymotec. INFAT®, a sn-2 palmitate (OPO) fat ingredient, manufactured by Advanced Lipids mimics the composition, structure and benefits of human milk fat.

INFAT® has been clinically proven to bring multiple benefits to babies:

- Reduces infant crying
- Promotes softer stools
- Benefits Night sleep
- Increases bone strength
- Increases fat and calcium absorption
- Enhances beneficial gut flora
- Controls intestinal health

Combining Enzymotec’s clinical know-how in lipid technologies with AAK’s international strength in food safety, production and logistics, Advanced Lipids offers customers a uniquely comprehensive and effective solution.
Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Patients with these life-threatening diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people’s lives depend on our work.

Applied Medical Technology, Inc. (AMT) is a global leader and manufacturer of enteral feeding devices and accessories; upholding the highest standard for performance and quality assurance. Since 1985, our core business has been enteral device product development, design, manufacturing and engineering in a state-of-the-art facility near Cleveland, Ohio. AMT strives to provide the best medical device products to our customers to increase patient comfort and improve patient outcomes. Our products include the MiniONE® line of low profile Balloon, Non-Balloon, and Capsule Non-Balloon buttons, the AMT G-Jet® low profile gastric-jejunal enteral tube, and the AMT Bridle™ and Micro Bridle™ Nasal Tube Retaining System.

The Association of European Coeliac Societies (AOECS) is a patient organisation, representing people with Coeliac Disease and or dermatitis herpetiformis (DH). The organisation currently has 35 enrolled Members which are comprised of national coeliac societies located in 29 countries across Europe. AOECS collaborates with international coeliac organisations to raise awareness of coeliac disease and to combine research resources. To achieve its aim for the best possible safety, availability and labelling of foods and products suitable for people intolerant to gluten AOECS has introduced the European licensing system for the use of the Crossed Grain symbol.
ONE DEVASTATING DISEASE. MANY LIFE-THREATENING CONSEQUENCES.¹

Lysosomal acid lipase deficiency (LAL-D) is a rare life-threatening genetic disease with ongoing, progressive, multiorgan damage that can cause premature death.¹

The devastating manifestations of LAL-D threaten multiple vital organs:¹,²,ᵃ

CARDIOVASCULAR MANIFESTATIONS: 87%¹
- Accelerated atherosclerosis¹
- Coronary artery disease¹

LIVER MANIFESTATIONS: 86%¹
- Liver dysfunction or failure²
- Ascites¹,²

SPLEEN MANIFESTATIONS: 36%¹
- Splenomegaly¹
- Anaemia¹

GASTROINTESTINAL (GI) MANIFESTATIONS: 22%¹
- GI bleeding¹
- Diarrhoea²

OTHER MANIFESTATIONS
- Growth Failure²
- Adrenal calcification²

To find out more about the severity of LAL-D and how you can help increase survival rates, visit us at booth n°17.

⁰Based on an analysis of 55 genotyped patients with LAL-D in a cohort of 135 cases.¹
NOTE: The aforementioned organ-specific symptoms associated with LAL-D are reported from published literature and are not limited only to those listed above.

References:

Date of preparation: January 2016, EMEA/UNB-LAL/16/0016
Ingredients for the next generation

Our segments

Our areas of expertise

Our ingredients

- Alpha-lactalbumin
- Hydrolysates
- Casein glycomacropeptide
- MFGM & phospholipids
- Phospholipids
- Osteopontin
- Lactose
- Whey protein concentrate
- Whey protein isolate
- Milk minerals

Booth #18
Arla Foods Ingredients
Ingredients for the next generation: Our overriding goal is to develop a range of scientifically documented ingredients that resemble key functionalities in human milk. Used in infant formula they contribute to healthy growth and development of formula fed infants. Our dedicated infant nutrition and product development teams draw expertise from a broad base of specialists from within human nutrition, molecular biology, dairy engineering, food technology, production engineering and marketing. As well as offering extensive support, our specialists work towards a common goal: to help you meet the current and future needs of both your business and your customers.

Baxter International Inc. provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation software and services. The company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.

For forty years now, Bedfont Scientific has specialised in the design and manufacture of exhaled breath and gas monitoring instruments throughout the world. We have several product ranges of breath analysers including the Smokerlyzer range, the NObreath FeNO monitor, and the Gastrolyzer range. The Gastrolyzer range offers a non-invasive method to diagnose food intolerances and gastrointestinal disorders, such as Lactose Intolerance which affects over 50% of the world’s population. With instant results, the Gastrolyzer range is unlike other methods which can take up to two weeks to diagnose. Breath analysis is the new blood test.
### BioGaia

**Booth No.** 9  
**Country** Sweden  
**More information** [www.biogaia.com](http://www.biogaia.com)

BioGaia is a Swedish health care company that develops, markets and sells probiotic products with documented health effects. Our products combine different strains of the probiotic bacterium *Lactobacillus reuteri* (L. reuteri) with unique and user-friendly package solutions that have long shelf-life. *Lactobacillus reuteri* is one of the world’s most well researched probiotics, especially in preterm newborns, infants and children. In addition to our in-house experts, we collaborate with specialists in some 40 research institutions and clinics in a global network. BioGaia products are available in over 90 countries. They are sold through partners with vast experience in the pharmaceutical and health area.

### Biostime Institute of Nutrition and Care (BINC)

**Booth No.** 8  
**Country** China  

Biostime Institute of Nutrition and Care (BINC) is a non-profit organization as well as an academic organization, whose member consist of scientific experts in their respective fields. BINC continues to be committed to providing a comprehensive health solution for families. Cooperating with authoritative experts, BINC focus its work on conducting scientific research, building professional communication platforms, promoting academic research and communication in the fields of nutrition & care & psychology.

BINC regularly holds academic activities, seminars, expert interviews, and lecture series. In order to promote scientific research, BINC also offers many academic organizations and noted universities with scientific research funding and scholarships.

### BÜHLMANN

**Booth No.** 21  
**Country** Switzerland  
**More information** [www.buhlmannlabs.ch](http://www.buhlmannlabs.ch)

Calprotectin is the best marker for IBD/IBS diagnosis and IBD therapy follow up. With the option of Quantum Blue® and the new IBDoc® calprotectin home test, invasive procedures can be avoided and the child and its parents empowered for their disease management. BÜHLMANN has developed into THE CALPROTECTIN COMPANY with highest quality standards and its determination to increase the knowledge and application of calprotectin in pediatrics. BÜHLMANNs new Quantum Blue® Infliximab trough level rapid assay, is the only available Point Of Care test that allows determination of infliximab levels in 15 minutes before the next infusion of the drug.
Come Meet Our New Arrival
Baxter Booth N-6
Cisbio Bioassays is a privately held life sciences company committed to improving human healthcare. With more than 30 years of experience in vitro diagnostics and drug discovery, we provide creative technological solutions and partnerships to the global scientific community. With more than 30 years of development in immunoassays (RIA and ELISA) in Oncology and Endocrinology, Cisbio Bioassays is a partner of choice for medical device in ELISA for specialized testing, like Chromogranin A, Renin and Aldosterone and S100A12. Cisbio Bioassays has facilities in France, the USA, China and Japan, and a network of distributors across the globe.

Nutricia Early Life Nutrition and Nutricia Advanced Medical Nutrition are divisions of Danone. Nutricia Early Life Nutrition’s mission is to partner with parents and healthcare professionals, providing complete range of nutritional solutions in allergy management, to complement breastfeeding and support child long life health around the world.

At Nutricia Advanced Medical Nutrition our mission is to establish medical nutrition as an integral part of healthcare. Nutricia’s broad portfolio is designed to improve clinical outcomes and restore quality of life for patients of all ages. In paediatrics, Nutricia brings proven solutions for children and their carers in cow’s milk allergy, faltering growth, neuro-disability, and metabolic conditions.

Dicofarm is a pharmaceutical group based in Italy. The group was founded in 1977 and since then has established a strong experience in developing high quality products. Our daily obligation is to realize products and solutions capable of improving people’s quality of life. Our portfolio embodies our profound commitment to innovation and include OTC medications, Food Supplements and Medical Devices in key therapeutic areas that cover many Pediatric fields such as Neonatology and Gastroenterology. Currently we are present with licensing agreements, joint ventures, co-marketing/co-promotion and distribution agreements in various territories of the word.
Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in life sciences and materials sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam.

The Early Life Nutrition Network, a registered charity, was established to enable members to debate and share knowledge on how to improve behaviours surrounding nutrition in early life. We connect academics and practitioners from around the world and across disciplines, both virtually and face-to-face, bringing together a global community of experts to tackle myths surrounding early life nutrition and change behaviours for the better.

The European Foundation for the Care of Newborn Infants (EFCNI) is the first pan-European organisation to represent the interests of preterm and newborn infants and their families. It gathers together parents and healthcare experts from different disciplines with the common goal of improving long-term health of preterm and newborn children by ensuring the best possible prevention, treatment, care and support.
Eurospital aims at being No. 1 in the specific markets where it operates in order to give its customers with the highest quality systems. Eurospital focuses its activities in specific sectors such as in vitro diagnosis of Autoimmune Diseases, Coeliac Disease and IBD. To succeed Eurospital has to be able to renew itself and progress continuously in time and to set for itself increasingly ambitious goals.

At the 49th Annual Meeting of ESPGHAN in Athens, Eurospital will launch the „ERA Eurospital Random Access“ chemilumuniscence system which represents the most advanced and complete diagnostic system for autoimmune disorders.

FASSKA is specialized since 1981 in the development, formulation, manufacturing and commercialization of high quality nutritional products for the whole family: infants, young children and adults. FASSKA offers a large selection of products: infant milk formulas, special infant milk formulas, infant cereals and special adult formulas. Our products are successfully marketed throughout the world by a network of Exclusive Agents specialized in nutrition in the pharmaceutical field.

All the formulas developed are fully compliant with the latest recommendations of major scientific and medical authorities and respects the regulations in force in EU and in the countries where products are marketed.

FrieslandCampina Domo is part of the business group FrieslandCampina Ingredients and a leading worldwide producer of a wide range of high-quality ingredients for the infant and medical nutrition markets. We have dedicated production locations in the Netherlands, Australia and USA. With over 75 years of experience in infant nutrition ingredients we are specialized in developing the next generation infant nutrition ingredients like Milk Fat and HMO’s. Our product range further consists of whey protein concentrates, demineralised whey products, galacto-oligosaccharides, lactose, hydrolysates and encapsulated nutritional oils.
Western European Manufacturer

Infant Milk & Cereals Formulas

A guarantee of Quality & Traceability

Distributed in more than 30 countries worldwide

Rue du Bosquet, 1 - Einstein Scientific Park
B-1348 Louvain-la-Neuve  BELGIUM
Tél : +32 10 45 17 19  Fax : + 32 10 45 19 25

www.fasska.com
New Friso
Now with LockNutri

Preserve native protein structure in infant formula during processing.

Friso also contains the following important nutrients:
- LCPUFA to support the immune system.
- Prebiotics to promote gut health.

In Friso 3 & 4:
- Probiotic (B. Lactis HNO19) to support respiratory and gut health.
- Increased Vitamin D levels to address Vitamin D deficiency and to support normal functioning of the immune system.

LockNutri, a single processing method to preserve milk protein in its native structure with minimal aggregation and glycation.

Breastfeeding is the best nutrition for healthy growth and development of babies. Mothers should seek guidance on proper maternal nutrition in order to help maintain adequate supplies and quality of breast milk. Unnecessary introduction of formula feeding partially or fully or of other complementary foods and drinks may have negative impact on breastfeeding, which may be irreversible. Mothers should consult their doctor and consider the social and financial implications before deciding to use breast milk substitutes or if they have difficulty breastfeeding. Usage, preparation and storage instructions of breast milk substitutes or of other complementary foods and drinks should be followed carefully as improper or unnecessary use may pose a health hazard.
<table>
<thead>
<tr>
<th>Country</th>
<th>Booth No.</th>
<th>More information</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Netherlands</td>
<td>15</td>
<td><a href="http://www.frieslandcampina.com">www.frieslandcampina.com</a></td>
</tr>
</tbody>
</table>

Royal Friesland Campina provides around 1 billion consumers all over the world with dairy products containing valuable nutrients. We supply consumer products such as dairy-based beverages, nutrition for children, cheese and desserts in many European countries and in Asia and Africa, while we also produces ingredients and half-finished products for manufacturers of nutrition for children, the food industry and the pharmaceutical sector around the world.

The Company is fully owned by Zuivelcoöperatie Friesland Campina U.A., with 19.487 member dairy farmers in the Netherlands, Germany and Belgium and is one of the world’s largest dairy cooperatives.

Innovation is an important part of our strategy aimed at generating growth as well as added value. Royal Friesland Campina innovates in response to continuously changing consumer habits, needs and tastes.

<table>
<thead>
<tr>
<th>Country</th>
<th>Booth No.</th>
<th>More information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Belgium</td>
<td>4</td>
<td><a href="http://www.halyardhealth.co.uk">www.halyardhealth.co.uk</a></td>
</tr>
</tbody>
</table>

Halyard Health is a medical technology company focused on advancing health and healthcare by delivering clinically-superior products and solutions in infection prevention, surgical solutions, respiratory health, digestive health, IV therapy and pain management.

Halyard sells its recognized brands and products in more than 100 countries, and holds leading market positions in multiple categories across the portfolio.

**DIGESTIVE HEALTH**

We developed the first balloon-retained low-profile feeding tube: MIC-KEY®. Today, we continue to lead the way with the HALYARD* Introducer Kit for gastric and intestinal access. Come and get a hands-on session at our booth. For more information, visit www.halyardhealth.co.uk
<table>
<thead>
<tr>
<th>Exhibitors &amp; Sponsors List</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HELLESCC</strong></td>
<td>Booth No.</td>
<td>Country</td>
</tr>
<tr>
<td>39</td>
<td>Greece</td>
<td><a href="http://www.crohnhellas.gr">www.crohnhellas.gr</a></td>
</tr>
<tr>
<td>The Hellenic Society of Crohn’s Disease’s and Ulcerative Colitis’ Patients (HELLESCC) is the evolution of the regional Attica’s Society of Crohn’s Disease’s and Ulcerative Colitis’ Patients (ASCC) which was established in 2006 and its main aims are:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• The care for at least 20,000 people with IBD in Greece.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• The provision of information to patients with regard to treatment methods on IBD.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• The inspiration of solidarity between members of the society, raising awareness on IBD and the effort to achieve a better quality of life for patients.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• The collaboration with similar Greek and International societies, associations etc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• The financial support to patients with low income.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HiPP</strong></td>
<td>Booth No.</td>
<td>Country</td>
</tr>
<tr>
<td>12</td>
<td>Germany</td>
<td><a href="http://www.hipp.com">www.hipp.com</a></td>
</tr>
<tr>
<td>HiPP GmbH &amp; Co. Vertrieb KG is Germany’s leading manufacturer of baby food with a strong focus on organic premium quality. It offers infant, follow-on and growing-up formula, a huge range of complementary feeding, a product range for pregnant and breastfeeding women and also provides baby care cosmetics. The company was founded in 1932 and is based in Pfaffenhofen, Bavaria, Germany.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Immundiagnostik AG</strong></td>
<td>Booth No.</td>
<td>Country</td>
</tr>
<tr>
<td>31</td>
<td>Germany</td>
<td><a href="http://www.immundiagnostik.com">www.immundiagnostik.com</a></td>
</tr>
<tr>
<td>Immundiagnostik AG, founded in 1986, is a globally operating diagnostics company represented in more than 60 countries. Focus is on the development and production of innovative immunoassays (ELISA, EIA) and other analytical detection methods (e.g. HPLC, LC-MS/MS and PCR) for medical routine and research. Immundiagnostik’s mission is to provide effective tools for prevention, differential diagnosis and therapy monitoring in the areas of gastroenterology, cardiovascular diseases, disorders of the skeletal system and oxidative stress. The product portfolio is completed by a broad range of antibodies and antigens.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
HiPP Combiotic®

Clinical studies prove safety and efficacy of *Lactobacillus fermentum*® + GOS** in infant and follow-on formula

✔ Safety: adequate growth and thriving
✔ Efficacy: significant reduction of diarrhoea

The studies meet the ESPGHAN³ requirement that safety and efficacy of pre- and probiotic formula should be established.

To find out more about HiPP Combiotic®, visit us at our exhibition stand no 12.

Important information: Breastfeeding is the best for your baby. Infant formula and follow-on milks should be used only on the advice of a healthcare professional.
For over 100 years Mead Johnson has been a global leader in pediatric nutrition. We develop, manufacture, market and distribute more than 70 products in over 50 countries worldwide, and our 8,000 employees are passionate about our mission to nourish the world’s children for the best start in life. The Mead Johnson Pediatric Institute (MJPNI) works in association with Mead Johnson to pioneer new discoveries that improve the health and well-being of children. Our team of MJPNI experts focus on advancing scientific understanding, engaging with global experts and enabling innovation to inform the development of nutrition solutions.

Lactalis Nutrition is part of the world leading dairy company Lactalis Group. With our expert infant nutrition brands (Celia, Picot, Damira) our ambition is to provide products to meet all the nutritional needs of the babies thanks to innovative infant milk formulas and weaning food.

Mendes SA is a pharmaceutical company that commercializes probiotic food supplements. Vivomixx® is the main product, a food supplement containing a combination of 8 different strains of live lactic acid bacteria and bifidobacteria and present in the market with two different formulation: boxes of 10 sachets, providing 450 billion bacteria per sachet, and boxes of 10 capsules, providing 112 billion bacteria per capsule.
Human milk. It is the foundation of the field of infant nutrition. Still, there is so much more we can learn: its unique qualities; how it changes over the life of an infant; and how environmental factors may shape its composition and function.

That is why the Mead Johnson Pediatric Nutrition Institute (MJPNI) developed its Human Milk Research Platform, a landmark initiative designed to give us new insights into the function of this vital source of nutrition. We are working with global experts to determine how maternal diet, genetics, lactation stage, and even geography can affect the composition of human milk and its impact on infant development.

This global, multiyear initiative has already advanced the body of knowledge in our field — and we are still just scratching the surface. It is another example of the way the MJPNI works to expand the boundaries of infant nutrition — and give infants their best start in life.
Measure with Miris. And make every drop count.

Neonatal medicine has made great strides in the care of preterm babies. Thanks to a better understanding of nutrition we now know that human milk gives preterm babies the best start in life. Miris helps you measure the macronutrient composition of human milk contributing to a better outcome for the baby, the family and the clinic.

Nestlé Nutrition helps the next generation of children to develop their full potential and live healthier lives by providing high quality, innovative, science-proven nutrition solutions and education for mothers and infants in the crucial first 1000 Days’ of life.

Nestlé Health Science is a health-science company engaged in advancing the role of nutritional therapy to change the course of health for consumers, patients and our partners in healthcare.

The Nestlé Nutrition Institute (NNI), a non-for-profit association based in Switzerland, shares leading science based nutrition information and education with health professionals, scientists, nutrition communities in an interactive way.
Novalac is a Spanish pharmaceutical company whose aim is to offer to patients and healthcare professionals innovative and effective products in fields like urology, gastroenterology, dermatology, ENT, and women’s health to improve treatment and quality of life. We oversee every stage required to market our products: from development and registration to marketing and promotion.

Present in more than 60 markets worldwide, Novalac is exclusively distributed through pharmacies and special shops by some of the world’s top pharmaceutical companies. With a strong commitment to supporting medical research, Novalac will deliver its International Medical Research Award at the 2016 N&G Congress.

Noventure is a Spanish pharmaceutical company whose aim is to offer to patients and healthcare professionals innovative and effective products in fields like urology, gastroenterology, dermatology, ENT, and women’s health to improve treatment and quality of life. We oversee every stage required to market our products: from development and registration to marketing and promotion.

A worldwide network of affiliates and partners allows us to implement in more than 40 countries a global market strategy with personalized, country-based strategies.
Shire enables people with life-altering conditions to lead better lives. Shire’s strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs. Shire’s focus is on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.

TNO and Triskelion are strongly involved in supporting a healthy start in life and are trusted partners for suppliers of infant nutrition. TNO offers key expertise in child health care, breast feeding and parent coaching. Understanding the complex requirements to optimize early healthy programming is the leading research theme. Triskelion offers advanced in vitro and in vivo models, world class analytical platforms and accompanying expertise. The knowledge is used in offering tailor made designs for industry’s needs in product development.

Wisepress.com, Europe’s leading conference bookseller, has a range of books and journals relevant to the themes of the meeting. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers. Follow us on Twitter for the latest news @WisepressBooks.
We proudly celebrate **150 years of Nestlé** with Infant Cereals, Henri Nestlé’s founding product; the first and favourite nutritious meal for infants.

Today we are contributing to address the global iron deficiency challenge with **iRON+**, an optimized combination of iron & other nutrients important for **brain and cognitive development**, thus helping children reach their full potential.

Important Notice: The World Health Organisation recommends exclusive breastfeeding during the first 6 months of life and continued breastfeeding for as long as possible. As babies’ needs vary, health professionals should advise the mother on the appropriate time when her baby should start receiving complementary foods.

Please join us at the Nestlé stand for more details.
Disclosure of Sponsorships

Please find below the contribution of the members of the Pharmaceutical Codes of Practice according to the respective rules and transparency regulations.

<table>
<thead>
<tr>
<th>N/N</th>
<th>COMPANY</th>
<th>SPONSORING AMOUNT</th>
<th>SPONSORING ITEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Abbott</td>
<td>6.300 €</td>
<td>Chrome-Sponsor-Package</td>
</tr>
<tr>
<td>2</td>
<td>AbbVie</td>
<td>54.500 €</td>
<td>Silver-Sponsor-Package</td>
</tr>
<tr>
<td>3</td>
<td>Applied Medical Technology, Inc.</td>
<td>6.300 €</td>
<td>Chrome-Sponsor-Package</td>
</tr>
<tr>
<td>4</td>
<td>Baxter Healthcare SA</td>
<td>15.950 €</td>
<td>Bronze-Sponsor-Package</td>
</tr>
<tr>
<td>5</td>
<td>Biostime Institute of Nutrition and Care</td>
<td>9.450 €</td>
<td>Chrome-Sponsor-Package</td>
</tr>
<tr>
<td>6</td>
<td>Danone Nutricia Early Life Nutrition &amp; Nutricia Advanced Medical Nutrition</td>
<td>169.740 €</td>
<td>Diamond-Sponsor-Package</td>
</tr>
<tr>
<td>7</td>
<td>DICOFARM</td>
<td>3.780 €</td>
<td>Sponsor-Package</td>
</tr>
<tr>
<td>8</td>
<td>DSM Nutritional Products</td>
<td>6.300 €</td>
<td>Chrome-Sponsor-Package</td>
</tr>
<tr>
<td>9</td>
<td>HALYARD</td>
<td>13.950 €</td>
<td>Bronze-Sponsor-Package</td>
</tr>
<tr>
<td>10</td>
<td>Lactalis Nutrition</td>
<td>13.230 €</td>
<td>Bronze-Sponsor-Package</td>
</tr>
<tr>
<td>11</td>
<td>Mead Johnson Nutrition</td>
<td>165.650 €</td>
<td>Diamond-Sponsor-Package</td>
</tr>
<tr>
<td>12</td>
<td>NOVENTURE</td>
<td>8.560 €</td>
<td>Chrome-Sponsor-Package</td>
</tr>
<tr>
<td>13</td>
<td>Shire</td>
<td>7.560 €</td>
<td>Chrome-Sponsor-Package</td>
</tr>
</tbody>
</table>

Status as of 29.04.2016
General Information
**Congress Venue**

Megaron Athens International Conference Centre  
Vass. Sofias & Kokkali  
115 21 Athens, Greece  

Hilton Hotel Athens  
(only for courses on 25 and 28 May 2016)  
46 Vassilissis Sofias Avenue  
11528 Athens, Greece

**Congress Office**

The congress office and registration desk is located in the hallway on the ground level of the Megaron, next to the entrance doors. Phone: +30 (210) 7282659

**Congress Language**

English is the official congress language. A simultaneous translation will not be available.

### Opening Hours

<table>
<thead>
<tr>
<th>Event</th>
<th>Day</th>
<th>Start Time</th>
<th>End Time</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Congress Hours</strong></td>
<td>Wednesday</td>
<td>25 May 2016</td>
<td>08:00 – 18:30 (Hilton*)</td>
</tr>
<tr>
<td></td>
<td>Thursday</td>
<td>26 May 2016</td>
<td>07:30 – 19:30</td>
</tr>
<tr>
<td></td>
<td>Friday</td>
<td>27 May 2016</td>
<td>07:30 – 19:45</td>
</tr>
<tr>
<td></td>
<td>Saturday</td>
<td>28 May 2016</td>
<td>07:15 – 14:00 (Megaron)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>14:00 – 18:00 (Hilton)</td>
</tr>
<tr>
<td><strong>Registration Desk</strong></td>
<td>Wednesday</td>
<td>25 May 2016</td>
<td>07:00 – 18:00 (Hilton*)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>15:00 – 19:00 (Megaron)</td>
</tr>
<tr>
<td></td>
<td>Thursday</td>
<td>26 May 2016</td>
<td>06:30 – 18:00</td>
</tr>
<tr>
<td></td>
<td>Friday</td>
<td>27 May 2016</td>
<td>06:30 – 18:00</td>
</tr>
<tr>
<td></td>
<td>Saturday</td>
<td>28 May 2016</td>
<td>06:30 – 14:00</td>
</tr>
<tr>
<td><strong>Speakers’ Ready Room</strong></td>
<td>Wednesday</td>
<td>25 May 2016</td>
<td>07:00 – 17:00 (Hilton*)</td>
</tr>
<tr>
<td></td>
<td>Thursday</td>
<td>26 May 2016</td>
<td>06:30 – 18:00</td>
</tr>
<tr>
<td></td>
<td>Friday</td>
<td>27 May 2016</td>
<td>06:30 – 18:00</td>
</tr>
<tr>
<td></td>
<td>Saturday</td>
<td>28 May 2016</td>
<td>06:30 – 12:00</td>
</tr>
<tr>
<td><strong>Poster Exhibition</strong></td>
<td>Wednesday</td>
<td>25 May 2016</td>
<td>no Poster Exhibition</td>
</tr>
<tr>
<td></td>
<td>Thursday</td>
<td>26 May 2016</td>
<td>08:00 – 18:00</td>
</tr>
<tr>
<td></td>
<td>Friday</td>
<td>27 May 2016</td>
<td>08:00 – 18:00</td>
</tr>
<tr>
<td></td>
<td>Saturday</td>
<td>28 May 2016</td>
<td>08:00 – 14:00</td>
</tr>
<tr>
<td><strong>Industry Exhibition</strong></td>
<td>Wednesday</td>
<td>25 May 2016</td>
<td>no Industry Exhibition</td>
</tr>
<tr>
<td></td>
<td>Thursday</td>
<td>26 May 2016</td>
<td>08:30 – 18:00</td>
</tr>
<tr>
<td></td>
<td>Friday</td>
<td>27 May 2016</td>
<td>08:30 – 18:00</td>
</tr>
<tr>
<td></td>
<td>Saturday</td>
<td>28 May 2016</td>
<td>08:30 – 14:00</td>
</tr>
</tbody>
</table>

* for Course/Working Group participants only.
Name Badge / Tickets
Upon registration all participants will receive a name badge which must be worn visibly for the entire duration of the congress. Your name badge acts as your entrance ticket for the congress.

Sessions marked with “Ticket Required” are subject to pre-registration as number of participants is limited.

ESPGHAN AGM
Annual General Meeting
Assembly of ESPGHAN members on Friday, 27 May 2016 from 17:30 – 19:45 (Room 2).

Abstracts
All abstracts will be published in the Journal of Pediatric Gastroenterology and Nutrition (JPGN).
The abstracts of the oral presentations, the ePoster and Poster will also be available on the Virtual Meeting Site.

CME-CPD Credits
The congress was granted 20 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME):

European Accreditation
European Accreditation is granted by the EACCME in order to allow participants who attend the above-mentioned activity to validate their credits in their own country.

The 49th Annual Meeting of ESPGHAN is designated for a maximum of 20 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

How to claim CME-Credits
6 CME Credits will be granted for each full congress day (Thursday and Friday), 5 CME credits will be granted for Saturday and 3 CME credits will be granted for Wednesday.

The evaluation of the conference is obligatory to obtain your CME-CPD credits. The link to the online feedback form will be sent to your email address at the end of the congress.

Please complete it and submit it before 17 June 2016 at the latest. You will then receive your personal CME-CPD Certificate by email.

Internet Lounge
The Internet Lounge is located next to the Poster Exhibition (ground level) at Megaron and has kindly been sponsored by Mead Johnson Nutrition.

Certificate of Attendance
Delegates are able to create their Certificate of Attendance in the Internet Lounge at Megaron (not the CME-CPD Certificate) by entering their registration number (printed on name badge). The certificate can either be printed directly or send as PDF to an email address.
Mobile Phones
Delegates are kindly requested to keep their mobile phones on silent in all rooms where scientific and educational sessions are being held, as well as in and around the poster and exhibition area.

ESPGHAN Head Office
European Society for Paediatric Gastroenterology, Hepatology and Nutrition
ESPGHAN OFFICE
office@espghan.org
www.espghan.org
ESPGHAN is the official organiser of the scientific programme of the 49th Annual Meeting.

Congress and Industry Organisation
EUROKONGRESS
Congress + Event + Exhibition Management
Schleissheimer Str. 2
80333 Munich, Germany
Phone +49 (0)89 210 98 60
Fax +49 (0)89 210 98 698
espghan@eurokongress.de
www.eurokongress.de

Coffee Breaks/Snacks
Snacks and refreshments are included in the registration fee during the official break times. The catering areas are located in the exhibition areas as well as next to the Poster Exhibition (1st Level, Foyer Room 5). A Cashbar can be found in the foyer of Room 2 (Level –1).
Kindly note that gluten- and lactosefree coffee and lunch breaks will be served at the catering area near booth 39/40.

Cloakroom
A cloakroom is provided for all delegates attending the Annual Meeting, located on the ground level, near Room 1. Any items can be left at the cloakroom within official opening hours. The cloakroom will close 30 minutes after the end of the last session each day.
Any items left there are the responsibility of the individual and ESPGHAN cannot be held accountable for any loss of personal items.

Silence Room
A place of peace and tranquility in the midst of a lively conference area, the silence room is available to members of all religions and all world views. It is accessible during the congress hours and is located next to the Conference Suites (follow the signage).

Welcome Reception
A Welcome Reception will take place at Hilton Hotel Athens on Wednesday, 25 May 2016 starting 18:30 (free of charge for congress participants, registration has been required).

Disclaimer
Neither the organiser nor EUROKONGRESS GmbH shall be liable for accidents, bodily injury, and theft as well as for additional costs due to the change of event date, location, programme or similar. Liability for additional costs due to delays, changes or cancellations of flights, trains or other means of transport as well as due to strike action, illness, weather or environmental disasters is also excluded. It is the responsibility of each participant to arrange appropriate theft-, accident-, health- as well as travel cancellation insurance. Participants as well as accompanying persons take part at their own responsibility and risk.
Registration fees

### Annual Meeting, 26 – 28 May 2016

<table>
<thead>
<tr>
<th>Category</th>
<th>Congress Ticket</th>
<th>Day Ticket</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESPGHAN Member(^1)</td>
<td>600 €</td>
<td>250 €</td>
</tr>
<tr>
<td>ESPGHAN Non-Member</td>
<td>865 €</td>
<td>300 €</td>
</tr>
<tr>
<td>Emeritus Member Fee</td>
<td>220 €</td>
<td>N/A</td>
</tr>
<tr>
<td>Allied Health Professionals – ESPGHAN Member(^1,2)</td>
<td>355 €</td>
<td>150 €</td>
</tr>
<tr>
<td>Allied Health Professionals – Non Member(^2)</td>
<td>450 €</td>
<td>150 €</td>
</tr>
<tr>
<td>Affiliated Society Member(^3)</td>
<td>750 €</td>
<td>275 €</td>
</tr>
<tr>
<td>Trainee ESPGHAN Member</td>
<td>355 €</td>
<td>150 €</td>
</tr>
<tr>
<td>Young Investigators(^4)</td>
<td>450 €</td>
<td>150 €</td>
</tr>
<tr>
<td>Student Fee</td>
<td>355 €</td>
<td>150 €</td>
</tr>
</tbody>
</table>

### Courses, 25 May 2016

<table>
<thead>
<tr>
<th>Course</th>
<th>Additional Course</th>
<th>Course Stand alone</th>
</tr>
</thead>
<tbody>
<tr>
<td>PG Course</td>
<td>205 €</td>
<td>245 €</td>
</tr>
<tr>
<td>AHP Course</td>
<td>180 €</td>
<td>225 €</td>
</tr>
<tr>
<td>IBD Course</td>
<td>205 €</td>
<td>245 €</td>
</tr>
</tbody>
</table>

### Learning Zones, 26 – 27 May 2016

<table>
<thead>
<tr>
<th>Zone</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endoscopy Learning Zone</td>
<td>35 €</td>
</tr>
<tr>
<td>Motility Learning Zone</td>
<td>35 €</td>
</tr>
</tbody>
</table>

### Social Programme

<table>
<thead>
<tr>
<th>Event</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome Reception 25 May 2016</td>
<td>Free of charge</td>
</tr>
<tr>
<td>ESPGHAN Members’ Evening 27 May 2016</td>
<td>50 €</td>
</tr>
</tbody>
</table>

The congress registration fees include:

- a name badge
- access to all sessions
- access to the poster and exhibition area
- all personal congress documents
- the coffee breaks and lunches
- invitation to the Welcome Reception

#### Congress Cancellation Policy

Registration cancellations had to be submitted in writing.

Cancellations for the Annual Meeting received in writing up until 11 March 2016 incurred a cancellation fee of 50 € for the Annual Meeting and of 25 € for courses. From this date onwards or in case of a no-show, reimbursements were no longer possible unless the organisers were provided with a named replacement who will take on the registration.

Please note that abstract submitters were admitted to cancel their registration free of charge up until 11 March 2016 in case their abstract was not accepted.

The Members’ Evening registration fees are non-refundable.

---

1. Please note that in order to qualify for the member rate all members need to be up to date with their membership fees. The organisers reserve the right to change the registration status if membership fees are not paid.
2. Allied Health Professionals include Nurses and Dieticians and must provide proof of their AHP certification upon registration in order to qualify at the stated rate.
3. Affiliated societies are FISPGHAN, NASPGHAN, LASPGHAN, APPSPGHAN.
4. A Young Investigator is defined as someone working in Paediatric GI, Hepatology or Nutrition for less than 10 years. They should ensure that they have a confirming letter from a sponsoring member of ESPGHAN.
5. The Allied Health Professional and Post Graduate course as well as the IBD course on 25 May 2016 must be registered and paid for in addition to the main ESPGHAN meeting from 26 – 28 May 2016. Please note that all courses will be held at Hilton Hotel (46 Vassilissis Sofias Avenue, Athens 11528) and are subject of availability.
Congress Venue

Megaron Athens International Conference Centre
Vass. Sofias & Kokkali
115 21 Athens, Greece
Metro station: Megaro Moussikis
Metro line 3 (blue line)

Hilton Hotel Athens
46 Vassilissis Sofias Avenue
115 28 Athens, Greece
Metro Station: Megaro Moussikis
Metro line 3 (blue line)
(5 min walking distance to Megaron)

Metro Athens
Only the best proteins in infancy can Build a Strong Foundation for Life

**COMPOSITION**
For healthy metabolic programming, and smooth digestion\(^1\)-\(^6\)

**CONCENTRATION**
For healthy growth, easy excretion, and support of immune defenses\(^2, 7\)-\(^{10}\)

**CONFORMATION**
For risk reduction of atopic dermatitis\(^{11}\)

Please join us at the Nestlé stand for more details.

**REFERENCES:**

**IMPORTANT NOTICE:** The World Health Organization (WHO\(^*)\) has recommended that pregnant women and new mothers be informed of the benefits and superiority of breastfeeding – in particular the fact that it provides the best nutrition and protection from illness for babies. Mothers should be given guidance on the preparation for, and maintenance of lactation, with special emphasis on the importance of a well-balanced diet both during pregnancy and after delivery. Unnecessary introduction of partial bottle-feeding or other foods and drinks should be discouraged since it will have a negative effect on breastfeeding. Similarly, mothers should be warned of the difficulty of reversing a decision not to breastfeed. Before advising a mother to use an infant formula, she should be advised of the social and financial implications of her decision: for example, if a baby is exclusively bottle-fed, more than one can (450g) per week will be needed, so the family circumstances and costs should be kept in mind. Mothers should be reminded that breast milk is not only the best, but also the most economical food for babies. If a decision to use an infant formula is taken, it is important to give instructions on correct preparation methods, emphasizing that unboiled water, unsterilized bottles or incorrect dilution can all lead to illness. * See: International Code of Marketing of Breast Milk Substitutes, adopted by the World Health Assembly in Resolution WHA 34.22, May 1981.
WHAT IS YOUR LIKELY DIAGNOSIS?

Challenging Presentation in Paediatric Hepatic Disease

Placing the spotlight on Lysosomal Acid Lipase Deficiency

26 May 2016; 13:00–14:00
Room 2 – Nikos Skalkotas Hall,
Megaron Athens International Conference Centre, Athens, Greece

Join our Expert Faculty for an insightful session on LAL-D

Diagnostic dilemma – Failure to thrive with chronic malabsorption and liver disease?
Prof. John J. Gargus, USA

A challenging diagnosis with liver involvement: what do you suggest?
Prof. Valerio Nobili, Italy

Nutritional imperatives in an infant with LAL-D
Ms. Fiona White, UK

Complex diseases need seamless cross-functional collaboration
Panel discussion of key takeaways